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T-bet (Tbx21) was first discovered to have a role in the adaptive immune system almost 20 
years ago. It was found to be a key regulator in the function of CD4+ T helper 1 (TH1) cells. T-
bet has been shown to be expressed and have a function in the other subsets of T helper cells. 
Understanding the role of T-bet and the role it plays in T cell differentiation and plasticity has 
become vital, as well as, the function of T-bet in other immune cells. 
Within the lab, a new mouse line has been developed that is able to fluorescently trace the 
lineage of T-bet expressed cells. Experiments have involved phenotyping this mouse line and 
determining the base-line level of T-bet expressing cells within each cell compartment. Further 
experiments will investigate the expression level of fate mapped T-bet cells, mainly the CD4+ 
T cells, in disease models in this mouse line.  
Further analysis of these T-bet traced cells have been performed to see whether these cells are 
more plastic and able to illicit a switch to a TH1 response and if there is a developmental aspect 
to expressing T-bet in development of CD4+ T cells. This thesis looks into these cells in more 
depth. 
I also have had the use of another mouse line which is able to delete T-bet in cells using 
tamoxifen treatment. This mouse line has given me the chance to delete T-bet from CD4+ T 
cells after they have developed and see if there is any change in plasticity and, also compare 
them with the deletion of T-bet in innate lymphoid cells.  
Finally, I have also used another mouse line which deletes T-bet in specifically regulatory T 
cells. This mouse line was used in a heart transplant model to see whether the deletion of T-bet 
would have any effect in the ability of Tregs to aid in tolerance of the heart transplant and prevent 
rejection of the graft. 
This thesis aims to learn more about the role of T-bet within the immune response and 
especially in the CD4+ T cell compartment, as despite the on-going research there is still a big 
unknown area of how the master regulators of CD4+ T cells regulate the plasticity and 
differentiation of these cells. Using these mouse models, I have discovered more about the 
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1.1 The many cellular mechanisms of the immune system aid in protecting 
and maintaining health 
 
Humans have evolved to form a complex and multifaceted immune system in order to maintain 
homeostasis and health against various pathogens (Chaplin, 2010). The immune system of a 
human comprises of two main arms: the innate immune system and the adaptive immune 
system (Medina, 2016, Parkin and Cohen, 2001).  
 
1.1.1 The innate immune system 
 
In brief, the innate immune system involves a large variety of immune cells and molecules that 
are able to recognise a broad range of molecule patterns, which are shared by microbes and 
toxins that are not found in the host (Chaplin, 2010). There are numerous cell types involved 
in the innate immune system, including dendritic cells, macrophages, neutrophils, eosinophils, 
basophils, mast cells, megakaryocyte, natural killer (NK) cells, γδT cells, and epithelial cells 
(Chaplin, 2010, Medina, 2016, Parkin and Cohen, 2001, Gandhi et al., 2010). One of the first 
defence mechanisms of the innate immune system is the response from epithelial cells to 
pathogens. Pathogens have conserved regions on their surface called pathogen-associated 
molecular patterns (PAMPs), which are recognised through various genes encoded pattern 
recognition receptors (PRRs), of which Toll-like receptors have been the most heavily studied, 
on the surface of these cells (Tosi, 2005, Akira et al., 2006, Medzhitov and Janeway, 2000). 
Once PRRs recognise PAMPs, a proinflammatory and anti-microbial response occurs by 
activating the cells to produce, signal or activate various adaptor molecules, signalling kinase 
pathways and transcription factors (Mogensen, 2009). PRR-induced signal transduction results 
in the activation of a variety of molecules, including cytokines, chemokines, cell adhesion 
molecules, and immunoreceptors (Akira et al., 2006), which are the cause of the early host 




immune response to the adaptive immune response (Iwasaki and Medzhitov, 2015, Turvey and 
Broide, 2010).  
 
Two of the more important innate host response cytokines are IL-1 and TNFα. Both IL-1 and 
TNFα have been shown to be produced after activation of LPS from TLRs (Lu et al., 2008). In 
an example of gram-negative bacteria induced sepsis, both these cytokines, subsequently, can 
activate other cytokine production, chemokines and reactive oxygen species. They both also 
cause the expression of adhesion molecules from both epithelial cells and other leukocytes 
(Beutler and Cerami, 1989, Cohen, 2002). Both IL-1 and TNF-α can also promote the 
production of IL-6 (Oppenheim, 2001, Tosi, 2005).  
 
The activation of chemokines has also been shown to be important in acute innate immune 
activation. Chemokines are a specialized group of cytokine-like polypeptides. All chemokines 
are ligands to G protein-coupled, 7-transmembrane segment receptors, which have an 
important role in activating other immune cells and promoting their cell migration to areas of 
inflammation (Baggiolini, 2001, Kim, 2004, Rossi and Zlotnik, 2000, Tosi, 2005). Chemokines 
and their receptors are classified into 4 different families, which are determined by the first two 
cysteine residues of the respective chemokine peptide sequence. Each of at least 16 CXC- 
chemokines binds to 1 or more of the CXC-receptors (CXCR), of which there are 6 CXCRs. 
Correspondingly, there are 10 CC- chemokine receptors (CCRs), which bind to at least 28 CC 
chemokines. The chemokine receptors tend to be expressed on all immune cells and the 
chemokines secreted by activated innate immune cells aid in recruiting further immune cells to 
the site of infection and help to link the innate and adaptive immune system by recruiting cells 
of the adaptive immune system. For example, Epstein-Barr Virus has been shown to induce 
chemokine production causing recruitment of NK cells, B cells and both CD4+ T helper cells 
and CD8+ cytotoxic T cells (Kim, 2004, Glass et al., 2003). The type of chemokine and 
chemokine receptors have been found to be associated with different inflammatory conditions, 
for example between a TH1 (IL-12 and IFNγ) versus TH2 (IL-4 and IL-13) immune response 
(Bisset and Schmid-Grendelmeier, 2005). The specificity of these immune responses has been 
strongly influenced by the chemokines released from specific cells, the vascular adhesion 
molecules expressed in those tissues, the chemokine receptors expressed by various 





As well as recruiting other immune cells to the area of foreign microbes, upon recognition of 
foreign pathogen molecules, the link between the innate and adaptive immune response has 
also been highlighted with antigen presentation. Antigen-presenting cells (APCs) are a 
heterogeneous group of immune cells that mediate the cellular immune response by processing 
and presenting antigens for recognition by both CD4+ T helper cells and CD8+ cytotoxic T cells 
(Thomson and Knolle, 2010). This occurs in APCs, which classically consists of dendritic cells, 
which are the most potent APC, macrophages and B cells (Knight and Stagg, 1993, Chaplin, 
2010). APCs initially phagocytose pathogens, degrade the pathogens into peptides and then 
load and present these foreign peptides onto either class I or class II major histocompatibility 
complex (MHC). MHC class I bind to CD8+ cytotoxic T cells and MHC class II are specific 
for CD4+ T helper cells. The high avidity interaction between either of the MHC and co-
stimulatory molecule of CD80 on the APC and the respective T cell receptor (TCR) and CD28 
on the surface of either CD4+ T cells and CD8+ T cells causes strong interactions of the TCR 
and leads to T cell stimulation and the production of IL-2 and the receptor for IL-2 (Sprent, 
1995). The specificity of the antigen peptide being presented to the specifically rearranged T 
cell receptor is also what provides the adaptive immune response to have specificity. Activated 
and stimulated T cells then proliferate and differentiate into effector T cells and an effective 
immune response against further infection from this specific pathogen occurs (Chaplin, 2010, 
Iwasaki and Medzhitov, 2015, Sprent, 1995). 
 
1.1.2 The adaptive immune system 
 
The two main arms of the adaptive immune system comprise of both T cells and B cells. T 
cells develop in the thymus, whereas B cells develop in the bone marrow. T cells can be 
separated into αβT cells and γδT cells. αβT cells CD4+ T helper cells and CD8+ cytotoxic T 
cells, which as explained above recognise either MHCII or MHCI respectively. Upon 
activation via their respective MHC interaction and costimulation, CD4+ T cells main role is to 
regulate cellular and humoral immune responses by their own secretion of anti- or pro-
inflammatory cytokines. Whereas, CD8+ T cells main purpose, after activation, is to kill 
infected cells with intracellular microbes (Chaplin, 2010, Parkin and Cohen, 2001). CD4+ and 
CD8+ T cells differentiate into different subsets depending on what type of antigen they are 
exposed to. The differentiation of T cells occurs upon the activation of either one of the naïve 




stimulation, stimulated naïve CD4+ TH cells produce IL-2 and are termed as TH0. TH0 cells 
differentiate into TH1, TH2, and TH17 depending on the milieu of the cytokines present. TH1 
cells express the transcription factor T-bet and by the production of IFNγ (Szabo et al., 2000). 
TH2 cells express the transcription factor GATA-3 and produce IL-4, IL-5, IL-13, and GM-
CSF (Zhang et al., 1997, Zheng and Flavell, 1997). Finally, TH17 cells express the transcription 
factor RORC2 (or RORγt) and produce the cytokines IL-6 and IL-17A (Ivanov et al., 2006, 
Unutmaz, 2009). TH17 cells have been shown to be early responders to extracellular bacteria 
and fungi and help to further recruit neutrophils in order to eliminate the invading pathogen 
(Bettelli et al., 2006, Harrington et al., 2005, Park et al., 2005). In general, TH1 cells 
predominantly support cell mediated immune responses to bacteria and viruses, whilst TH2 
cells support humoral and allergic responses (Hsieh et al., 1993, Le Gros et al., 1990, Swain et 
al., 1990, Zheng and Flavell, 1997).  
 
Similarly to CD4+ T cells, CD8+ T cells also have the ability to produce TH1, TH2 and TH17 
like cytokine responses, and are termed T cytotoxic cell type 1 (TC1), T cytotoxic cell type 2 
(TC2), T cytotoxic cell type 17 (TC17) (Thomas et al., 2001, Mittrücker et al., 2014). TC1 cells, 
like TH1 cells, produce IFNγ and are regulated by the expression of T-bet. However, TC1 cells 
also require Blimp-1, Id2 and IRF4 expression and they also produce TNFα, granzymes and 
perforin (Kaech and Cui, 2012b, Kim et al., 2011, Man et al., 2013). TC2 cells also produce 
granzymes and perforin, as well as the similar cytokines and requirement of GATA3 like TH2 
cells. (Tang et al., 2012, Omori et al., 2003, Cho et al., 2012). TC17 cells, like TH17 cells, also 
express RORγt and produce IL-17A (Huber et al., 2013, Hinrichs et al., 2009, Hamada et al., 
2009). 
A small subset of αβT cells express NK1.1 and are termed NKT cells. NKT cells also develop 
in the thymus from the T cell lineage committed CD3+ cell, but NKT cells are CD4- and CD8- 
and recognise glycolipid antigens presented by the CD1d molecule. They are predominantly 
immunoregulatory and are based on their production of large quantities of cytokines such as, 
IFNγ, IL-4, granulocyte-macrophage colony stimulating factor (GM-CSF) and TNFα (Godfrey 
et al., 2004, Godfrey et al., 2005, Godfrey et al., 2010). The development of the NKT cells in 
the thymus will be further discussed in Chapter 3; and since T-bet plays a vital role in the 






γδT cells are another small subset of T cells, typically accounting for 0.5-5% of all T cell 
populations (Zhao et al., 2018, Kobayashi and Tanaka, 2015). They were initially discovered 
in the late 1980s, after the discovery of the γ chain of the TCR (Born et al., 1987, Hayday et 
al., 1985), and since then a large amount of research has been undertaken in order to discover 
more about the function and development of these cells. γδT cells also CD4- and CD8- and 
develop in the thymus from the T cell lineage committed CD3+ cell. Different subsets of γδ T 
cells develop in the thymus of either murine or human species. In mice the different peripheral 
subsets exist as: CD44+ CD122+ dendritic epidermal T cells (DETCs), which are found in the 
epidermis and produce IFNγ, CD44+ CD25+ CCR6+ IL-17-producing γδ T cells and CD27+ 
IFNγ-producing γδ T cells (Turchinovich and Pennington, 2011, Ribot et al., 2009). γδ T cells 
have been shown to be a vital source of IL-17A in lymphoid organs and peripheral tissue 
(Jensen et al., 2008, Sutton et al., 2009, Martin et al., 2009). In humans, γδ T cells are also a 
minority population and are identified in the periphery, especially in the epithelial layer of 
mucosal surfaces. Identification of human γδ T cells can be done using the variable regions of 
TCR‐δ: Vδ1 or Vδ2 (Hayday, 2000). Vδ1+ cells have been shown to be largely found in the 
mucosal sites and share similar phenotypes to mouse γδ intraepithelial cells (Pang et al., 2012, 
Ribot et al., 2009). These Vδ1+ cells have a function in wound healing and tissue homeostasis 
and also produce IFNγ. Whereas, Vδ2+ cells are mainly Vγ9+ and are predominately found in 
the peripheral blood. These Vγ9Vδ2+ cells are only found in humans and not in murine subsets 
of γδ T cells 
 
Lastly, the final arm of the adaptive immune system are B cells. B cells comprise of around 
15% of the peripheral lymphocyte population in the blood. The main function of B cells is their 
ability to produce immunoglobulins (Ig) in response to invading pathogens. There are five 
subclasses of Igs: IgG, IgM, IgD, IgE and IgA, which all have differing immune function and 
responses (Schroeder and Cavacini, 2010). IgG and IgA are subdivided again into four and two 
classes respectively: IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2 (Schroeder and Cavacini, 2010). 
The immunoglobulin is made up of a light and heavy chain and within these chains are variable 
regions the antigen binding site of the immunoglobulin are created. The different antibodies 
become incredibly variable in their ability to recognise many different antigens due to each of 
the heavy and light chains containing 3 highly variable subregions(Medina, 2016, Schroeder 
and Cavacini, 2010, Thomas et al., 2009). Each Ig, therefore, consists of two antigen-binding 




in the five subclasses of antibodies. The heavy chain constant domains pair to form Fc regions, 
which is responsible for the majority of the effector functions of the Ig molecule, including 
binding to Fc receptors and activating the complement system. B cells develop in the bone 
marrow and differentiate from haematopoietic stem cells. The RAG1 and RAG2 genes 
rearrange the antigen receptors of B cells, similar to the reassembly of the TCR (Jankovic et 
al., 2004, Thomas et al., 2009). The amino terminal region of both heavy chains is made by the 
combination of encoded genes for a variable (VH), diversity (DH) and joining (JH) region. This 
VDJ formation makes up one of the hypervariable regions and contributes to the antigen-
binding site of a B cell. This process occurs during the pre-B cell development stage and when 
B cells reach an immature stage, they begin to express IgM on their surface (LeBien and 
Tedder, 2008). Upon reaching maturity, naïve mature B cells express both IgM and IgD on 
their surface (LeBien and Tedder, 2008). As explained above, different CD4+ T helper cells 
become activated and produce cytokine responses depending on the pathogenic environment 
they are found. These cytokines influence mature B cells into class or isotype switching of the 
immunoglobulin. Class switching involves the process whereby the established surface 
immunoglobulin on the mature B cell are able to rearrange their VDJ regions into an alternative 
heavy chain). It has been shown that IL-10 production from T cells causes class switching from 
IgG1 to IgG3 (Malisan et al., 1996). TH2 cytokines of IL-4 and IL-13 cause the switching to 
IgE. Whilst, production of TGF-β switches to IgA. IFNγ production from TH1 cells causes the 
switching to IgG2. B cells simultaneously undergo somatic hypermutation, whilst the process 
of class switching is occurring. Somatic hypermutation causes increased affinity of the B cell 
to the antigen. The resulting process of somatic hypermutation, class switching and clonal 
expansion results in the formation of plasma cells and the secretion of the surface 
immunoglobulin into antibodies and provides an effective response against that specific 
pathogen. The process of somatic mutation and clonal expansion usually occurs in the germinal 




T-bet, or T-box expressed in T-cells, is coded in the genome by Tbx21 gene on chromosome 
11 in mice and chromosome 17 in humans, is a member of the T-box family of transcription 
factors and comprises of a 62kDa 530 amino acid protein. The identification of the 




determine a possible link between the evolution of the adaptive immune system from primitive 
innate-like B and T cell subset of cells, which has been recognised in jaw-less organisms, for 
example lampreys and amphioxus (Horton Amy and Gibson‐Brown Jeremy, 2002). The 
research in the 1970’s in the genetic composition of the adaptive immune system was hugely 
influential in discovering the process of somatic hypermutation (Weigert et al., 1970) and 
variable-diversity-junction rearrangement (VDJ rearrangement) of both the T cell receptor 
(TCR) and B cell receptor (BCR) (Tonegawa, 1976) at their antigen recognition sites; and it 
was discovered that these regions were shared within the RAG gene. The recombination of 
antigen recognition sites at the TCR and BCR contributes to the adaptive immune system 
having specificity and memory. Therefore, this understanding of how the two antigen 
recognition receptor sites were involved in the adaptive immune system of T and B cells helped 
to analyse the role of other genes in the adaptive immune system. Studying the early pre-
evolutionary organisms such as lampreys and amphioxus, made startling new understandings 
into these innate-like B and T cells. They required genes such as eomesodermin (EOMES), T-
box brain protein 1 (TBR1) and T-bet subfamily of T-box genes. T-bet being first described as 
the master regulator of differentiation for naïve CD4+ T cells into T helper 1 (TH1) cells (Szabo 
et al., 2000). Furthermore, better understanding of T cell transcriptional pathways have allowed 
for more defined knowledge into the regulation of T cell polarity. In understanding how the 
evolution of organisms and their immune systems developed has been able to shed new 
knowledge into T-bet being expressed in innate cells as well (Lazarevic et al., 2013). 
 
Since then, using new and more developed genome analysis techniques has allowed further 
expansion of knowledge about how transcription factors behave within the genome. As T-bet 
plays an important role in many cells, not just CD4+ T cells, their molecular mechanisms have 
been further understood using these techniques. Transcription factors, like T-bet, bind to their 
target genes at accessible promotor and enhancer regions, thus either activating or repressing 
them. Chromatin immunoprecipitation (ChIP) analysis is one of these new techniques and has 
allowed identification of the role T-bet plays in immune cells. ChIP-sequencing, or ChIP-seq 
has allowed for even further understanding of the promoter and enhancer regions which T-bet 
controls. Extensive understanding can be gained by investigating the parallel roles of T-bet in 





As already stated, T-bet was first cloned in 2000 by Szabo et al. and it was found to be the 
master regulator of TH1 cells. It was found to bind to the promotor regions of both Il2 and Ifng 
gene loci. In T cell skewing experiments, it was found that T-bet was quickly induced in naïve 
CD4+ T cells in TH1 conditions, but not in other T helper cell polarising conditions (Szabo et 
al., 2000). Also, further understanding was found that the Ifng gene was regulated and activated 
by T-bet and CD4+ T cells highly produced IFNγ when T-bet was retrovirally transduced into 
CD4+ T cells. (Szabo et al., 2000). Szabo et al., lastly discovered that T-bet was able to drive 
the plasticity of already committed TH2 cells back to a TH1 lineage. IFNγ production and 
inhibition of IL-4 and IL-5 in in vitro differentiated TH2 cells was observed with retroviral 
transduction of T-bet was performed within these cells.  
 
1.3 T-bet expression in the immune system 
 
T-bet has been shown to be expressed solely in the immune system. As well as in CD4+ T cells, 
T-bet has also been found to be expressed in CD8+ T cells (Intlekofer et al., 2005), natural killer 
(NK) cells (Townsend et al., 2004), ILCs (Powell et al., 2012), dendritic cells (DCs) (Lugo-
Villarino et al., 2003), monocytes (Lighvani et al., 2001), B cells (Liu et al., 2003), NKT cells 
(Matsuda et al., 2006), γδ T cells (Yin et al., 2002) and is summarised in Figure 1. T-bet being 
expressed in so many different cell types demonstrates that it has a vital role in the immune 












Figure 1: T-bet expression in immune cell populations 
Schematic showing the different cell types currently known to express T-bet, and the function of T-bet within 




1.4 The role of T-bet in CD4+ T cells 
 
1.4.1 CD4+ T helper cell differentiation 
 
A vast amount of knowledge about the different subsets of CD4+ T helper cells has been 
discovered over the past 30 odd years. A brief history of CD4+ T cell discovery is first described 
to understand the importance of T-bet in this population of cells. Initially CD4+ T cells were 
thought to have two important immune responses: one being antibody-mediated and the second 
as cell-mediated (Zhu and Paul, 2008). The first important discovery, by Mosmman and 
Coffman, showed that there were two subtypes of CD4+ T cells giving them different functions. 
They discovered that TH1 cells were producers of IL-2, IFNγ, GM-CSF and IL-3 as a response 
to antigen presenting cells (Mosmann et al., 1986). During this time, IL-4 producing CD4+ T 
helper cells were also discovered by Kim Bottomly (Killar et al., 1987). In vitro differentiation 
of helper CD4+ T cells were first reported by two groups, William Paul and Susan Swain. They 
both found that naïve CD4+ T cells were unable to make any of the effector cytokines and 
instead required T cell receptor (TCR) activation to produce any cytokines. They also found 
that IL-4 stimulation drove the CD4+ T cells to produce even more IL-4 (Le Gros et al., 1990, 
Swain et al., 1990). It was within these first studies that also identified the DNA-binding factor 
GATA-3 and the signal transducer and activator of transcription (STAT) 6 (Zhang et al., 1997, 
Zheng and Flavell, 1997). In vitro studies were also carried out on CD4+ T cells and 
subsequently found that naïve CD4+ T cells could be differentiated into producing IFNγ after 
TCR stimulation and response to antigen presenting cells (APCs) with Listeria antigens 
presented. The APCs produced IL-12, which has since been found to be crucial for TH1 
differentiation and to cause IFNγ to be produced (Hsieh et al., 1993). Originally, it was thought 
that CD4+ T cells were controlled by the interaction between the cytokines that were within 
their environment, with IL-4 working as a positive feedback loop for TH2 and IL-12 for TH1 
differentiation.  However, it was later discovered that T-bet was the main transcription factor 
that caused the increase positive feedback loop on TH1 CD4
+ T cell differentiation and IFNγ 
production (Szabo et al., 2000).  
 
After discovering the key transcription factors for TH1 and TH2 cells were T-bet and GATA3 
respectively, the next subset of CD4+ T helper cells to be discovered were T helper 17 (TH17). 




or TH2 cytokines, despite lowly expressing T-bet and GATA3. Furthermore, it was found that 
conventional TH1 and TH2 cytokines, IFNγ and IL-4, suppressed TH17 differentiation 
(Harrington et al., 2005, Park et al., 2005). Similar to the in vitro studies performed on TH1 and 
TH2 cells, in vitro experiments showed that naïve CD4
+ T cells would differentiate into TH17 
cells upon stimulation of the TCR when provided with IL-6 and TGFβ (Bettelli et al., 2006, 
Mangan et al., 2006, Veldhoen et al., 2006). Despite TH17 cells expressing T-bet and GATA3 
at low level, it was found that the main transcription factor to control the differentiation of 
naïve CD4+ T cells into TH17 cells was the orphan nuclear receptor RORγt (Ivanov et al., 2006).  
 
Finally, the final major subset of T helper cell to be discovered were regulatory T cells (Tregs). 
Tregs are known to express CD25, whereas other differentiated T cell subsets do not express 
CD25 (Sakaguchi et al., 1995). However, it was not until years later when the transcription 
factor Foxp3 would be discovered to be the master transcription factor to regulated the 
differentiation into natural Tregs (nTregs) (Hori et al., 2003, Fontenot et al., 2003). This was 
further proved in mice suffering from the autoimmune disease scurfy and from human IPEX 
patients, both of which have mutations in their Foxp3 gene and therefore lack the presence of 
any CD4+ CD25+ Tregs. Again, in vitro studies were carried out to how that TGFβ was essential 
for the differentiation of naïve CD4+ T cells into Foxp3+ CD4+ T cells. These TGFβ driven Tregs 
develop without the presence of proinflammatory cytokines and the TGFβ has been shown to 
work in a positive feedback mechanism to drive Tregs to differentiate. These Tregs were coined 
as induced Tregs (iTregs) (Chen et al., 2003). 
 
The differentiation pathway of the main four subsets of CD4+ T helper cell from a naïve CD4+ 






Figure 2: Schematic diagram showing the differentiation pathway of naïve CD4+ T cells into helper T cells 
Schematic showing the requirements for naïve CD4+ T cells to differentiated into the four different subsets of T 
helper cell, adapted from (Lazarevic et al., 2013). 
 
As can be seen on the schematic, T helper cells, not only require transcription from the master 
transcription factors that control each subset, but also rely on the activation and repression of 
STATs in order to activate these transcription factors to begin with. The JAK-STAT pathway 
involves both a canonical and non-canonical pathway. In the canonical pathway of JAK-STAT 
activation, when the receptor recognises its respective ligand, for example a cytokine, the 
receptor becomes dimerized (Li, 2008). This dimerization leads to activation of receptor-
associated JAK kinases (Seif et al., 2017, Villarino et al., 2015, Bright and Sriram, 1998, 
O'Shea and Murray, 2008, Li, 2008). The activation of JAK kinases phosphorylates tyrosine 
residues in the tail of the receptors. The phosphor-tyrosine residues work as a docking region 
for STAT proteins, which become phosphorylated by JAKs. Phosphorylated STAT proteins 
also then dimerize via Src-homology 2 (SH2)-domain–phospho-tyrosine interactions and these 
dimerized phosphorylated STATs then translocate to the nucleus, where they activate 
transcriptional activators, inducing expression of target genes, for example T-bet or GATA3 




In TH1 cells, IFNγ receptor (IFNγR) and IL-12 receptor (IL-12R) are both dependent on the 
expression of T-bet after TCR signalling via STAT1 and STAT4 respectively in naïve CD4+ T 
cells (Mullen et al., 2001, Schulz et al., 2009, Szabo et al., 2000, Thieu et al., 2008). As said 
already, TH2 cells require STAT6 and is highly upregulated after the induction of IL-4 on the 
IL-4R (Takeda et al., 1996, Zhu et al., 2001). TH17 cells need STAT3 activation and are 
activated by IL-6, IL-21 and IL-23, and increased STAT3 activation has shown to have an 
increase in the number of TH17 cells present (O'Shea et al., 2011). Lastly, STAT5 expression 
is highly necessary for Treg differentiation. Mice that were deficient for STAT5, were unable 
to survive and it was found that STAT5 was important in regulating Foxp3 (Burchill et al., 
2007, Yao et al., 2007).  
 
With this background knowledge of T cell differentiation, it was initially believed that each 
subset was terminally differentiated. However, it has since been found that the T helper cell 
subsets are able to switch on and off the different master transcription factors that control them, 
even after initial differentiation. Therefore, it has since been found that T-bet has a role in the 
other T helper subsets as well as just controlling TH1 differentiation. 
 
1.4.2 The role of T-bet in TH1 cells 
 
As explained previously, T-bet is induced when naïve CD4+ T cells are activated by their TCR, 
IFNγ and IL-12. IL-12 activates STAT4 signalling which further induces more T-bet 
expression. The IFNγ production from TH1 functions as a positive feedback to also enhance T-
bet expression within these TH1 cells via STAT1 signalling.  
 
Zhu et al., used a T-bet reporter mouse line, whereby a ZsGreen (an improved variant of the 
fluorescent green protein) coding region was inserted in the start of the T-bet translational site 
of the bacterial artificial chromosome (BAC) clone (Zhu et al., 2012). They found using this 
mouse line that ZsG protein would be expressed but not the complete T-bet protein from the 
BAC meaning that T-bet can continue to be expressed from the endogenous Tbx21 gene. They 
found a few different fundamental properties regarding T-bet expression using this green 
reporter mouse. Firstly, the induction of T-bet was not actually required for its own 




bet expression was found to induce itself in IL-12 and IFNγ independent pathways (Zhu et al., 
2012).  
 
As well as T-bet inducing TH1 cells to produce IFNγ, T-bet was found to have a major role in 
the creation of transcriptionally able TH1 cell-specific genes in CD4
+ T cells (Lazarevic et al., 
2013). T-bet has been shown to modify the chromatin in the genome. T-bet recruits enzymes 
that creates chromatin histone modifications by either activating genes, with H3 or H4 
acetylation and H3 lysine demethylation, or repressing genes with H3K27 trimethylation 
(Miller Sara and Weinmann Amy, 2010). TH1 polarised cells have been shown to increase 
expression at gene loci, which are known to be positively regulated by T-bet. Whereas, T-bet 
repression of genes in TH1 cells were observed by H3K27 trimethylation repression (Hatton et 
al., 2006). T-bet has been shown to bind to the promotor region of the Ifng gene causing 
remodelling of the Ifng locus by epigenetic chromatin modifications as described above. 
Additionally, it was observed that T-bet binds to enhancer regions downstream of the Ifng gene 
(Hatton et al., 2006). The Ifng gene has been shown to be more enhanced by H2.0-like 
homeobox protein (HLX) and the run-related transcription factor 3 (RUNX3) (Djuretic et al., 
2006). Both of these proteins are mediated by transactivation of T-bet in TH1 cells (Djuretic et 
al., 2006).  
 
CCCTC-binding factor (CTCF) is a highly conserved zinc finger protein and is involved in the 
transcriptional regulation, insulator activity and regulations of the chromatin architecture 
(Phillips and Corces, 2009). In TH1 cells, T-bet also organises the three-dimensional 
architecture of Ifng locus promoting definite Ifng expression. It achieves this by enhancing the 
binding of CTCF (Phillips and Corces, 2009) to the Ifng locus (Sekimata et al., 2009). The 
binding of T-bet to this location causes looping of the CTCF-dependent chromatin and in turn 
brings T-bet-binding enhances and the CTCF-binding region closer together at the promotor 
region of Ifng (Sekimata et al., 2009). This change in configuration by T-bet promotes Ifng 
expression in TH1 cells. 
 
However, T-bet not only drives the Ifng gene expression but also directing activates half of TH1 
cell-specific genes. These range from cytokines, such as IFNγ and TNFα, chemokines, like 
CC-chemokine ligand 3 (Ccl3) and Ccl4, and chemokine receptors, for example CXCR3 and 




al., 2008, Jenner et al., 2009, Lord et al., 2005). However, T-bet expression can also indirectly 
drive the differentiation of other CD4+ T helper cells. In T-bet knockout mice, an increase in 
TH2 and TH17 cytokines and transcription factors have been witnessed (Lazarevic et al., 2010, 
Szabo et al., 2000). This suggested that T-bet has a role in inhibiting the other CD4+ T helper 
cells.  
 
1.4.3 The role of T-bet in TH2 cells 
 
In comparison with T-bet for TH1 cells, GATA3 has been found to be the master transcription 
factor for TH2 cells. However, GATA3 is expressed in naïve CD4
+ T cells, unlike with T-bet 
expression. When naïve CD4+ T cells are activated, the genomic transcripts cause non-selective 
histone acetylation of TH1 and TH2 genes (Avni et al., 2002). Therefore, during the initial 
activation of the naïve CD4+ T cell, T-bet and GATA3 gene expression compete to become 
their respective subtype. Hwang et al., showed that T-bet was able to inhibit GATA3 expression 
in TH2 cells. T-bet and GATA3 interact when TCR activation coupled with IL-2-inducible T 
cell kinase (ITK)-mediated phosphorylation of T-bet occurs (Hwang et al., 2005). Furthermore, 
they showed that T-bet binding to RUNX3 causes TH2 inhibition (Kanhere et al., 2012, Djuretic 
et al., 2006, Hwang et al., 2005). Zhu et al., further showed that in TH1 cells T-bet binds to the 
GATA3 gene locus and causes the promotion of repressive chromatin modifications, resulting 
in less GATA3 expression. 
 
As well as T-bet being able to control the initial differentiation of TH2 cells, there have also 
been studies showing that CD4+ T cells can be redirected into other helper T cell lineages with 
the expression of the master transcription factors. TH1 and TH2 cells have been shown to 
counter each other during differentiation, where IFNγ production inhibits TH2 cytokines and 
the reverse has also been shown that IL-4 stops the IFNγ and IL-12 production (Fiorentino et 
al., 1989). However, differentiated TH1 and TH2 cells have also been shown to be plastic 
(Hegazy et al., 2010). Hegazy et al. showed that in infections of Lymphocytic choriomeningitis 
virus (LCMV) differentiated TH2 cells were able to become more TH1-like when cultured in 
vitro with IL-12 and IFNγ. The in vitro cells expressed both GATA3 and T-bet (Hegazy et al., 
2010). In vitro studies, performed by Sundrud et al, have shown that when CD4+ T cells are 
cultured in TH1 skewing conditions to form polarised TH1 cells are placed into TH2 polarising 




Furthermore, proof of TH1-TH2 plasticity has been shown by the conversion of TH1 polarised 
cells into a more TH2 polarised subtype when GATA3 was overexpressed. The opposite 
happened in T-bet overexpressed TH2 skewed cells, with them becoming TH1-like (Sundrud et 
al., 2003). In vivo studies by Murphy et al., showed that TH1 CD4
+ T cells were able to produce 
both TH1 and TH2 cytokines in infections of Leishmania major. These TH1 differentiated CD4
+ 
T cells produced IFNγ in vivo, however when they were presented with IL-2 and IL-4 ex vivo 
the TH1 CD4
+ T cells appeared to have a TH2 phenotype (Murphy et al., 1996).  
 
1.4.4 The role of T-bet in TH17 cells 
 
The master transcription for TH17 cells is RORγt, which controls the differentiation of the naïve 
CD4+ T cell to commit to the TH17 lineage (Ivanov et al., 2006). However, it has been found 
that TH17 cells also express both T-bet and GATA3 at low levels (Wilson et al., 2009). TH17 
cells, especially under inflammatory conditions, have shown to be able to produce IFNγ 
(Harbour et al., 2015). Therefore, T-bet has a role in both directing the differentiation of TH17 
in conjunction with RORγt and is able to plastically convert TH17 cells into TH1-like cells. In 
naïve CD4+ T cells, T-bet has been shown to block RUNX1 induced commitment to TH17 cells 
and in T-bet knockout mice, a larger proportion of TH17 cells producing IL-17A, IL-17F and 
IL-21 was observed when CD4+ T cells were skewed towards TH17. Further studies have 
shown that Runx expression drove the development of IFNγ production in TH17 cells and T-
bet and STAT4 were also induced in these cells. However, it was shown that the STAT4 was 
not vital, and the T-bet expression was more important, to produce maximum IFNγ from these 
cells (Wang et al., 2014). 
 
TH17 have also been shown to behave plastically with the ability to convert into TH1- and TH2-
like phenotypes. In vitro experiments have shown that TGF-β and IL-6 derived TH17 cells can 
become IL-12-producing TH1 or IL-4-producing TH2 cells due to the ability of TH17 cells to 
express both T-bet and GATA3 (Wilson et al., 2009). Furthermore, Wilson et al. found that T-
bet and RORγt have been shown to be co-expressed in TH17 cells, which produce both IFNγ 
and IL-17A. During disease response and autoimmunity, TH17 cells have shown plasticity. The 
conversion of TH17 into a TH1-like phenotype has been shown to cause diabetes, arthritis and 
IBD and blocking IFNγ can reduce the disease phenotype in animal models (Bending et al., 




al., 2013). A model of experimental autoimmune encephalomyelitis (EAE), using a lineage fate 
mapped IL-17A mouse, was able to identify subsets of “ex-TH17” cells which were responsible 
for IL-17A production in the spinal cord producing the EAE (Hirota et al., 2011).  
 
1.4.5 The role of T-bet in Tregs cells 
 
Despite the main function of Tregs being to control the proinflammatory cytokines produced by 
the other T helper subsets, T-bet has been shown to have a role in Tregs. Foxp3 is the main 
transcription factor responsible for naïve CD4+ T cell differentiation into Tregs (Fontenot et al., 
2003). This was mainly observed in induced Tregs (iTregs) in the periphery. Koch et al. found 
that the T-bet was expressed in iTregs during TH1 driven inflammation and the gene locus itself 
was open (Koch et al., 2012, Koch et al., 2009a, Koch et al., 2009b). They also found that when 
T-bet-/- Tregs were transferred into recipient scurfy mice, which lack their own functional Tregs 
due to scurfy mice having a mutation in Foxp3, they were unable to overcome a TH1 mediated 
disease phenotype. However, it is still poorly known how T-bet is able to control the function 
of iTregs and how T-bet and Foxp3 are regulated in the genome when both are expressed in 
iTregs. But, Koch et al. have shown that the expression of T-bet in iTregs is expressed a lot lower 
compared to the expression of T-bet in TH1 cells (Koch et al., 2009b). Therefore, full TH1 cell 
differentiation does not occur in iTregs, and low levels of T-bet expression is maintained by 
silencing the Il12rb2 locus. But, iTregs have shown to require T-bet expression to induce 
CXCR3 expression and aid their migration, thus migrating and suppressing TH1 mediated 
inflammatory responses (Koch et al., 2009a, Pandiyan and Zhu, 2015, Tan et al., 2016a). 
 
Lastly, as well as expressing T-bet, Tregs also have plasticity with TH17 cells. TH17 and Tregs 
are both activated by TGFβ and therefore during differentiation, and even afterwards, are both 
able to co-express Foxp3 and RORγt (Lee et al., 2009). During differentiation, the determining 
factor that causes intermediate Foxp3+RORγt+ cells to either differentiate into TH17 or Tregs are 
the cytokine environment in which they are present. Much research has been performed to 
show that proinflammatory cytokines from TH17 impedes Tregs and IL-10 from Tregs prevents 
conversion to TH1 and TH17 (Chen et al., 2007b, Josefowicz and Rudensky, 2009). When taken 
ex vivo into IL-6 media, Tregs have been shown to convert to TH17 and produce IL-17A. 
Furthermore, a proportion of TH17 cells have been shown to be from Foxp3 iTregs within the 




1.4.6 The role of T-bet in formation of CD4+ memory cells 
 
Although much is known about the differentiation and plasticity of effector CD4+ T cells, not 
much has been reported on CD4+ memory T cells. Therefore, a defined role of T-bet in CD4+ 
memory cell formation is even less well documented. However, TH1 effector CD4
+ T cell have 
been shown to require T-bet to develop into memory CD4+ T cells. In TH1 cells two subsets 
have been identified using the expression of Ly6C, with either Ly6Chi or Ly6Clow cells. Both 
of these subsets of TH1 effector cells also express P-selectin glycoprotein ligand 1 (PSGL1) 
(Lazarevic et al., 2013). TH1 PSGL1
+ Ly6Chi cells were the fully differentiated effector cell and 
PSGL+ Ly6Clow cells were found to be TH1 memory cells (Marshall et al., 2011). Marshall et 
al. also found that PSGL1+Ly6Chi cells had higher expression of T-bet, IFNγ, granzyme B and 
CXCR3 whereas PSGL1+Ly6Clow had lower levels of T-bet expression. They also showed that 
T-bet expression was graded, whereby increased T-bet expression was essential for the PSGL1+ 
Ly6Chi to proliferate and fully differentiate and lower T-bet expression was necessary to form 
PSGL+ Ly6Clow memory cells (Marshall et al., 2011).  
 
1.5 The role of T-bet in CD8+ T cell function and memory CD8+ formation 
 
The main function of CD8+ T cells, or cytotoxic T cells, are to remove intracellular pathogens 
and viruses by producing IFNγ in response. CD8+ T cells are also able to lyse cells during an 
infection by secreting cytotoxic granules containing granzyme B and perforin. However, it was 
originally found that despite T-bet being expressed in CD8+ T cells, it is not necessary to drive 
their IFNγ production (Szabo et al., 2000). It has been found that CD8+ T cells require both T-
bet and Eomes. When CD8+ T cells have both T-bet and EOMES knocked out, they are unable 
to function properly. T-bet-/- Eomes-/- CD8+ T cells were found to produce minimal IFNγ and 
also were unable to clear lymphocytic choriomeningitis virus (LCMV) infection (Intlekofer et 
al., 2005).  
 
Furthermore, T-bet and EOMES together have been found to have a role in generating memory 
CD8+ T cells (Joshi et al., 2011, Intlekofer et al., 2005). Like CD4+ T cells, when the TCR is 
stimulated in CD8+ T cells, T-bet expression is quickly upregulated. Afterwards, short-lived 
effector cells, or SLECs, become fully differentiated due to the enhancement and preservation 




2010). This results in the induction of T-bet expression and EOMES repression by inhibiting 
FOXO1 (Takemoto et al., 2006). After an infection is cleared from the system, many of the 
effector CD8+ T cells die. Memory precursor effector cells (MPECs) have been described as 
the small proportion of effector CD8+ T cells that survive apoptosis. They require both IL-7 
and IL-15 in order to survive. T-bet was shown to suppress IL-7R and has been found to cause 
a switch from effector memory cell to central memory cell in CD8+ T cells (Intlekofer et al., 
2007). Joshi et al. also reported that in CD8+ T cells the expression of T-bet decreases and 
Eomes expression increases to form MPECs. However, T-bet expression is still required at low 
levels in MPECs to maintain induction of CD122, thus allowing for the survival and future 
proliferation of memory CD8+ T cells (Intlekofer et al., 2005, Joshi et al., 2011).   
 
1.6 The role of T-bet in B cells 
 
Since certain subsets of B cells are able to produce IFNγ in response to viral infection, T-bet 
expression was highly likely in B cells. Peng et al. found that T-bet had a role in B cells to 
generate IgG2A antibodies during class switching (Peng et al., 2002). IgG2A is the most 
abundant immunoglobulin isotype produced during bacterial and viral infections. During class 
switching, T-bet in B cells induces the expression of Iγ2a transcripts, thus aiding in the 
switching to an IgG2A class (Peng et al., 2002, Barnett et al., 2016, Myles et al., 2017). 
 
As well as class switching, T-bet has also had a role in promoting IgG2A B cell memory 
survival. It achieves this by regulating STAT1 transcription in IgG2A B cells (Wang et al., 
2012).  
 
1.7 The role of T-bet in γδ T cells 
 
γδ T cells are a type of T cell that develops from the thymus during the same double negative 
stages as CD4 and CD8 T cell development, as described before in Chapter 1.1.2. γδ T cells 
are a small population of immune cell and in humans, at healthy steady state there are typically 
around 3-5% found in the peripheral blood (Kobayashi and Tanaka, 2015). Naïve γδ T cells 
have been shown to not require T-bet expression to mature, but only express T-bet upon γδ 
TCR activation (Yin et al., 2002). This IFNγ production has been found to the regulated by 




important for the IFNγ production function of CD27+ IFNγ-producing γδ T cells and in T-bet-
/- mice only half the normal proportion of CD27+ IFNγ-producing γδ T cells were found (Chen 
et al., 2007a). Other work by Sumaria et al. showed that there are T-bet+ expressing CD24− γδ 
thymocytes located in the thymus of mice. These IFNγ-committed CD45RB+ cells gradually 
express T-bet but not RORγt, compared to the IL-17A-committed CD44hiCD45RB− γδ 
thymocytes that express RORγt but not T-bet (Sumaria et al., 2017). 
 
1.8 The role of T-bet in NKT cells 
 
NKT cells, like γδ T cells, are another small population of immune cell. They express both a 
CD3 associated TCR and a few of the typical NK cell markers, like NK1.1, CD122 and some 
of the Ly49 markers (Matsuda et al., 2006). The TCR in NKT cells is a semi-invariant TCR 
which comprises of a Vα14-Jα18 rearrangement, which usually associates with either Vβ8, 
Vβ7, or Vβ2. NKT cells recognise glycolipids by MHC class I-like CD1d (Godfrey et al., 2005, 
Lantz and Bendelac, 1994). T-bet expression is required for iNKT development and maturation 
in the thymus (Townsend et al., 2004). In T-bet-deficient mice, the number of iNKT cells are 
markedly decreased. As CD122 is a target gene of T-bet and aids in the survival of cells, the 
T-bet-/- iNKT cells are unable to survive (Matsuda et al., 2006, Townsend et al., 2004). 
However, the remaining iNKT cells that were present in the T-bet-/- mice were still fully 
functioning and able to produce IL-4 and IL-13 to cause airway hyperreactivity.  
 
1.9 The role of T-bet in NK cells 
 
Szabo et al. not only discovered that T-bet was the master transcription factor in CD4+ T cells, 
but T-bet was also highly expressed in NK cells (Szabo et al., 2000). Since then, the role of T-
bet has been found to be important in regulating the development and terminal maturation of 
NK cells (Gordon et al., 2012, Townsend et al., 2004). However, both groups found that T-bet 
was not solely responsible for NK cell development. In T-bet-/- mice, there is a marked 
reduction in the number of NK cells, but they are not completely removed. Therefore, they 
found that NK cells also relied on Eomes expression, and when T-bet was deleted, Eomes 
expression was able to compensate (Gordon et al., 2012, Townsend et al., 2004). Furthermore, 
TNF-related apoptosis inducing ligand (TRAIL) expression in developing immature NK cells 




Eomes was shown to be more essential in NK cells (Gordon et al., 2012, Townsend et al., 
2004). Soderquest et al. further found that in T-bet-/- mice, NK cell were unable to progress 
from the CD27hi CD11bhi stage (Soderquest et al., 2011). 
 
1.10 The role of T-bet in dendritic cells 
 
Dendritic cells (DCs) are antigen presenting cells (APCs), which function to present antigen to 
naïve CD4+ T cells via MHCII or naïve CD8+ T cells via MHCI. However, DCs have also been 
shown recently to be able to produce IFNγ themselves and also express T-bet. T-bet expression 
in DCs was also found to be essential in efficiently priming TH1 cells, and Lugo-Villarino et 
al. showed that during Listeria infection experiments, T-bet-/- DCs were unable to mount an 
effective immune response with adjuvant activity of CpG DNA compared with normal 
wildtype DC cells treated with the same (Lugo-Villarino et al., 2005). 
 
T-bet expression in DCs play an important role in gut inflammation. In mice that have had both 
T-bet and the RAG2 gene knocked out, spontaneous colitis was observed and have since been 
named TRUC (Tbx21−/−Rag2−/−ulcerative colitis) mice, due to the colitis resembling human 
ulcerative colitis (Garrett et al., 2007). This model of colitis was driven by the microbiota of 
the mice, namely Helicobacter typhlonius and mice that lacked this pathogen were protected 
from colitis. This colony of mice that did not generate colitis were named TRnUC 
(Tbx21−/−Rag2−/− no ulcerative colitis) (Powell et al., 2012). T-bet has been shown to regulate 
TNFα production in colonic DCs. In TRUC mice, there is an increase in TNFα production from 
CD103- CD11b+ colonic DCs. The production of TNFα results promotes apoptosis and 
epithelial cell permeability, this allowing the microbiota to infiltrate and cause an inflammatory 
response (Garrett et al., 2007). Anti-TNFα antibodies have shown to be able to prevent and 
reverse the disease pathology (Lazarevic and Glimcher, 2011, Mohamed and Lord Graham, 
2016). However, in TRUC mice, TNFα blockade only alleviates the disease up to twelve 
weeks. Therefore, in the TRUC mice, another innate cell drives the disease after this period. 
ILC3s have since been found to be cell which mediates the disease in TRUC mice after TNFα-







1.11 The role of T-bet in innate lymphoid cells 
 
Recently a novel cell type was discovered named innate lymphoid cells (ILCs). It has been 
reported by many groups that ILCs share many functional, differential pathways and genomic 
characteristics with CD4+ helper T cells. The main difference between ILCs and CD4+ T cells 
are that ILCs do not respond to antigens as ILCs lack a somatically rearrangeable receptor like 
in T and B cells. ILCs also lack typical cell lineage markers used to identify other immune cell 
types. They have been found to express CD25 and IL7-R (Artis and Spits, 2015, Diefenbach et 
al., 2014, Spits et al., 2013). The ILCs consist of ILC1s, which also includes NK cells, ILC2 
and ILC3s, which also includes LTi cells. ILCs are mainly tissue resident immune cells and 
have been found mainly in mucosal barrier sites, as well as in immune surveillance organs, like 
the liver and spleen. 
 
1.11.1 ILC differentiation and the differences between subsets 
 
ILC1s have been shown to be like TH1 cells, where both express T-bet and produce IFNγ and 
TNFα. ILC1s, like TH1, also respond to intracellular pathogens (Fuchs et al., 2013, Bernink et 
al., 2017, Klose et al., 2014).  ILC1s also require IL-12 cytokine stimulation, like TH1 cells, 
and upon activation are potent producers of IFNγ. Since the discovery of ILCs, NK cells have 
also been grouped into ILC1s and are often described as “cytotoxic ILC1s”. ILC1s have been 
shown to be phenotypically different depending on which tissue they reside in. The three main 
tissue-specific ILC1s are: liver ILC1s, thymic ILC1s and intestinal ILC1s. Liver ILC1s are 
distinct from liver NK cells by their differing expressions of CD49b and TRAIL, whereby 
ILC1s are TRAIL+ CD49b- and NK cells are TRAIL- CD49b+ (Takeda et al., 2005, Tang et al., 
2016). Liver ILC1s do not circulate through the body and instead only reside within the liver 
(Peng et al., 2013).Thymic ILC1s were generated both in vitro and in vivo from the double 
negative 1 subset of cells (Vargas et al., 2011). Thymic ILC1s again differ to normal NK cells, 
as they require GATA3 to develop and express IL-7R. (Vosshenrich et al., 2006). Thymic 
ILC1s mimic liver ILC1s though, in that they both express Ly49 at low levels and are CD69high 
and CD11bhigh (Seillet et al., 2016). Lastly, ILC1s found in the intestine do not require IL-15R 
activation for development or survival (Fuchs et al., 2013). Fuchs et al. identified intraepithelial 
ILC1s as CD56+ within the non-T cell gate in the tonsils. They found that intraepithelial ILC1s 





ILC2s have similarities to TH2, whereby both express GATA3 and produce IL-4, IL-5 and IL-
13. Both cell types also require the stimulation from IL-25, IL-33 and thymic stromal 
lymphopoeitin (TSLP) to become activated. They also require the expression of amphiregulin, 
which is an epidermal growth factor receptor ligand. Comparatively with TH2 cell, ILCs 
respond to helminth infection, allergens and are involved in tissue repair (Mjösberg et al., 2011, 
Monticelli et al., 2011, Price et al., 2010). The production of IL-4, IL-5 and IL-13 from ILC2s 
promotes the recruitment of neutrophils and eosinophils to sites of inflammation. Similar to 
ILC1s, different subsets of ILC2s exist depending on where the ILC resides. There are four 
subtypes of ILC2s: natural helper ILC2s, nuocytes, innate helper ILC2s and multipotent 
progenitor (MPP) ILC2s. Natural helper ILC2s typically express c-Kit, Sca-1, IL-33R and IL-
25R and are predominantly found in adipose tissue in fat-associated lymphoid structures (Moro 
et al., 2009). Nuocytes, like natural helper ILCs, express c-kit, Sca-1, IL-33R and IL-25R, but 
they also express ICOS. Nuocytes are classically found residing in the mesenteric lymph nodes, 
intestines and lungs (Licona-Limón et al., 2013). Nuocytes have been shown to be highly 
activated producers of IL-13 in response to helminth infections (Neill et al., 2010). Innate 
helper ILC2s are found in the spleen, liver and mesentries and express similar surface markers 
to nuocytes and natural helper ILCs, except they lack the IL-25R marker. Lastly, MPP ILC2s 
are found in the gut only and appear to be a separate subtype of ILC2 compared with natural 
helper ILC2s, nuocytes and innate helper ILC2s. The expression of surface markers on MPP 
ILC2s are different from the other ILC2 subsets too. They do not express ICOS or CD25 and 
have been found to have intermediate expression of c-kit and IL-33R. They are still Sca-1+ and 
IL-25R+ though, and it is the presence of IL-25, which has been observed to drive the 
proliferation of the MPP ILC2 population in the gut (Saenz et al., 2010).     
 
ILC3s resemble TH17 cells, as they both express RORγt and produce IL-17A and IL-22 in 
response to microbiota pathogens in the mucosa. ILC3s are generally found in mucosal tissue, 
mainly in the intestines and lungs. In comparison to TH17 cells, a subset of ILC3s also express 
T-bet and produce IFNγ. Before ILCs were discovered, lymphoid tissue inducer (LTi) cells 
were thought to be a separate subset of cell, but since the discovery of ILCs, LTis have been 
grouped into the ILC3 category. LTis express CCR6 (Cella et al., 2008) and are found in the 
intestinal lamina propria forming clusters in the crypts of the intestine, which formed the peyers 




and Spits, 2015, Bernink et al., 2017, Diefenbach et al., 2014, Spits and Cupedo, 2012). ILC3s 
respond to IL-1β, IL-23 (Melo‐Gonzalez and Hepworth, 2017) and more recently IL-6 (Powell 
et al., 2015). Nkp46+ ILC3s do not express CCR6 though. Despite this T-bet expression in 
ILC3s, the expression of RORγt is the most crucial for driving the development and 
differentiation of ILC3s (Luci et al., 2008, Sanos et al., 2008). The different types of ILC3s: 
LTi, NKp46- ILC3s and NKp46+ ILC3s have different functions and role in the immune 
system. 
 
The differentiation pathway of ILCs is summarised in Figure 3: 
 
 
Figure 3: Schematic diagram showing the differentiation pathway of innate lymphoid cells 
Schematic showing the requirements for ID2+ ILCp to differentiated into the different subsets of ILCs, adapted 
from (Lazarevic et al., 2013) 
 
1.11.2 The role of T-bet in ILCs during mucosal immune responses 
 
As well as being responsible for ILC1 differentiation and maintenance, T-bet has been shown 




plasticity of ILCs. ILCs have mainly been found to be necessary in mucosal immunity and are 
predominately found to be present in sites of mucosal immune barrier sites, for example the 
intestinal lamina propria. In TRUC mice, after twelve weeks of the disease, NKp46- ILC3s 
produced increased amounts of IL-17A and IL-22 (Powell et al., 2012). Use of TRUC mice 
have allowed further understanding of the role T-bet has in ILCs. As explained above, after 12 
weeks ILC3s drives the disease in TRUC mice. TRUC disease phenotypes were improved in 
mice either administered with an anti-CD90 antibody or when IL-23 blocking antibody was 
administered. The deletion of T-bet also prolongs the survival of ILC3s via increased 
expression of IL-7R (Mohamed and Lord Graham, 2016). The TRUC model has been a useful 
model for studying the role T-bet the regulation of mucosal inflammation in response to the 
microbiota in DCs and T-bet-/- ILC3s. 
 
However, there is also an important role of T-bet in ILC1s and NKp46+ ILC3s in pathological 
immune responses in the mucosal tissue. ILC1s have been found to be highly involved in the 
immune response to Clostridium difficile (Abt et al., 2015) with their high production of IFNγ 
in response to the pathogen. ILC1s are also incredibly important in regulating the disease in 
Crohn’s disease (Bernink et al., 2013). In coeliac disease, there also has been shown to be an 
increase in IFNγ producing ILC1s. Interestingly IFNγ therapy in IBD trials were unable to treat 
the disease (Kortekaas Krohn et al., 2017). ILCs have been observed to be incredibly plastic, 
especially with Nkp46+ ILC3s being able to express T-bet to become ILC1-like and produce 
IFNγ during mucosal inflammation (Rankin et al., 2013). Nkp46+ ILC3s switch due to the 
presence of IL-12, which causes the increased expression of T-bet via STAT4 expression, 
similar to the TH17 switch to TH1-like phenotype. ILC1s have been shown to be highly 
activated in the inflamed colonic lamina propria (cLP) in anti-CD40 induced colitis. The anti-
CD40 colitis model in RAG-/- mice causes myeloid cells to become activated in the cLP and 
produce prolific amounts of IL-12, which in turn drives the ILC1s in the cLP to produce vast 
amounts of IFNγ and cause inflammation of the tissue (Buonocore et al., 2010, Powell et al., 
2012, Uhlig et al., 2006). 
 
As well as NKp46+ ILC3s being able to plastically switch to a T-bet expressing ILC1-like 
phenotype, ILC2s have been reported to be able to switch to ILC1-like properties too (Belz, 
2016). As explained, IL-1 cytokines are heavily involved in the activation and stimulation of 




Ohne et al. showed that ILC2 also express the IL-1R and can also be primed and stimulated by 
IL-1β. However, they also showed that IL-1β activation of the ILC2s is unable to cause the 
Ifng promotor to be upregulated and expressed. The ILC2s also required stimulation from IL-
12 in order to express T-bet and produce IFNγ, whilst still expressing GATA3 (Ohne et al., 
2016). Both Silver et al. and Bal et al. also showed that during airway inflammation ILC2s 
were able to switch to an ILC1-like phenotype under IL-1β and IL-12 conditions. These ILC1-
like T-bet+ ILC2s drove pathogenesis of the airway inflammation in their experiments (Bal et 
al., 2016, Silver et al., 2016) 
 
These observations show that T-bet has a crucial role in ILCs, in not only the differentiation of 
ILC1s, but also in the plasticity of ILC subtypes to express T-bet in ILC2s and ILC3s to form 
ILC1-like cells. Furthermore, with the comparisons between ILCs and CD4+ T cells, the role 
of T-bet in ILCs has shown even greater importance, especially during inflammatory responses. 
 
1.12 Experimental mouse models of IBD 
 
In humans, IBD is an inflammatory condition that affects the gastrointestinal (GI) tract. There 
are two main types of IBD: Crohn’s Disease (CD) and ulcerative colitis (UC). UC typically 
only affects the colon but CD causes disease in any of the GI tract (Baumgart and Sandborn, 
2007). Both CD and UC can relapse and remiss and have similar symptoms consisting and 
ranging from: diarrhoea, abdominal pain and rectal bleeding. Currently, there are only 
treatments for IBD but no cure. These treatments have emerged from studies with either animal 
models and then patient studies, resulting in clinical trials for specific immunomodulatory 
drugs and immunosuppression (Baumgart and Sandborn, 2007). With this lack of cure in mind, 
more mouse models have become vital in order to understand more about specific cell 
responses in mouse IBD-induced models. There are already around fifty well established and 
widely used mouse models of IBD (Uhlig Holm and Powrie, 2009, Mizoguchi, 2012). As quite 
a few different colitis models were used in this thesis, a brief overview of each of the IBD 
mouse models used will be given below. 
 
As mentioned above, the TRUC model has been extensively used by this group already to study 
the role T-bet has in IBD, with respect to both DCs and ILCs. In this thesis, the non-




to study IBD. The other models used within this thesis were: The T cell transfer model, the 
DSS model, Nippo and H. Poly parasite infection models and lastly the anti-CD40 model. 
 
1.12.1 The T cell transfer model 
 
The T cell transfer (TCT) model is a very important model, which allows studying the naïve 
CD4+ T cell response to foreign microbiota in the recipient mice. The TCT model also allows 
studies into the effect of Tregs on regulating the immune response from these transferred CD4
+ 
T cell (Eri et al., 2012). In 1993, Fiona Powrie first discovered the T cell transfer model as a 
viable model of IBD and further developed the model to be able to investigate the effectiveness 
of Tregs against CD4
+ T helper cell responses to IBD (Mottet et al., 2003, Powrie et al., 1993, 
Powrie et al., 1994). In this model, naïve (CD4+ CD25- CD62L+ CD44-) CD4 T cells from 
wildtype mice are sorted and adoptively transferred into adaptive immune deficient Rag-/- mice. 
Care must also be taken to match gender and mouse genetic background in this model. The 
donor naïve T cells cause colitis in the Rag-/- mice by identifying the foreign intestinal 
microbiota antigens and cause severe gut inflammation in both the small intestine and colon. 
The activated CD4 T cells secrete high amounts of IFNγ and a smaller amount of IL-17A, both 
of which are proinflammatory and cause the gut inflammation observed in this model. The 
model normally takes about six to eight weeks to develop post injection. Histology from the 
colon typically shows excessive neutrophil and eosinophil infiltration, crypt destruction and 
transmural inflammation (Eri et al., 2012, Ostanin et al., 2009).  
 
As mentioned above, co-transfer of the naïve CD4+ T cells with CD4+ CD25+ Tregs into the Rag
-
/- mice allowed investigations into the interaction between the regulation of the inflammation 
of IBD by Tregs. It was found that the onset of colitis is prevented in this model when both naïve 
CD4 T cells and Tregs were transferred. However, it was also shown that the transfer of natural 
Tregs can overturn an established TCT colitis via an IL-10 dependent method (Izcue et al., 2006, 
Izcue and Powrie, 2008). 
 
1.12.2 The DSS model 
 
The dextran sodium sulphate (DSS) model is an acute model of colitis that has been used for 




colitis that they have been able to induce in hamsters (Ohkusa, 1985). This led to more studies 
being established and induced in mice (Okayasu et al., 1990). The DSS model involves 
typically giving concentrations of 2-5% DSS in the drinking water for around 4-9 days. The 
variations in concentration, duration and even molecular weight of DSS have different effects 
(acute, chronic or relapsing colitis) on the mice. Different mouse strains, backgrounds and gut 
microbiota have also been found to have different susceptibility and disease outcomes (Perše 
and Cerar, 2012). The DSS model has shown to provide great insights into the clinical aspects 
of UC and the impact and outcome from the use of many therapeutic drugs used in human IBD 
treatments. DSS causes colitis in mice due its toxicity to the epithelial cells in the colon. This 
causes destruction and damage to the epithelial cells and the integrity of the epithelial layer 
itself becomes compromised. This ultimately causes the permeability of the mucosal layer to 
be increased and allows bigger molecules like DSS through the epithelial layer. The loss of the 
tight junctions in the colon occurs after the first day of DSS treatment and there is a marked 
increase in production of proinflammatory cytokines, like IFNγ, IL-17A, IL-6, IL-12, IL-13, 
TGFβ and TNFα, produced from CD4+ T helper cells, B cells, macrophages and neutrophils 
(Ito et al., 2008, Ito et al., 2006, Kiesler et al., 2015). On day three, there is the first visible 
signs by histology of basal crypt damage and loss and an increase in infiltration by 
inflammatory cells like neutrophils and eosinophils. This immune response to the destruction 
of the epithelial layer during DSS treatment mimics human IBD in the physical cell damage of 
the colon and causing a dysregulation of the microbiota and the intestinal mucosa (Chassaing 
et al., 2014b, Eichele and Kharbanda, 2017, Kiesler et al., 2015, Perše and Cerar, 2012). 
 
1.12.3 Parasite models: using Nippo and H.Poly 
 
Parasitic infections can result in IBD in humans and therefore, there are many animal models 
that have been developed and used to investigate the effect of each parasite in causing colitis, 
and also during colitis. For this thesis, Nippostrongylus brasiliensis and Heligomosomoides 
polygyrus were used to test potential inflammatory TH2 and ILC2 responses in the intestines. 
Experiments using the Nippo parasite infection were used to induce an IL-13 TH2 response in 
these mice. IL-13 is induced more strongly than IL-4 and IL-5 in response to Nippo (Harvie et 
al., 2010, Urban et al., 1998). In H. Poly infections, by day three larvae have developed and 
positioned themselves in the wall of the small intestine. When the larvae become full adult 




from B cells and IL-4 from CD4+ TH2 cells and ILC2s (Donskow-Łysoniewska et al., 2013, 
Mohammadi et al., 2015, Wahid and Behnke, 1992). These parasite models are important for 
being able to study the interactions between the immune system, and in particular TH2 and 
ILC2 responses, to parasite infections. 
 
1.12.4 The anti-CD40 model  
 
The anti-CD40 model of colitis has been widely used by groups for around the last twenty 
years. This model of colitis was defined and established in 2006 by Holm Uhlig et al. (Uhlig 
et al., 2006). Although it had been previously shown by other groups that CD40-CD40L 
activation of myeloid cells caused T cells to become activated and produce proinflammatory 
cytokines like IFNγ, IL-12 and IL-23p40 in IBD. (Radtke et al., Watanabe et al., 2004, Luckett-
Chastain et al., 2015, Liu et al., 1999, Liu et al., 2000, Uhlig et al., 2006). This had not been 
shown to influence the innate lymphocytes. However, when anti-CD40 is given to immune 
competent and complete mice, the anti-CD40 activated the B cells and the disease readouts 
were generally B cell driven (Blair et al., 2009). Therefore, in this model, an agonistic 
monoclonal antibody for anti-CD40 is injected via intraperitoneal injections into mice lacking 
an adaptive immune system, Rag-/- mice. In this system, there is a very acute onset of 
inflammation in the mouse (Uhlig et al., 2006). The mice develop both systemic inflammation, 
observed by splenomegaly and severe wasting disease, and local inflammation, observed by 
both colitis and hepatitis (Uhlig et al., 2006). In the Rag-/- mice, the main inflammatory 
cytokines responsible for this colitis model were IL-12 and IFNγ (Uhlig et al., 2006). The 
difference in background of the Rag-/-, either Balb/c or C57BL/6, have different severities of 
disease and therefore different doses are required upon providing the anti-CD40. Since 
C57BL/6 background mice generally illicit a more TH1 response and produce more IFNγ than 
IL-4, and Balb/c background respond more with TH2 cytokines like IL-4 than IFNγ (Luckett-
Chastain et al., 2015). These cytokine differences have also been seen to occur with the innate 
immune responses from the ILCs in these differing background mice (Watanabe et al., 2004). 
Therefore, the typical dose of the anti-CD40 drug for Balb/c Rag-/- mice is 125-150μg and for 
C57BL/6 Rag-/- mice is 25-50μg. The mice take around seven days to develop acute colitis, 
despite regaining weight from the wasting disease suffered during this time. The colitis remains 
and if further dosing is provided then the mice suffer further acute trauma and severe wasting 




either T cells, NK cells or ILCs to cause the APC to produce IL-12, which in turn cause a 
positive feedback to produce more IFNγ (Uhlig et al., 2006). This anti-CD40 proves to be 
incredibly useful at defining the role played by APCs, T cells, ILCs and NK cells in developing 












Figure 4: Schematic diagram showing the activation pathway of APCs with NK cells or ILCs via the 
costimulatory molecules CD40 and its ligand CD154 in the anti-CD40 model of colitis 
 
Below is a summary table of the mouse models of IBD used throughout this project:   
 
Summary table of the mouse models of IBD used 
Mouse Model Main result References 
Knockout of T-bet and T and 
B cells 
(Tbx21-/- x Rag2-/- mice) 
Mice develop spontaneous colitis within 
4 weeks in a TNFα via DCs and IL-17 
via ILC3s causing manner. Disease has 
been found to also be dependent on 
microbiota within the intestine and was 
mainly driven by Helicobacter 
typhlonius. 
(Garrett et al., 2007, 
Powell et al., 2012) 
Adoptive transfer of CD4+ T 
cells into Rag-/- mice 
Mice develop colitis after 6-8 weeks of 
transfer of naïve CD4+ T cells. Main 
response comes from pathogenic 
(Powrie et al., 1993, 




effector TH1 responses to pathogens in 
the intestine of the recipient mice. 
DSS chemical induced colitis Like most chemically induced colitis, 
DSS disrupts the epithelial barrier of the 
intestinal mucosa causing inflammation, 
diarrhoea and bleeding and neutrophil 
infiltration. Both acute and chronic 
models can be induced depending on 
cycle of treatment. DSS can be 
performed on both immunocompetent 
and immunodeficient mice. 
(Chassaing et al., 
2014a, Ohkusa, 
1985, Okayasu et 
al., 1990, Perše and 
Cerar, 2012) 
Parasitic helminth models of 
IBD 
Helminths, for example 
Nippostrongylus brasiliensis and 
Heligomosomoides polygyrus were used 
in this project. Immune responses to 
helminth have shown a switch to TH2 or 
ILC2 immune responses, like IL-4, IL-5, 
IL-13, in both adaptive and innate 
immune system 
(Elliott et al., 2007, 
Filbey et al., 2014, 
Harvie et al., 2010, 
Mohammadi et al., 
2015, Reynolds et 
al., 2012) 
Agonistic anti-CD40 activated 
induced colitis 
Showed severe acute colitis develops 
after 7 days of intraperitoneal injections 
of the agonist anti-CD40 in 
immunodeficient (Rag-/- mice). Data 
showed colitis was caused from IFNγ 
NK cells and IL-17A from ILC3s driven 
by dendritic cells producing IL-12 and 
IL-23.   
(Hue et al., 2006, 
Uhlig Holm and 
Powrie, 2009, 
Uhlig et al., 2006) 









1.13 Hypothesis and aims 
 
The hypotheses to be tested in this thesis are: 
1. The expression of T-bet has been shown in many cell types, as described already, 
however the ontogeny of these T-bet expressing cells is still not fully known. Learning 
about where and when T-bet becomes expressed in developing cells will provide further 
insight into known T-bet expressing cells. Using a new T-bet fate mapping mouse line 
that can trace any cell, which previously has expressed T-bet. This thesis hypothesises 
that utilising this mouse line will be able to predict and identify the ontogeny of T-bet 
expressing cells within the immune system and will be able to classify any novel and 
previously unobserved T-bet expressing cells. 
2. T-bet has already been shown to play a role in the plasticity of CD4+ T cells in disease, 
as explained already above. This thesis will aim to test the hypothesis that certain 
subsets of plastic TH17 cells are already pre-determined to become TH1-like, by using 
the fate mapping mouse line. Furthermore, that temporal deletion of T-bet in CD4+ T 
cells will cause a switch to more TH2 and TH17 settings. 
3. T-bet has been shown to regulate CXCR3 expression in Tregs. Using a model of cardiac 
transplantation with Foxp3cre x T-betfl/fl mice, the hypothesis that knocking T-bet from 
Tregs will not prevent cardiac transplant rejection.  
4. T-bet expression has been shown to be important in anti-CD40 mediated ILC1 IFNγ 
driven colitis. Using the same colitis model, the hypothesis that administering anti-
CD40 would drive acute hepatitis by IFNγ production from ILC1s and be dependent on 
T-bet.    
 
The aims of this thesis, in order to address these hypotheses, are: 
1. Characterise T-bet in immune cells, using a newly bred T-betcre x ROSA26fl/fl mouse 
line that can identify and trace previously expressed T-bet expression in cells 
2. Characterise the role T-bet has in differentiation of naïve CD4+ T cells, using the newly 
bred mouse line  
3. Characterise the role T-bet has in regulating the plasticity of CD4+ T cells, using the 
newly bred mouse line 






Materials and Methods 
 
2.1 Animal husbandry 
 
C56BL/6 wildtype (WT) (Charles River), BALB/c Rag2-/- (Jackson labs), C56BL/6 Rag1-/- 
(Jackson labs), Rosa26YFP/+ (Jackson labs), Cre-ERT2 (Jackson labs) and CD45.1 (Jackson labs) 
were sourced commercially. T-betfl/fl and T-betcre/+ mice were previously generated by our 
group (Gökmen et al., 2013, Garrido-Mesa et al., 2019) and made using Genoway. T-betcre/+ 
mice were then bred with Rosa26YFP/+ to generate the T-betcre/+ Rosa26YFP/+ line and subsequent 
genotyping was performed to check for usability. Foxp3gfpcre mice were generously given to us 
by A. Rudensky, which were then bred with the T-betfl/fl line and subsequent genotyping was 
performed to check for usability. Cre-ERT2 were bred with the T-betfl/fl line and subsequent 
genotyping was performed to check for usability. Tbx21-/- x Rag2-/- (TRnUC) mice were 
generated from the original described TRUC colony (Garrett et al., 2007, Powell et al., 2012). 
Mice were housed and bred at Charles River, apart from the experiments for embryo and 1-week 
old T-betcre Rosa26YFPfl/fl mice. They were maintained by staff at King’s College London in 
facilities that are Home Office approved and regulated. All mice used were aged between 6-12 
weeks, unless stated otherwise. All animal experiments were performed in accredited facilities 
in accordance with the UK Animals (Scientific Procedures) Act 1986 (Home Office Licence 





DNA was isolated by digestion at 56°C of ear or tail samples in 200μl of lysis buffer (5 mM 
EDTA, 100 mM Tris-HCl pH 8.5, 0.2% SDS, 200 mM NaCl, 1mg/ml Proteinase K). Digested 
samples were then diluted 1:4 in nuclease-free water. PCR reaction comprises 12.5μl of 2x 
Mango Mix (Bioline Ltd., London, UK), 1 μl of each of PCR primers, which were diluted in 
nuclease-free water to 25μM (primers from Sigma-Aldrich), 1μl genomic DNA and then 




with (Tris-acetate-EDTA) TAE and run on a electrophoresis and then bands were viewed on a 
UV spectrometer.  
 
2.3 Cell Isolation and preparation 
 
Adult mice were euthanized using approved Schedule 1 methods by inhalation of a rising 
concentration of carbon dioxide gas and then followed by cervical dislocation. Embryo and 
neonatal mice were euthanised by using approved Schedule 1 methods of decapitation. Organs 
were dissected in a laminar flow cabinet using aseptic technique. Spleen, thymus, liver, 
mesenteric lymph nodes (mLN), peripheral (axillary, inguinal and cervical) lymph nodes 
(pLN), colon and small intestines were excised and placed in cold Phosphate Buffered Saline 
(PBS) solution.   
 
Colon and small intestine lamina propria cells were isolated using the protocol developed by 
Sanos and Diefenbach (Sanos and Diefenbach, 2010). Small intestine and colon were cleaned, 
and faeces were removed. Afterwards, they were cut into 1-2cm pieces using surgical scissors 
and put into 10mls of Hank’s Balanced Salt Solution (HBSS) without Mg2+/Ca2+ (Invitrogen) 
mixed with 5mM of EDTA and 10mM HEPES (Fisher Scientific) and incubated at 37.5oC with 
agitation for 20 minutes. Next, intestinal pieces were filtered, and the subsequent intestinal 
pieces were sliced into fine pieces using scalpels and were collected in complete animal 
medium consisting of: Roswell Park Memorial Institute Medium (RPMI) (Gibco, Grand Island, 
NY) with 10% heat-inactivated fetal calf serum (FCS) (Gibco, Grand Island, NY), 2mm 
glutamine, 100U/ml penicillin and 100µg/ml streptomycin, HEPES (Fisher Scientific), non-
essential amino acids, sodium pyruvate and 2-mercaptoethanol (Sigma). Digestion enzymes 
were then added at a concentration of 0.5mg/ml collagenase (Roche), 10μg/ml DNase (Roche) 
and 1.5mg/ml dispase II (Roche), and the intestinal pieces were incubated for a further 20 
minutes at 37oC with agitation. After incubation, the digestion mix was filtered once more and 
centrifuged at 860g for 10 minutes at 4oC. The pellet was then resuspended in 10mls of 40% 
Percol (Sigma) (made up with complete RPMI, as listed above) and layered on top of 5mls of 
80% Percol and spun at 900g for 20 minutes at 20oC without brakes. After the centrifugation, 
the cloudy interface layer of intestinal lamina propria cells was retrieved and washed in PBS 





Splenic, thymus, liver, mLN and pLN cells were isolated into a single cell suspension in 
complete animal RPMI with the use of mesh filter and general mechanical destruction. The 
suspension was spun down at 860g for 5 minutes at 4oC and mLN and pLN were resuspended 
and kept on ice until ready to be used. Spleen, thymus and liver cell pellets were resuspended, 
and red blood cells were lysed using a standard red blood lysis buffer (ACK) consisting of: 
155mM NH4Cl, 10mM KHCO3, 0.1mM EDTA with a pH of 7.3. This was then spun down at 
860g for 5 minutes at 4oC and afterwards the spleen and thymus cells were resuspended in cold 
PBS and were ready to be use. The liver pellet was then resuspended in 4mls of 40% Percol 
(Sigma) (made up with complete RPMI, as listed above) and layered on top of 2mls of 60% 
Percol and spun at 900g for 20 minutes at 20oC without brakes. All cells were counted using 
trypan-blue staining in a haemocytometer to assess cell viability and count live cells. 
 
2.4 Cell separation technique 
 
 2.4.1 CD4+ magnetic bead separation 
 
Mouse spleens, mLNs, pLNs, livers, thymuses, colons and small intestines were processed into 
single cell suspensions as described above. CD4+ cells were purified using LS positive 
selection magnetic-activated columns (MACs) and anti-CD4 (L3T4) beads (MACS; Miltenyi 
Biotec, Bergisch Gladbach, Germany).  
 
 2.4.2 Cell sorting 
 
CD4+ MACs sorted cells described above were further sorted for higher purification. Cells 
were stained using surface marker antibodies for fluorescence activated cell sorting. Cell 
sorting was performed after CD4+ MACs bead separation using a FACS Aria machine (BD 
Biosciences). CD4+ MACs sorted cells were pooled into 100 x 106 total in 600µl of PBS and 
stained for 20 minutes at 4°C in the dark. The following antibodies were used: anti-CD4-
PerCPCy5.5, anti-CD25-PE, anti-CD62L-PECy7 (MEL-14; Thermo Fisher) and anti-CD44-
Pacific Blue (IM1.8.1; Thermo Fisher). Single positive compensation controls and unstained 
controls were used to set up instrument settings and for gating strategies. Sort gating strategies 
for the various sorts are shown in the corresponding results section. The FACS Aria had a 




The Aria sorting machine was operated by a member of the BRC flow cytometry core and used 
the manufacturer’s recommended settings for the drop delay and sort stream amplitude and 
frequency. Sheath fluid used in the Aria was sterile PBS, which sorted cells were collected into 
tubes and kept at 4°C to maintain viability of sorted cells. Purity of cells are performed post-
sort with at least a purity of 95% and viability of the cells were accessed using tryphan-blue 
staining in a haemocytometer.  
 
2.5 Naïve T cell transfer model of colitis 
 
Spleens and mLNs were harvested from either WT donor C56/BL6 mice or T-betcre x 
ROSA26YFPfl/fl mice and mechanically disrupted, as described before. Erythrocytes were 
lysed using in ACK buffer, similar to before. CD4+ cells were extracted using MACs separation 
as explained before. Naïve CD4+ T cells (CD4+ CD25- CD44low CD62Lhigh) were sorted using 
the FACS Aria to a purity of <95%, washed and resuspended in sterile PBS. Rag2-/- mice were 
injected via intraperitoneally with 0.5 x 106 naïve CD4+ cells per mouse, and humanely culled 
after 6-8 weeks following adoptive transfer of cells. Mice were monitored for their health every 
week for signs of illness. Gating for the T-betcre x ROSA26YFPfl/fl sorting is shown in Figure 





















2.6 Anti-CD40 model of severe inflammation of the liver  
 
125µg of agonistic anti-CD40 mAb (clone FGK4.5) or rat IgG2a isotype control mAb (clone 
2A3) (both from BioXCell, West Lebanon, US) was used for BALB/c Rag2-/- mice, or, 50µg 
was used for C56BL/6 Rag1-/- and were administered via intraperitoneal injection in sterile 
PBS. Mice were observed and weighed on a daily basis for signs of disease including: 
diarrhoea, rectal bleeding, clinical features of peritonism, hunched appearance and 
piloerection. Mice were sacrificed on day 7 post injection of anti-CD40. Following culling, 
organs were harvested and weighed, including colon, mLN, spleen and liver. 
 
2.7 DSS-induced colitis mouse model 
 
Colitis was induced in Cre-ERT2 x T-betfl/fl Het/Hom mice and littermate WT/Hom control 
mice by adding dextran sulphate sodium (DSS) (36-50 KDa, MP Biomedicals, Ontario, USA) 
to the drinking water at the concentration of 3% for a period of 5 days, after which DSS was 
removed and put back onto sterile drinking water. Mice from the non-colitic group were 
administered sterile drinking water throughout. Mice were sacrificed 5 days after the DSS was 
removed. Body weight, rectal bleeding and stool consistency were assessed daily for each 
mouse and these parameters were each assigned a score according to the criteria proposed 
(Cooper et al., 1993) and these data were used to analyse an average daily disease activity index 
(DAI) score. 
 
2.8 Parasite infections of mice  
 
Cre-ERT2 x T-betfl/fl Het/Hom mice and littermate WT/Hom control mice were infected with 
either Nippostrongylus brasiliensis (Nippo) or Heligmosomoides polygyrus (H. poly) via oral 
gavage. The mice were sacrificed after either 7 or 9 days depending on the experiment and 
intestinal egg and worm counts were performed. Upon sacrifice, organs were excised and taken 
to King’s College London, where the cells were extracted using the above methods and flow 
cytometry analysis could be performed. These parasite infections were set up and analysed in 






2.9 Cell culture 
 
Unfractionated single cell suspensions of splenocytes (2x106/mL), mLN (1x106/ml) and cLP 
cells (1x106/mL) were cultured in complete animal medium (as described before) for 48 hours 
in a CO2 controlled incubator at 37°C and 5% CO2. Sorted CD4
+ T cells were also cultured on 
pre-incubated anti-CD3/anti-CD28 bound plates and given IL-2 (Sigma-Aldrich).  
 
For CD4+ T cell skewing experiments, sorted CD4+ T cells were also cultured on pre-incubated 
anti-CD3/anti-CD28 bound plates and then specific cytokines were added for either TH0, TH1, 
TH2, TH17 and Treg skewed conditions. These cultures were kept in sterile conditions and in a 
CO2 controlled incubator at 37°C and 5% CO2 for 7 days. Cells were split and monitored under 
a microscope during the entire culture period. These conditions are listed in Table 1 below. 
Supernatants were harvested, and cytokines concentrations measured by ELISA (R&D systems 
or eBiosceince).  
 
Table 2: List of T cell skewing conditions 
All skewing conditions for CD4+ T cell skewing cultures used and cultured for seven days, with the first two days 
on pre-incubated anti-CD3/anti-CD28 plate.  
 
 












































2.10 Ex vivo colon organ culture 
 
3mm punch biopsies (Miltex) were used to acquire colon biopsies from murine colons at full 
thickness. 3 biopsies were cultured in 500μL of complete animal RPMI for 48 hours in a CO2 
controlled incubator at 37°C and 5% CO2. Culture supernatants were harvested, and cytokine 




Cytokine concentrations from the supernatants of cultured cells and ex vivo colon organ 
cultures were measured by ELISA. Samples and standards were measured in duplicate. 
Standard curves were created with the standards provided in the kits, in accordance to the 
manufacturer’s protocols. ELISA kits were purchased from Thermo Fisher for the following 
cytokines; IL-17A, IFN, IL-22 and TNFα. 
 
2.12 Flow cytometry 
 
Single suspension extracted cells from the various tissues used were plated out into flow 
cytometry tubes (Sarstedt) at a concentration of 1 x 106 per ml. Cells were stimulated with 
50ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich) and 1μg/ml ionomycin 
(Sigma Aldrich) for 4 hours. For any intracellular staining, 2μM monensin (Sigma Aldrich) 
was added for the final 2 hours to inhibit intracellular protein exportation. FcR receptor 
blocking antibodies were added at a concentration of 1:100 for 15minutes at 4°C. Next, surface 
staining antibodies were added together with live/dead stain (Invitrogen) and incubated for 20 
minutes at room temperature in the dark. After incubation, cells were washed and spun down 
in sterile PBS. Cells were ready to be analysed by the BD LSRFortessa machine (BD 
Biosciences). For intracellular staining, cells were fixed and permeabilised using the Foxp3 
fixation/permeabilization buffer kit (Thermo Fisher). The Foxp3 fix/perm buffer was used 
following the manufacturer’s instructions. Following staining, cells were washed and 
resuspended in sterile PBS and stored in the dark at 4°C awaiting acquisition. Cells were 
acquired within 24 hours of staining. Fluorochromes used are listed in Table 2. Samples were 




in FCS 3.0 data format using BD FACSDiva 6.0 software (BD Biosciences). Analysis of the 
data was performed using FlowJo software (Treestar Inc., Ashland, OR, USA).  
 
Compensation of the experiments were carried out using compensation beads, OneComp Beads 
and UltraComp Beads (BD Biosciences). Compensation beads were stained with a single 
fluorochromes conjugated with monoclonal antibody, which are the same as used to label the 
cells in the same experiment. Compensation beads were labelled and stained for 20 minutes at 
room temperature and in the dark. Unstained cells were also used for negative staining. 
Unstimulated and monensin only administered cells were also used for negative stimulation 
staining of cytokines. Isotype and Fluorescence-Minus One (FMO) samples were also used to 
set up negative control staining of either surface markers or intracellular staining of 
transcription factors. BD FACSDiva software automatically calculate the compensation for the 
spectral overlap values. These were inspected manually, and any necessary manual corrections 
or fine tuning of the compensation values were adjusted.  
 
Antigen Clone Company 
Live Dead Fixable blue or aqua Thermo Fisher 
CD45.1 A20 Biolegend 
CD45.2 104 Biolegend 
CD3 17A2 Thermo Fisher 
CD4 RM4-5 Biolegend 
CD8 53-6.7 Biolegend 




CD62L MEL-14 Biolegend 
CD25 PC61 Biolegend 
CD127 (IL-7R) A7R34 Biolegend 
CD27 LG.7F9 Thermo Fisher 
CD28 37.51 Biolegend 
CD49d R1-2 Thermo Fisher 
CD95 15A7 Thermo Fisher 




CD122 (IL-2R) TM-b1 Thermo Fisher 
CCR7 4B12 Biolegend 
CXCR3 CXCR3-173 Biolegend 
T-bet 4B10 Biolegend 
RORγt B2D Thermo Fisher 
Foxp3 FJK-16S Thermo Fisher 
GATA3 LS0-823 BD Biosciences 
IL-10 JES5-16E3 Thermo Fisher 
IL-5 TRFK5 Biolegend 




γδTCR GL3 Thermo Fisher 
CD1d tetramer PBS57-loaded or -unloaded CD1d tetramers  
NIH Tetramer 
Core Facility 
F4/80 BM8 Thermo Fisher 
B220 RA3-6B2 Thermo Fisher 
TRAIL N2B2 Thermo Fisher 
DX5 DX5 
BD Biosciences 
/ Thermo Fisher 
CD11c N418 Thermo Fisher 
CD11b M1/70 BD Biosciences 
Ly49D eBio4E5 Thermo Fisher 
Ly49H 3D10 Thermo Fisher 
Ly49E/F CM4 Thermo Fisher 
Ly49G2 eBio4D11 Thermo Fisher 
Granzyme B NGZB Thermo Fisher 
Perforin eBioOMAK-D Thermo Fisher 
Nkp46 29A1.4 Thermo Fisher 
NK1.1 PK136 Thermo Fisher 
NKG2D CX5 Thermo Fisher 




c-kit ACK2 Thermo Fisher 




consisting of: CD3 (17A2), B220 (RA3-6B2), CD11b 
(M1/70), TER-119 (TER-119), Gr-1 (RB6-8C5) Thermo Fisher 
ICOS C398.4A Thermo Fisher 
Ter119 Ter119 Thermo Fisher 
Gr-1 RB6-8C5 Thermo Fisher 
MHCII M5/114.15.2 Thermo Fisher 
CCR6 29-21.17 Biolegend 
Flt3 A2F10 Thermo Fisher 
α4β7 DATK-32 Thermo Fisher 
Table 3: List of flow cytometry antibodies used for the various panels and experiments.  
All antibodies are anti-mouse antibodies used for flow and have the clone used and the company from where the 
antibody was purchased. 
 
2.13 Cytokine secretion assay 
 
As can be seen from the above, flow cytometry can be used to identify production of cytokines 
from specific cells. However, this also requires fixation and permeabilising the cells 
beforehand and makes the cells unusable.  Therefore, a cytokine secretion capture kit was used 
in order to identify, sort and obtain specific cytokine secreting cells. The mouse IFN-γ secretion 
assay (PE) and mouse IL-17A secretion assay (APC) kit were purchased from Miltenyi Biotec 
and an adapted protocol from a previous PhD student was used. In brief, after cells were 
isolated from colon and mLN, in the previously described protocol, they were resuspended in 
complete media at 1 x 107/ml and stimulated using 1μg/ml ionomycin and 10ng/ml PMA for 4 
hours. After stimulation, cells were then washed and centrifuged twice in 2mls of cold PBS. 
The cells were then resuspended into 90μl/106 of total cells of cold complete media and 
10μl/106 of total cells of mouse IFNγ capture reagent and mouse IL-17A capture reagent were 
added. These cells were then vortexed and incubated on ice for 5 minutes. Next, 1ml/106 of 
total cells of warm (37oC) media was added to the suspension and the cells were incubated for 
45 minutes at 37oC. The cells were gently inverted every 5 minutes during this 45-minute 
incubation in order to resuspend settled cells. Once cells had been incubated for 45 minutes, 




were then washed and centrifuged twice, and cells were once again resuspended into 90μl/106 
of total cells. FcR receptor blocking antibodies were added at a concentration of 1:100 and 
incubated at 4°C for 15 minutes. After this, 10μl per 106 total cells of mouse IFN-γ Detection 
antibody (PE) and mouse IL-17A Detection antibody (Biotin) were added and vortexed and 
incubated on ice for 10 minutes. Cells were then washed with 2mls of cold PBS and 
resuspended again resuspended into 90μl/106 of total cells. Whereby, 10μl per 106 total cells 
of mouse Anti-Biotin-APC and antibodies for CD4 and a Live/Dead stain were added. Cells 
were then vortexed and incubated for 10 minutes on ice. After this, cells were once again 
washed and centrifuged and resuspended in PBS and were ready to be sorted on the BD Aria 
like before with gating on Live CD4+ cells and the different IFNγ+ and IL-17A+ cells. These 
cytokine-producing cells were then further gated by their positive or negative expression of 
YFP.  
 
2.14 Heterotopic Heart Transplant 
 
Heart allotransplantation was performed between whole MHC mismatched BALB/c (H2d 
donors) and C57BL/6 (H2b recipients) mice as described in the protocol by Corry et al. [48]. 
The allograft was kindly performed by a very competent and trained person from Wilson 
Wong's group. After surgery, mice were monitored daily in particular with close attention of 
the graft viability via direct palpitation of the abdomen where the transplanted heart was in 
position. Graft rejection was defined when a cardiac pulse from the graft had stopped. 
 
2.15 Donor Specific Antibody (DSA) Assay 
 
Anti-donor-specific IgG were determined by flow cytometry. This was to determine the level 
of rejection in the cardiac transplant in the Foxp3cre control vs Foxp3cre T-betfl/fl mice. Donor 
splenocytes were used as target cells and single cell suspensions of the splenocytes were 
extracted using the method as previously described. Splenocytes were first incubated with 2% 
BSA, 5% normal goat serum and FcR receptor blocking antibodies for 20 minutes at 4°C. After 
this, a surface stain for CD3 was added and incubated for a further 20 minutes at 4°C. Cells 
were then washed and centrifuged at 1800RPM and the supernatant was resuspended. 
Afterwards, 5µl of serum was added and incubated again at 4°C for 20 minutes. Cells were 




added and incubated at 4°C for 20 minutes. After this last incubation, cells were washed and 
centrifuged and resuspended at a suitable volume and ready to be acquired using a BD 
LSRFortessa (BD Biosciences) flow cytometer.  
 
2.16 RNA extraction 
 
RNA extraction was performed using Trizol (Invitrogen) according to the manufacturer’s 
instructions, in an allotted RNA workspace. Equipment and surfaces were cleaned with RNase 
Zap (Ambion Inc., Austin, TX, USA) to decrease nuclease contamination. Cells were 
resuspended in 1ml of Trizol. Samples were either processed immediately or stored at -80°C. 
After culling animals, whole liver segments (3cm) were harvested and snap frozen in liquid 
nitrogen and then stored at -80oC pending RNA extraction. Frozen liver segments were then 
homogenised using a Tissue Lyzer II (Qiagen) with a Stainless-Steel Bead (5mm) (Qiagen) set 
to 25Hz/s for 5 minutes in 1mL Trizol reagent (Invitrogen). 200μl of chloroform (Sigma 
Aldrich) was then added to cells or tissue homogenates, with the sample then mixed and 
incubated at room temperature for 2 minutes. Next, this was centrifuged at 12000 RPM for 15 
minutes at 4°C prior to allow phase separation. The upper aqueous layer was carefully 
transferred to a fresh eppendorf without interrupting the interphase layer, with 500μl of cold 
isopropanol was then added. After mixing the suspension with a vortex, the sample was 
centrifuged for 15 minutes at 4°C. The supernatant was cautiously pipetted out, and 1 ml of 
75% ethanol was added to the pellet to ash it and the suspension was centrifuged for another 5 
minutes at 7500RPM at 4°C. The supernatant was, again, then removed, and the pellet was air 
dried before it was resuspended in an appropriate volume of nuclease-free water. RNA samples 
were then checked for the quality, contamination and concentration using a NanoDrop 
spectrophotometer. RNA was then stored at -80°C awaiting further analysis. 
 
2.17 cDNA synthesis and quantitative PCR 
 
cDNA was generated with the cDNA synthesis kit (Bioline) according to the manufacturer’s 
protocol. Quantitative PCR was used in order to quantify mRNA transcripts, with the use of 
TaqMan gene expression assays (Applied Biosystems, Warrington, UK). Gene expression was 
normalized to the expression of β-actin, as the control housekeeping gene, to generate ΔCT 




The following Taqman qPCR primers were used: IL-17A (Mn00439619), IFN- 
(Mn01168134), IL-4 (Mn99999154), IL23p19 (Mn00518984), IL12p40 (Mn00434165) and β-
actin (4352341E). 
 
2.18 Liver histology  
 
2-3cm segments of liver were fixed in 10% paraformaldehyde. 5μm sections were stained with 
either haematoxylin and eosin, NKp46 or F4/80 depending on the sample and slides. Liver 
histology preparation and staining was performed by Professor Robert Goldin at the 
Department of Cellular Pathology at Imperial College London. 
 
2.19 ALT measurements of mouse serum 
 
After an approved Schedule 1 method of CO2 killing, around a maximum of 1ml of blood was 
drawn up via a cardiac puncture. The blood was then spun down in a centrifuge at 1000g for 
20 minutes and carefully pipette out the aqueous serum layer. The serum was then analysed for 
ALT levels by staff at the Pathology and Diagnostic Laboratories at the Royal Veterinary 
College  
 
2.20 In vitro Tamoxifen treatment 
 
For the in vitro tamoxifen experiments, specific in vitro 4-OHT tamoxifen was purchased from 
Sigma (Cat no: H7904). After the spleens and mLNs of ERTH2cre x T-betfl/fl mice were 
harvested via approved Schedule 1 method and cells were extracted as previous described. CD4 
T cells were sorted and plated out on a pre-incubated CD3/CD28. In vitro tamoxifen was given 
to the cells at a concentration of either 0, 0.25, 0.5, 1 or 2µM and for either 0, 4, 6, 12 or 24 
hours. In other experiments, cells were plated out at 0.5x106 per well and TH1 skewing 
cytokines, as shown in Table 1, were given. After day 2, the cells were removed from the anti-







2.21 In vivo Tamoxifen treatment 
 
For in vivo tamoxifen treatment of the ERTH2cre x T-betfl/fl mice, the specific in vivo 4-OHT 
tamoxifen was purchased from MP Biomedicals (Cat no: 02156738). The stock was initially 
dissolved in ethanol, before then being diluted in sunflower oil at a concentration of 
10mg/1000µl and then stored at -80°C. Before injecting the diluted tamoxifen, this tamoxifen 
was heated to 37°C prior to administration. 100µl (1mg) of warmed tamoxifen was given per 
mouse by intraperitoneal injection on 3 days either consecutively or over a 5 day period (Geiser 
et al., 2012), after which were left for two weeks before analysis. Mice were monitored for 
their weight for the duration of the period. Mice were checked for T-bet deletion two weeks 
after administering tamoxifen. 
 
2.22 Statistical analysis 
 
Statistical analyses were carried using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, 
CA, USA). Non-parametric data were analysed using the Mann-Whitney test and normally 
distributed data were analysed using the Student’s T-test. For grouped data, a non-parametric 
1-way ANOVA test (Kruskal-Wallis test) with Dunn’s corrections were performed.  Statistical 



















Results: Characterisation of immune cells in T-betcre x 
ROSA26YFPfl/fl mice 
 
As described in Chapter 1, T-bet is expressed in many subsets of cells within the innate and 
adaptive immune system, including CD4+ T cells, CD8+ T cells, NK cells, ILCs, DCs, 
macrophages, B cells, NKT cells and γδT cells (Intlekofer et al., 2005, Lighvani et al., 2001, 
Liu et al., 2003, Lugo-Villarino et al., 2003, Powell et al., 2012, Szabo et al., 2000, Townsend 
et al., 2004, Yin et al., 2002).  
 
Since T cells (CD4, CD8, NKT and γδT cells) develop in the thymus, phenotyping of the 
thymus was performed in these cells. Upon entering the thymus, these lymphoid progenitors 
become committed to becoming T cells (Germain, 2002). At this stage, the cells are called 
“Double-Negative” (DN) as they do not yet express CD4 or CD8, but double negative 
thymocytes have been shown to express differing levels of CD44 and CD25 depending on what 
stage of the double negative development they are in (Godfrey et al., 1993).  DN1s are 
identified as CD3- CD25- CD44+ and are able to give rise to αβ T cells, γδ T cells, NK cells, 
dendritic cells, macrophages, and B cells. DN1s actually consist of 5 DN1 stages (DN1a-e), 
which are characterised by their expression of CD117 and CD24. The expression of CD117 at 
the DN1a-b stage has been shown to be the most important for the DN1 to give rise to the T 
cell lineage (Porritt et al., 2004). Upon establishing the T cell specific lineage DN1s progress 
onto DN2s by expressing CD25 as well, thus are identified as CD3- CD25+ CD44+. After 
progressing into DN2, where they migrate to the cortex of the thymus, the T cells begin 
rearrangement of their T cell receptors using the recombinant-activating genes 1 and 2 (RAG1 
and RAG2) to rearrange the V(D)J rearrangement of the variable (V), diversity (D) to the 
joining (J) region (Mombaerts et al., 1992). DN2s that have successfully formed an invariant 
pre-TCRα stop expressing CD44 and express CD25 only and become DN3s. DN3s which have 
been able to successfully rearrange their TCRβ associates with the invariant pre-TCRα chain. 
At this point, it also associates with CD3 to form the pre-TCR complex(van Oers et al., 1995) 




progression to the DN4 stage. Upon becoming DN4s, the thymocytes quickly express CD8 
first, followed by CD4; becoming double positive cells (DP) (C A Janeway, 1992). DP cells 
then begin TCRα rearrangement to produce the αβ T cell receptor. DP cells in the thymus make 
up around 90% of the lymphoid cells in a young individual’s thymus. Positive selection occurs 
at the DP stage, where the cells are exposed to either MHCI or MHCII on cortical epithelial 
cells, to define if they are CD4s or CD8s. Positive selection supposedly takes a few days to 
occur and interaction between the TCRαβ and either MHCI or MHCII needs to be continual in 
order for that DP to be positively selected. Most DPs do not interact and have enough signal 
from the MHC and/or costimulatory molecules and are left to die by neglect. Depending on 
their interaction with MHCI or MHCII and costimulatory molecule interaction, the DP 
becomes a “single-positive” (SP) CD4+ or CD8+ T cell. MHCI defines the DP into CD8+ and 
MHCII defines it into a CD4+ T cell. These CD4+ and CD8+ SP cells enter the medulla of the 
thymus and undergo negative selection. This is where the SP cells interact with medullary 
epithelial cells and thymic dendritic cells, some of which have self-antigen presented on their 
MHC. A small proportion of these SP cells that interact with these self-antigens are negatively 
selected and receive apoptosis signals and the cells that respond to self-antigen are killed (E 
Robey and Fowlkes, 1994, Starr et al., 2003, von Boehmer et al., 1989, Radtke et al., 1999). 
The resulting SP CD4+ and CD8+ T cells are the mature naïve T cells that leave the thymus and 
enter the periphery. As T-bet expression has been reported in these cells after they have 
developed, the expression of any YFP cells in these cell populations during development would 
be interesting and novel.  
 
NKT cells express T-bet during their development process in order to gain their effector 
functions and be able to produce IFNγ (Townsend et al., 2004). NKT cells also develop from 
within the thymus, during the DP stage of lymphocyte T cell development (Godfrey and 
Berzins, 2007). NKT cell selection requires their ligation to glycolipid antigens presented by 
CD1d on DP T cells, and then go through a 4 stage developing stage of maturity in order to 
become mature (Godfrey and Berzins, 2007). These are identified by different surface markers 
and are: Immature stage 1 (NK1.1- CD24+ CD44low DX5-), immature stage 2 (NK1.1- CD24- 
CD44low DX5-), immature stage 3 (NK1.1- CD24- CD44+ DX5-), immature stage 4 (NK1.1- 
CD24- CD44+ DX5+) and finally mature NKT cells (NK1.1+), which then exit the thymus and 




mice would be able to identify any T-bet expressed NKT cells within the thymus as they 
develop further to maturity.  
 
γδT cells also develop within the thymus during the DN2-DN3 stage where T cell receptor 
rearrangement occurs. It has also been shown that γδT cells in the periphery can induce the 
expression of T-bet, after signalling through its T cell receptor has been activated. These have 
been shown mainly in the IFNγ-producing γδT cells as opposed to the IL-17A-producing γδT 
cells (Turchinovich and Pennington, 2011). Progenitor γδT cells are the γδT cells that have 
first come from the DN2 phase of T cell development with γδTCRs and express CD24, CD27 
and CD25 (Pang et al., 2012, Ribot et al., 2009). This population then very quickly 
downregulates CD25 and the expression of the γδ receptor rises to form the immature γδT cells, 
which is therefore CD24+ CD27+. From this immature γδT cells, the three mature populations 
arise in the thymus, which all lack CD24 expression. The IL-17A-producing γδT cells is CD24- 
CD27- CD25- CD44+ and the IFNγ-producing γδT cells is CD24- CD27+ CD25-. T-betcre x 
ROSA26YFPfl/fl mice will be capable of identifying any T-bet fate expressed γδT cells, and not 
just in the expected IFNγ γδT cell. 
 
The lymphoid progenitor, which enters the thymus for the T cell development described above, 
develops and originates from the bone marrow. Thus, the bone marrow was phenotyped with 
respect to the expression of YFP. The common lymphoid progenitor (cLP), which can 
differentiate into T, B and NK cells, the common helper-like ILC progenitor (ChILP), which 
is the progenitor for ILC1s and ILC3s, and lastly the ILC2 progenitor (ILC2p), which only give 
rise to GATA3+ ILC2s all originate from the bone marrow. cLPs are identified as being lineage- 
IL-7R+ α4β7- Flt3+ c-kit+, ChILPs are identified by lineage- IL-7R+ α4β7+ Flt3- CD25- and 
ILC2ps are identified as lineage- IL-7R+ α4β7+ Flt3- CD25+ (Klose et al., 2014, Kondo et al., 
1997, Parigi et al., 2018, Xu et al., 2015). 
 
For the periphery, the spleen is the main organ that helps to polarise the immune cells during 
an infection. It is the largest lymphoid organ and its main function is to drain the blood (Morris 
and Bullock, 1919). Therefore, the spleen was the first site in the periphery to be extensively 




main mucosal sites of inflammation during inflammatory bowel disease. Colitis models will be 
used in Chapter 4 to phenotype the YFP+ cells in a disease setting. 
 
The use of mouse models has allowed research into subsets of cells during development at both 
a steady healthy state and also during an inflammatory response. For the purposes of this thesis, 
in order to study the role of T-bet in these immune cells, a newly developed mouse line has 
been crossed using two genetic manipulated mouse breeds. The T-betcre line was generated 
within the lab by a previous colleague (Gökmen et al., 2013). In brief, a knock-in by introducing 









Figure 6: Schematic showing the strategy of generating the T-betcre line 
 
The ROSA26YFP flox line was bought from Jackson and they were bred as heterozygous 
genotype (Rosa-YFPfl/fl+/-) with the homozygous genotype of the T-betcre (T-betcre+/+) in order 
to use the litters from this line. The litters should all be T-betcre+/-(Het) x Rosa-YFPfl/fl+/-(Het). 
 
Use of the T-bet fate mapping mouse line allows the tracking of cells which have previously 
expressed T-bet. This is a novel mouse line which has not been previously documented. The 
initial aim was to characterise the different immune cell compartments: this would give more 
insight into the expression of T-bet in immune cells and aid the understanding of the ontogeny 




3.1 Initial phenotyping of CD45+ lymphocytes in blood, and lymphoid 
organs and mucosal sites of the T-betcre x ROSA26YFPfl/fl mice 
 
Initial phenotyping of the blood of the mouse was performed to ensure that the use of the T-
betcre model was not going to cause excess expression of YFP. The use of cre-lox model can 
cause leakiness especially when cre expressing mice are crossed using homozygous mice (Song 
and Palmiter, 2018). The double homozygous mice (T-betcre+/+(Hom) x Rosa-
YFPfl/fl+/+(Hom)) only had YFP expression in CD4, CD8 and B cells, in comparison with the 
wild type control, which expressed no YFP (Figure 1). This observation made it clear that under 
double homozygous (T-betcre+/+(Hom) x Rosa-YFPfl/fl+/+(Hom)) breeding, the mice 
expressed too much Cre, resulting in all cells expressing YFP. The double heterozygous mice 
(T-betcre+/-(Het) x Rosa-YFPfl/fl+/-(Het)) showed YFP+ cells in the CD4+, CD8+ and B cell 













Figure 7. Phenotyping the blood of the T-betcre x ROSA26YFPfl/fl showed all subtypes of cell to only express 
YFP in double homozygous mice 
A. Representative flow cytometry plots showing CD4, CD8 and B220 cells in stained samples in blood of either 
wildtype, T-betcre+/- x Rosa-YFPfl/fl+/- Het/Het or T-betcre+/+ x Rosa-YFPfl/fl+/+ Hom/Hom mice. Cells were 
gated on live cells using flow cytometry, (n=3 of each genotype) 
7A Phenotyping of the blood of T-betcre





Once the use of T-betcre+/- x Rosa-YFPfl/fl+/- Het/Het mice was established, further initial 
phenotyping was performed on CD45+ lymphocytes in the colon, mLN and spleen of healthy 
T-betcre x ROSA26YFPfl/fl mice. This was to estimate the percentage of YFP expected within 
the lymphocyte population in this mouse. The percentage of YFP expressing CD45+ cells was 
small but significantly different within each organ: 15% in the spleen and around 5-10% in the 














Figure 8. Phenotyping YFP expression in the CD45+ lymphocytes in the colon, mLN and spleen 
A. Representative flow cytometry plots and dot plot showing CD45+ cells in stained samples in either normal 
C56BL/6 wildtype or T-betcre x ROSA26YFPfl/fl Het/Het mice. Cells were gated on live cells using flow cytometry 
(n = 3, colon pooled into 1). Kruskal-Wallis test performed with Dunn’s corrections showing overall analysis for 
all groups.  
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3.2 Phenotyping YFP expression in lymphoid and myeloid cells of the T-
betcre x ROSA26YFPfl/fl mice 
 
After initial phenotyping of the blood and CD45+ population, a basic investigation into specific 
cell types was performed to determine YFP expression within the lymphocyte and myeloid 
compartments. Three simple panels to look at NK cells, ILCs, T cells, B cells and myeloid cells 
in adult mice were used. Figure 9A, 9B and 9C show the gating strategy for each of the panels 
using the spleen of these mice. The spleen, being the main secondary lymphoid organ, would 
be ideal to identify these cell populations as it is where most immune regulation occurs.  
For these panels, NK cells were identified as lineage- (consisting of CD3, CD5, Gr-1, CD11c, 
F4/80, CD19, Ter119) CD45+ NKp46+ NK1.1+; and NKT cells as lineage+ CD45+ NKp46+ 
NK1.1+. Although this very loosely identified the NK cells, the gate also included NKp46+ 
ILC1s and ILC3s. As NKT cells were gated on lineage, and, as CD3+ staining and gating for 
the NKp46+ population within this, was used to identify the NKT cells. NKT cells recognise 
glycolipids via presentation by MHC-like CD1d molecules and this marker will be used later 
in NKT cell development in the thymus.  
The lymphoid panel gave an initial, but useful, phenotyping of YFP+ expression in CD4+ T 
cells, CD8+ T cells and CD19+ B cell as shown by the gating strategy below. 
Finally, the myeloid panel used gave an early insight into the YFP expression in these mice for 
the populations identified as dendritic cells (CD45+, CD11c+, MHCII+ and F4/80-) and F4/80+ 

































Figure 9. Phenotyping YFP expression in subsets of innate and adaptive immune cells in the spleen 
A. Flow cytometry gating strategy showing the strategy for gating of NK and NKT cells in the T-betcre x 
ROSA26YFPfl/fl. B. Flow cytometry gating strategy showing the strategy for gating of lymphoid cells in the T-
betcre x ROSA26YFPfl/fl. C. Flow cytometry gating strategy showing the strategy for gating of myeloid cells in the 
T-betcre x ROSA26YFPfl/fl. D. Flow plots of the different populations highlighted from the gating strategies 
showing the amount of YFP+ expression in each population. E. Dot plot of the different populations highlighted 
from the gating strategies showing the amount of YFP+ expression in each population (n = 3). Kruskal-Wallis test 















































































































The flow plot and the dot plot for the results of the phenotyping panels displayed significantly 
differing percentage of YFP+ cells in the different identified populations (P=0.0043). From the 
initial phenotyping, there was around 10% of YFP+ CD4+ T cell and 20% of CD8+ YFP+ T 
cells. NKT and NK cells were almost all YFP+ and this was consistent as T-bet expression is 
required for both NKT and NK cells to become fully mature during development, but once they 
have reached terminal maturation they no longer require T-bet in order for their survival 
(Godfrey et al., 2010, Matsuda et al., 2006, Townsend et al., 2004). The 3% of splenic B cells 
were shown to be YFP+. B cells have been shown to express T-bet in a pathological response 
disease during class switching to IgG2A and promote the survival of these subsequent IgG2A 
memory B cells (Liu et al., 2003). These mice were healthy and therefore, as expected, only a 
small proportion of B cells were YFP+. The F4/80+ and CD11c+ cell populations were identified 
to be monocytes and dendritic cells respectively and both require the expression of T-bet to 
produce IFNγ in response to disease (Lighvani et al., 2001, Lugo-Villarino et al., 2005, Lugo-
Villarino et al., 2003). Again, since these mice were phenotyped during a steady healthy state, 
the percentages of YFP+ F4/80+ and CD11c+ shown are relatively low. 
3.3 Extensive phenotyping of immune T cells within the thymus 
The initial phenotyping of most cell types in the spleen showed that the mouse itself was a 
beneficial and reliable model. Since the key role of T-bet is the master regulator of TH1 cell 
differentiation from naïve T cells in the periphery, phenotyping of the thymus was performed 
next, as this is the site of CD4+ T cell development. However, as already stated, T-bet has been 
shown to be expressed in developing NKT cells and γδT cells. Both these populations also 
develop in the thymus before entering the periphery, therefore these developing cell types were 
also extensively phenotyped. 
3.3.1 Phenotyping CD4+ and CD8+ T cell development in the thymus 
Gating strategy (Figure 10) of the YFP expression in the developing T cells in the thymus of 









Figure 10: Gating strategy used to identify the different CD4 and CD8 T cells in the thymus 
A. Representative flow plots showing the gating strategy used for each T-betcre x ROSA26YFPfl/fl thymus. Each 
important subtype is outlined in blue. 
 
 
T-bet is not required for the development of CD4+ or CD8+ T cells as the cells should still be 
naïve and not have been exposed to any antigen. Therefore, no YFP expression should be seen 
in the thymus. Using the gating strategy from Figure 10, Figure 11 shows the results of YFP 













Figure 11: Phenotyping the YFP expression within the CD4 T cell compartment in the thymus 
A. Representative flow plots (all gated as shown previously) showing expression of YFP in the T-betcre x 
ROSA26YFPfl/fl compared with a litter mate wild-type control for DN1 (CD3- CD44+ CD25-), DN2 (CD3- CD44+ 
CD25+), DN3 (CD3+ CD44- CD25+), DN4 (CD3+ CD44- CD25-), DP (CD3+ CD4+ CD25+), naïve CD4+ T cells 
(CD3+ CD4+ CD8- CD62L+ CD44-), memory CD4+ T cells (CD3+ CD4+ CD8- CD62L- CD44+) and regulatory 
CD4+ T cells (CD3+ CD4+ CD8- CD25+). B. The dot plot showing the compiled results of the phenotyping results 
of the T-betcre x ROSA26YFPfl/fl mice (n = 12). Kruskal-Wallis test performed with Dunn’s corrections showing 






T cell development in the thymus in the T-betcre x ROSA26YFPfl/fl showed significantly 
interesting results when comparing the amount of YFP+ cells in some of different developing 
cell types (P<0.0001). DN1s and DN2s seemed to have a high percentage of YFP+ cells (around 
30% and 5% respectively), which should not have been the case in terms of developing T cells. 
The initial hypothesis was that these YFP+ T cells were being negatively selected due to their 
expression of T-bet. However, due to this limited panel and gating these experiments do not 
rule out these cells as either thymic resident NK cells or developing NKT cells and as CD117 
and CD24 were not included in this panel they could not be defined as solely T cell specific 
lineage DN1s and DN2s. Further analysis using extensive panels for thymic NK and 
developing NKT cells will be shown in the next section. As expected, in the other developing 
T cells, the DN3s, DN4s and DP cell populations were completely negative (0%) for YFP 
expression. Single positive naïve CD4s were also fully negative (0%) for expression of YFP, 
which is expected as the naïve CD4s had yet to leave the periphery, encounter antigens and 
become activated. There was a small population (around 2-3%) of effector (CD62L- CD44+) 
CD4+ T cells found within the thymus that expressed high levels (around 50%) of YFP. These 
effector memory CD4+ T cells are the effector memory CD4+ T cells that are found within the 
thymus to help protect it during disease (Mueller and Mackay, 2015) and explains the high 
level of YFP. Lastly, CD4+ CD8- CD25+ T regulatory cells showed around 5% of YFP 
expression. A small proportion of Tregs have been shown to express T-bet as TH1-like Tregs that 
are able to produce IFNγ and rely on the expression of CXCR3 to migrate to areas of 
inflammation and disease (Pandiyan and Zhu, 2015, Stock et al., 2004).  
3.3.2 Phenotyping YFP+ thymic resident NK and NKT cells in the 
thymus 
The CD25- CD44+ and CD25+ CD44+ identified cells shown previously had unexpectedly high 
levels of YFP expression. These could not be solely defined as specifically T cell specific 
lineages of DN1s or DN2s; due to the lack of CD117 and CD24 markers within the gating 
strategy. Moreover, surface markers used previously did not encompass thymus resident cells, 
for example thymic NK cells. Further experiments were performed to identify these cells. 
Figure 12 shows analysis of the YFP+ CD25- CD44+ and CD25+ CD44+ in comparison with the 
YFP- CD25- CD44+ and CD25+ CD44+ cells. This experiment looked at expression of NK and 































Analysis of the YFP+ vs YFP- CD25- CD44+ cells in the thymus 
12A 
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Figure 12: Flow cytometry analysis of the CD44+ CD25- YFP+ and CD44+ CD25+ YFP+ cells in the thymus 
A. Representative flow plots of live CD4- CD8- CD44+ CD25- from the thymus of T-betcre x ROSA26YFPfl/fl mice. 
B. Representative flow plots of analysis of live CD4- CD8- CD44+ CD25+ from the thymus of T-betcre x 
ROSA26YFPfl/fl mice. C. Representative flow plots showing analysis of individual NK and NKT markers on YFP- 
and YFP+ cells in both CD44+ CD25- and CD44+ CD25+. (n = 6) 
 
Analysis of the CD44+ CD25- (Figure 12A) showed that the majority (77%) of YFP+ CD44+ 
CD25- cells expressed either NK (35% for CD127+ NK1.1+ CD122+) or NKT (42% for CD122+ 
NK1.1+ CD3e+) markers. These YFP+ cells could be either thymic resident NK cells that 
develop from the CD44+ CD25- population or developing NKT cells. Figure 12B shows the 
analysis of the CD44+ CD25+. This population of cells are present in a smaller number and are 
12C 
Analysis of the individual NK and NKT markers on both YFP- and YFP+ CD25- 




therefore more difficult to analyse, but they follow the same general pattern as the CD44+ 
CD25- population. 90% of the YFP+ cells expressed CD127+ and NK1.1+ identifying them as 
thymic resident NK cells. As there is no YFP expression after the DN2 stage (in the DN3 and 
DN4 shown in Figure 11) and with cells entering the DN3 stage believed to have fully 
committed to the T cell lineage, this is also evidence to support the notion that the YFP+ DN 
cells are not cells, which are committed to the T cell lineage: T-bet is not expressed by DN T 
cell precursors. Both CD44+ CD25- YFP+ and CD44+ CD25+ YFP+ cell populations expressed 
high levels of either NK markers in comparison with their YFP- counterparts (Figure 12C).  
3.3.3 Phenotyping γδT cell development in the thymus 
As previously described, γδT cells develop within the thymus too. Since IFNγ production is 
dependent on T-bet expression to be able to produce IFNγ, use of this mouse line will be able 
to trace the lineage of these IFNγ-producing γδT cells from their developmental stages. As 
stated before, γδT cells also develop within the thymus (Turchinovich and Pennington, 2011). 
Using the below gating and flow cytometry panel, I have potentially identified some of the 
developing γδT cells for the purpose of analysing T-bet fate mapped γδT cells. In this case, 
progenitor γδT cells were identified as CD3+ TCRγδ+ CD25+ CD24+ CD27+, immature γδT 
cells were identified as CD3+ TCRγδ+ CD25- CD24+ CD27+, IFNγ-producing γδT cells that 
eventually leave the thymus were identified as CD3+ TCRγδ+ CD25- CD24- CD27+, which 
typically encompasses the γδT cells found in the lymph nodes, gut, spleen and liver. Finally 
there were possibly two IL-17A producing γδT cells that could potentially exist within this 
gating strategy from the thymus, CD3+ TCRγδ+ CD25- CD24- CD27- which are usually found 
in the lymph nodes, and CD3+ TCRγδ+ CD25+ CD24- CD27-, which are typically found in the 















































Gating Strategy for γδ T cells in the thymus 
13B 


















Figure 13: Phenotyping the YFP expression in developing γδT cell in the thymus of T-betcre x 
ROSA26YFPfl/fl mice. 
A. Representative flow plots showing the gating strategy used to identify γδT cell in the thymus of T-betcre x 
ROSA26YFPfl/fl mice. B. Representative flow plots showing YFP+ expressing cells of the four populations of 






), immature γδT cells (CD25- CD27+ CD24+), 
IFNγ-producing γδT cells (CD25- CD24- CD27+) and the two IL-17A-producing γδT cells (CD25- CD27- CD24- 
and CD25+ CD27- CD24+), from the thymus of T-betcre x ROSA26YFPfl/fl mice. C. Dot plot showing the mean 
percentage of YFP+ expressing cells from the different stages of γδT cells development (n = 6). Kruskal-Wallis 
test performed with Dunn’s corrections showing overall analysis of P<0.0001 for all groups. Individual 
comparisons are shown also using the same Kruskal-Wallis test. 
 
Figure 13B and 13C show significant differences in the percentage of YFP+ cells from the 
phenotyping results of the γδT cells in the thymus during development. As expected, in the 
progenitor (CD3+ TCRγδ+ CD25+ CD24+ CD27+) γδT cells there was no YFP+ expression in 
any of the cells. Surprisingly, there is a significant increase when the progenitor γδT cells 
downregulate CD25 expression and become immature (CD3+ TCRγδ+ CD25- CD24+ CD27+) 
γδT cells and this was shown by around 20% of them being YFP+, meaning that some of the 
cells have expressed T-bet despite not being fully mature. These YFP+ immature γδT cells could 
be predisposed to becoming IFNγ-producing γδT cells. As expected, the biggest population of 
YFP+ γδT cells were the IFNγ-producing (CD3+ TCRγδ+ CD25- CD24- CD27+) γδT cells with 
almost 60% of the cells being YFP+. Interestingly, there was a small population (around 8%) 



















































































of CD25- CD24- CD27- IL-17A-producing γδT cells that are YFP+, but there was no YFP+ cells 
in the CD25+ CD24+ CD27- IL-17A-producing cells.  
3.3.4 Phenotyping NKT cell development in the thymus 
Similar to the γδT cell and CD4 and CD8 T cell populations, mature NKT cells also develop in 
the thymus from an immature state. NKT cells were gated as shown below in Figure 14A. 
Developing NKT cells were identified as immature stage 1 (NK1.1- CD24+ CD44low DX5-), 
immature stage 2 (NK1.1- CD24- CD44low DX5-), immature stage 3 (NK1.1- CD24- CD44+ 
DX5-) and finally mature NKT cells (NK1.1+ CD44+). Interestingly, immature stage 4 NKT 




















































Figure 14: Phenotyping the YFP expression in developing NKT cells in the thymus of T-betcre x 
ROSA26YFPfl/fl mice 
A. Representative flow plots showing the gating strategy used to identify NKT cell in the thymus of T-betcre x 
ROSA26YFPfl/fl mice. B. Representative flow plots showing YFP+ expressing cells of the four populations of 
developing NKT cells: Immature 1 NKT cells (CD44- CD24+), immature 2 NKT cells (CD44- CD24-), immature 
3 (CD44+ CD24- NK1.1-) and mature NKT cells (CD44+ NK1.1+), from the thymus of T-betcre x ROSA26YFPfl/fl 
mice. C. Dot plot showing the mean percentage of YFP+ expressing cells from the different stages of NKT cells 
development. (n = 12) Kruskal-Wallis test performed with Dunn’s corrections showing overall analysis of 
P<0.0001. 


















































































Figure 14C show that there is a significant difference in the percentage of YFP+ cells in the 
developing NKT cell stages. Both Figures 11B and 11C show that the immature stage 1 NKT 
cell begin demonstrating no YFP expression, but as the NKT cell develops further along its 
developmental stages the percentage of YFP+ expressing cells increases substantially per stage 
of development. The immature stage 2 NKT cells showed around 5-10% cells expressing YFP, 
the immature 3 NKT cells varied from around 15% up to 40% of cells expressing YFP and 
lastly a majority of the mature NKT cells were YFP+ (around 60-90%).  
3.4 Phenotyping of progenitor cells in the bone marrow 
Upon phenotyping the T lymphocyte populations in the thymus, it was important to research 
the cells in the bone marrow; since the common lymphoid (cLP) enters the thymus after 
developing from within the bone marrow. Phenotyping of the bone marrow was performed to 
investigate the YFP expression of progenitor cells. The cells phenotyped were the cLP, ChILP 
















































Figure 15: Phenotyping of YFP expression in the lymphoid precursors in the bone marrow of T-betcre x 
ROSA26YFPfl/fl mice 
A. Representative flow plots showing the gating strategy used to identify the different precursor cells (labelled in 
blue) in the bone marrow of T-betcre x ROSA26YFPfl/fl mice. B. Representative flow plots showing YFP+ 
expressing cells of the three populations of progenitor cells: common lymphoid progenitor (lineage- (CD3- CD5- 















CD25+), from the bone marrow 
of T-betcre x ROSA26YFPfl/fl mice. C. Dot plot showing the mean percentage of YFP+ expressing cells from the 
progenitor population in the bone marrow (n = 4). 
 
From these results, there was a trend to see that potentially there was no YFP+ expression in 
either the cLP, ChILP, ILC2p, in the bone marrow as expected. However, this was only tested 
on a small number of mice and should be checked on a few more mice just to absolutely confirm 
the lack of YFP+ cells in the bone marrow of these mice.  
3.5 Phenotyping of immune cells in the peripheral organs 
3.5.1 Phenotyping T cells in the spleen and colon 
Following on from the developing T cells in the thymus, the focus was to phenotype the CD4+ 
and CD8+ T cells in the periphery. Figures 16A show the gating strategy used to identify the 
different subpopulations CD4+ and CD8+ T cells in the spleen and colon. 
Analysis of the YFP+ progenitor cells  
in the bone marrow 
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Gating Strategy of CD4 and CD8 T cells in both spleen and colon 16A 



























Figure 16: Phenotyping of the spleen and colon showing YFP+ expression in naïve CD4+ T cells in the T-
betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots showing the gating strategy used to identify the different CD4+ and CD8+ cells in 
the spleen and colon of T-betcre x ROSA26YFPfl/fl mice. B. Representative flow plots showing YFP+ expressing 
cells of the six populations gated for: naïve CD4+ T cells (CD3+ CD4+ CD8- CD25- CD62L+ CD44-), effector 
CD4+ T cells (CD3+ CD4+ CD8- CD25- CD62L- CD44+), regulatory T cells (CD3+ CD4+ CD8- CD25+), naïve 
CD8+ T cells (CD3+ CD4- CD8+ CD62L+ CD44-), effector CD8+ T cells (CD3+ CD4- CD8+ CD62L- CD44+) and 
central memory CD8+ T cells (CD3+ CD4- CD8+ CD62L+ CD44+) from the spleen of T-betcre x ROSA26YFPfl/fl 
mice. C. Representative flow plots showing YFP+ expressing cells of the six populations gated for: naïve CD4+ T 
cells, effector CD4+ T cells, central memory CD4+ T cells (CD45+ CD4+ CD8- CD62L+ CD44+), regulatory T 
cells, naïve CD8+ T cells and central memory CD8+ T cells from the colon of T-betcre x ROSA26YFPfl/fl mice. D. 
Dot plot showing the mean percentage of YFP+ expressing cells from the different subtypes of T cells in the spleen 
(n = 9) and colon (n = 6). Kruskal-Wallis test performed with Dunn’s corrections showing overall analysis of 
P<0.0001 for all groups. Individual comparisons are shown also using the same Kruskal-Wallis test. 
YFP expression in T cell populations in the colon 16C 


























































































































































































































































Both CD4+ and CD8+ of naive T cells had not yet encountered foreign antigen on their 
respective TCR to undergo differentiation and activation. However, both naïve cell types left 
the thymus completely YFP-, and yet in the spleen and colon, the two naïve subsets of CD4+ 
and CD8+ T cells both showed cells that were YFP+. Around 2-3% of naïve CD4s and around 
16% of naïve CD8s in the spleen, and around 2-3% of naïve CD4s and 1% of naïve CD8s in 
the colon were YFP+. The effector CD4s showed around 25% of YFP+ cells in both the spleen 
and the colon. Some Tregs express T-bet, and the same percentage as seen in the thymus, around 
5% of YFP+ cells, were also identified in the spleen and colon of the mice. The effector CD8+ 
cells were only present in the spleen of the mice at a healthy state and they had a small 
proportion (around 5%) of YFP+ expressing cells. The central memory CD8+ T cell population 
had a high percentage (around 60% in the spleen and 40% in the colon) of cells that were YFP+.  
 
3.5.2 Phenotyping ILCs in the spleen and colon 
 
ILCs share many features with T cells, as explained previously. The role of T-bet in their 
plasticity and function was investigated using this mouse line, since T-bet plays a role in the 
function and differentiation of ILCs. As the ILC precursor in the bone marrow showed no YFP+ 
cell expression, the ILC populations were loosely phenotyped in the spleen and colon. Figure 
17A shows the gating strategy used for both organs. Data from this initial phenotyping laid 










































Figure 17: Phenotyping of YFP expression in NK cells and ILCs in the spleen and colon of T-betcre x 
ROSA26YFPfl/fl mice 
A. Representative flow plots showing the gating strategy used to identify the different ILC subsets (labelled in 
blue) in the spleen of T-betcre x ROSA26YFPfl/fl mice. B. Representative flow plots showing YFP+ expressing cells 
of the 4 populations gated for: NK cells (lin- (same lineage cocktail as before) IL-7R- Nkp46+ NK1.1+), ILC1s 
(lin- IL-7R+ Nkp46+ NK1.1+), ILC2s (lin- IL-7R+ Nkp46- NK1.1- CD25+ ICOS+), NCR- ILC3s  (lin- IL-7R+ Nkp46- 
NK1.1- CD25- ICOS+) and ILC3s (lin- IL-7R+ Nkp46+ NK1.1-), from the spleen and colon of T-betcre x 
ROSA26YFPfl/fl mice. C. Dot plot showing the mean percentage of YFP+ expressing cells from the different 
subtypes of ILCs in the spleen (n=9) and colon (n=6). Kruskal-Wallis test performed with Dunn’s corrections 
showing overall analysis of P<0.0001 for all groups in both spleen and colon. Individual comparisons are shown 
also using the same Kruskal-Wallis test. 
Percentage of YFP+ ILC populations in the spleen and colon 






Figures 17B and 17C show that in the spleen and colon of this mouse there are significant 
differences (P<0.0001) with YFP expressing ILCs in the periphery, despite the precursor cells 
leaving the bone marrow as YFP-. Furthermore, in a healthy state there are not many (around 
0.5-1% in the spleen and colon) lin- IL-7R+ cells present in the periphery. The percentage of 
NK cells in the spleen that expressed YFP+ was high (around 60%) but low (around 10%) in 
the colon. ILC1s require T-bet to develop and differentiate into ILC1s, and around 50% of the 
ILC1s in the spleen and colon were YFP+. There were very few YFP+ ILC2s and NCR- ILC3s 
in both the spleen and colon. Although in the spleen there was still around 10% of YFP+ ILC2s 
and NCR- ILC3s. Whereas in the colon there were hardly any ILC2s to gate on, but there were 
no YFP+ NCR- ILC3s. Finally, ILCs are known to express T-bet when differentiating into 
NCR+ ILC3s upon activation and stimulation. In these mice, there was interestingly around 
33% of the NCR+ ILC3s which were YFP+. Again, the lack of ILCs in the colon made it 
difficult to see the true percentage of YFP+ cells in this organ. 
3.6 Discussion 
The results presented in this chapter show the YFP expression of T-bet in the lineage of 
different cell types in the mouse at a stable phenotypic manner. This novel mouse line has been 
innovative in being able to trace the lineage of cells that have expressed T-bet despite not 
necessarily being T-bet+ at the time. This chapter focussed on the phenotyping of developing 
cells in both the thymus and the bone marrow and subsequent peripheral mature cells. 
 
As expected, the developing thymic SP CD4+ and CD8+ T cells were all YFP-. Double negative 
T cells in the thymus were also YFP-. The results showing the DN1 and DN2 population would 
need further surface markers of CD24, CD117 and CD127; in order to fully determine the 
lineage of the double negative T cell lineage and determine if those DN1 T cells and DN2 T 
cells are truly YFP- or not (Ceredig and Rolink, 2002, Allman et al., 2003, Porritt et al., 2004). 
However, the data shown in these mice showed that the DN3, DN4 and DP cells were all YFP-
. Therefore, since in this mouse model if a cell starts to express the YFP then it stays YFP 
forever due to the excision of the STOP codon. Therefore, since the subsequent phenotyping 
data showed that the T cells further down the development pathway were not yellow, this most 
likely means that the DN1 and DN2 T cell lineage will also be YFP-. Furthermore, the 




CD44+CD25+ they were mainly either thymic resident NK and/or thymic NKT cells with their 
expression of CD122, NK1.1, DX5 and/or CD3e. It has also been shown by others that CD127+ 
thymic NK cells develop from the DN1 (CD44+CD25-) (Vargas et al., 2011). 
 
This model has also demonstrated YFP expression in γδT cell development in the thymus. 
There were interesting findings in the results for the γδT cell development in the thymus. 20% 
of the CD25- CD27+ CD24+ immature γδT cells being YFP+, meaning that some of the cells 
expressed T-bet despite not being fully mature. These YFP+ immature γδT cells could be 
predisposed to becoming IFNγ-producing γδT cells. As expected, a majority of the CD25- 
CD27+ CD24- IFNγ-producing γδT cells showed to be YFP+. A small population of CD25- 
CD24- CD27- IL-17A-producing γδT cells were shown to be YFP+, but there was no YFP+ cells 
in the CD25+ CD24+ CD27- IL-17A-producing cells. It has been shown that γδT cells are able 
to produce both IL-17A and IFNγ spontaneously and do not need to undergo clonal expansion 
(Paul et al., 2014, Ribot et al., 2009). Under inflammatory conditions, it has been shown that 
CD27- γδT cells are also able to produce both IL-17A and IFNγ, which explains why some of 
the CD27- conventional IL-17A-producing γδT cells are YFP+ (Sheridan et al., 2013). The 
limitations of the flow cytometry panel in these experiments meant that it was unable to fully 
characterise the γδT cells in the thymus. Unfortunately, further surface markers are necessary 
for identifying some of the CD25- CD24- CD27+ IFNγ-producing γδT cells, which are CD122+ 
and CD44+, and CD25- CD24- CD27- IL-17A-producing γδT cells have also been shown to be 
CD44+ (Hayday and Pao, 1998, Pang et al., 2012, Ribot et al., 2009, Sheridan et al., 2013). 
Further analysis of γδT could also be achieved using this mouse model since T-bet is required 
for IFNγ in CD27+ γδT cells (Yin et al., 2002), as well as T-bet has also been shown to be 
important in IFNγ production in CCR6+ CD27- IL-17A-producing γδT cells (Barros-Martins 
et al., 2016). Therefore, the lineage of mature γδT cells could be traced back to their 
development in the thymus with further experiments. 
 
Regarding the NKT cell development phenotyping in the thymus, the amount of YFP+ cells 
increased throughout the maturity stages of the NKT cell. As has been shown previously by 
many groups, T-bet is progressivly upregulated and, when absent NKT cells do not mature 






The cLP, ChILP and ILC2 progenitor cells in the bone marrow cells also were shown to be 
YFP-. The cell types in the periphery that were expected to be YFP+ (NK cells, memory CD4, 
memory CD8s, ILC1s and NCR+ ILC3s) were observed. Both naïve cell types left the thymus 
completely YFP-, but there was a small subset of both CD4+ and CD8+ T cells that were YFP+. 
The effector CD4s showed around 25% of YFP+ cells in both the spleen and the colon. Some 
activated CD4+ helper T cells, which have previously seen antigen and become memory cells, 
will have been TH1 T-bet
+ cells and therefore YFP+. Within the thymus, regulatory T cells can 
express T-bet, and the same percentage, around 5% of YFP+ cells that were found in the 
thymus, were also identified in the spleen and colon of the mice. The effector CD8+ cells were 
only present in the spleen of the mice at a healthy state and they had a small proportion (around 
5%) of YFP+ expressing cells. In healthy steady state mice, there will not be as many effector 
CD8s without the activation of the TCR receptor. Upon activation via their TCR by viral 
antigens, CD8s strongly upregulate T-bet (and also EOMES) in order to produce a high amount 
of IFNγ, granzyme B and perforin (Intlekofer et al., 2005). It has been shown that T-bet itself 
becomes downregulated after effector CD8s have cleared a pathogen (Joshi et al., 2011). The 
central memory CD8+ T cell population had a high percentage (around 60% in the spleen and 
40% in the colon) of cells that were YFP+. After an infection has been cleared, 95% of effector 
CD8s die by apoptosis (Kaech and Cui, 2012a), but the remaining cells become central memory 
CD8 T cells. Therefore, of the remaining central memory CD8s, these YFP+ CD8+ T cells may 
be the ones that came from the effector CD8 T cells and allow for early IFNγ response when 
the same virus antigen infection is presented again. 
 
NK cells have been shown to require T-bet in order to mature and also aid in their function to 
produce IFNγ, but they do not require T-bet for NK cell development (Simonetta et al., 2016). 
The high proportion of YFP+ expressing NK cells identified in the spleen was therefore 
expected. In the colon only 10% of the NK cells were shown to be YFP+, but the mucosal sites 
contained fewer cells within the tissue at healthy state. It may be only during inflammation that 
these cells proliferate and migrate into the colon. 
 
ILC1s and NCR+ ILC3s require T-bet to differentiate from the ChILP (Artis and Spits, 2015). 
Around 50% and 30% of the ILC1s and NCR+ ILC3s respectively expressed YFP in the spleen, 
and a mean of 30% of the ILC1s expressed YFP in the colon. Lastly, in the bone marrow the 




the spleen were found to be YFP+. Subsequent data in another project looking at the T-bet+ 
ILC2s has been carried out in this model to identify the plasticity of ILC2s. However, the 
staining for ILCs in this panel were not sufficient to fully identify the different subsets of ILC1, 
ILC2 and ILC3s. Therefore the addition of T-bet itself, GATA3 and RORγt to identify ILC1s, 
ILC2s and ILC3s respectively would have been more decisive (Dutton et al., 2018, Diefenbach 
et al., 2014).  
 
However, the data from this chapter showed that the T-betcre x ROSA26YFPfl/fl mice line was 
a valuable and working mouse line to trace the lineage of T-bet expressing cells and would 
possibly be useful in identifying any previously T-bet expressed cells that no longer are T-bet+ 



























Results: Characterising the naïve YFP+ CD4 T cells 
 
T-bet is the master transcription factor of TH1 differentiation from naïve T cells (Szabo et al., 
2000). A small percentage (around 5%) of T-bet fate mapped YFP+ naïve (CD4+ CD25- CD44- 
CD62L+) CD4 T cells have been identified in the spleen of heathy T-betcre x ROSA26fl/fl mice. 
“Naïve” implies that the CD4 T cell has not yet experienced any antigen and thus not become 
activated. Naïve T cells are identified by the difference in their surface markers compared to 
their memory CD4 T cell counterparts. Traditional phenotyping methods simply define naïve 
CD4+ T cells to be only CD62L+ and CD44-, central memory CD4+ T cells to be both CD62L+ 
and CD44+, whilst effector CD4+ T cells are only CD44+ and CD62L- as shown in the previous 
chapter. However, to fully phenotype these mice and their CD4+ T cell compartment, more 
extensive surface markers were necessary. Additional phenotyping of other organs and 
secondary lymphoid organs were also performed to widen the scope of the phenotyping data. 
Additional surface markers used to differentiate between naïve, central memory and effector 
CD4+ T cells are CCR7, CD28 and CD27, whereby naïve CD4+ T cells are CD62L+ CD44- 
CCR7+ CD28+ CD27+, central memory CD4+ T cells are CD62L+ CD44+ CCR7+ CD28+ CD27- 
and effector CD4+ T cells defined as CD62L- CD44+ CCR7- CD28+ CD27- (Hu and August, 
2008, Sallusto et al., 1999, Williams et al., 2011, Zhu et al., 2010, Berard and Tough, 2002). 
CCR7 is a chemokine receptor and is known to be expressed on naïve T cells, central memory 
T cells, dendritic cells and B cells. The ligands for CCR7 are two chemokines CCL19 and 
CCL21. Unlike most chemokines, which are induced by inflammation and infections, CCL19 
and CCL21 are always expressed. Chemokines are vital in controlling immune cell movement 
in homeostasis. This is especially important for naïve T cells, which are required to migrate to 
secondary lymphoid.  CD28 and CD27 are costimulatory molecules found on the surface of 
CD4+ T cells and require sufficient binding and activation. Along with the stimulation of the T 
cell receptor, they are essential for the CD4+ T cell to become activated. All three of these 
molecules are highly expressed in the naïve CD4+ T cell population as they circulate through 
the periphery and organs. Upon activation of naïve T cells into effector cells, they stop 
expressing these markers, and CD62L, and express CD44. Central memory cells have been 
shown to express CCR7, CD62L and CD27, because they are recirculating memory cells that 




these more extensive surfaces markers to identify naïve and memory T cell have enabled others 
to report on small CD4+ and CD8+ T cell populations and have identified these as: stem cell-
like naïve T cells, memory naïve-like T cells and virtual memory T cells. 
 
In 2011, Gattinoni et al. described a subset of CD4 and CD8 T cells that were stem cell-like 
memory cells (Gattinoni et al., 2011). These cells appear naïve and express many similar 
surface markers. Much of the previous research on these cells focused on human stem cell-like 
memory cells and other groups have mainly focussed on CD8s (Ahmed et al., 2016, Gattinoni 
et al., 2009). However, as there are many similarities between CD4 and CD8 naïve and memory 
T cells, the CD4+ T cells were phenotyped for the possibility that they were stem cell-like 
memory. Stem cell-like memory cells are also CD62L+ CD44- CCR7+ CD28+ and CD27+ like 
naïve T cells. Stem cell-like memory cells have also been shown to express higher levels of 
CD95, CD122 (IL-2R), CXCR3, LFA-1 and Sca-1 (Gattinoni et al., 2011, Gattinoni et al., 
2009). Many of these additional markers share common expression on the CD44+ memory cell 
populations. 
 
Haluszczak et al, in 2009, reported on another possible small cell population derived from the 
standard CD8+ CD44+ memory cells (Haluszczak et al., 2009). They showed that there was a 
population of memory cells which they termed “virtual memory” T cells which are different to 
the homeostatic proliferating memory T cells. Since then more research by multiple groups has 
investigated these virtual memory cells, although always in CD8 T cells (Lee et al., 2013, White 
et al., 2016). Virtual memory CD8 T cells have been shown to be CD62L- CD44+ CD122+ 
CD49d- CXCR3+.  
 
Another study, by Pulko et al in 2016, also identified another memory T cell with naïve-like 
phenotype, which they named “TMNP cells”. These TMNP cells again were only identified in 
human samples and in the CD8 population and they have not been reported in the CD4 
population. They identified TMNP cells as CD62L
+ CD44- CD49d+ CXCR3+ (Pulko et al., 
2016).  
In 2017, Kawabe et al. reported on a new CD4+ CD44+ CD62L- memory cell type that can 




cells (Kawabe et al., 2017, Sprent and Surh, 2011). These MP cells have been identified in both 
germ-free and antigen free (defined by having offspring of GF mice that were weaned onto and 
subsequently raised on the elemental Ag-free diet being specifically dietary commensal antigen 
free) mice (Kim et al., 2016). Furthermore, these MP cells appear to develop from naïve 
CD62L+ CD44- cells, which are still present in mice that have had a thymectomy during 
development. Kawabe et al. showed that these cells require MHCII and CD28 for their 
development. They also found that MP cells arise from CD5hi naïve cells, but that naïve CD5+ 
CD4s have a lower level of T-bet expression compared to MP cells, which they showed have 
T-betlo, T-betint and T-bethi states. Lastly, they also showed that  T-bethi MP cells are crucial in 
host defences against pathogens and were responsible for IFNγ production (Kawabe et al., 
2017). 
 
Summary table on the small CD4+ and CD8+ T cell populations 





Gattinoni et al. CD8+ CD62L+ CD44- CCR7+ 
CD28+ CD27+ CD95+ CD122+ 
CXCR3+ LFA-1+ Sca-1+ 
(Gattinoni et al., 
2011) 
Virtual memory T 
cells 
Haluszczak et al. CD8+ CD62L- CD44+ CD122+ 
CD49d- CXCR3+ 
(Haluszczak et al., 
2009) 
Memory T cell with 
naïve-like phenotype 
– “TMNP cells” 
Pulko et al CD8+ CD62L+ CD44- 
CD49d+ CXCR3+ 
(Pulko et al., 2016) 
Memory-phenotype 
(MP) cells 
Kawabe et al. CD4+ CD44+ CD62L- CD5hi T-
bethi 
(Kawabe et al., 
2017) 
Table 4: Summary table showing the surface markers used to define stem cell-like memory cells, virtual 
memory T cells, naïve-like memory T cells (TMNP)  and memory-phenotype cells. 
 
From Table 4, all three small T cell populations express CXCR3. CXCR3 is another chemokine 




it, these are: CXCL9, CXCL10 and CXCL11. Furthermore, T-bet has been shown to have an 
important role in regulating the expression of CXCR3, and in T-bet-/- mice, the ability of 
effector cells to infiltrate and home to sites of inflammation was greatlt defected due to the loss 
of CXCR3, since T-bet was shown to directly transactivate CXCR3 (Groom and Luster, 2011, 
Oghumu et al., 2013, Tan et al., 2016b). CXCR3 has been shown to not be expressed on naïve 
T cells, but effector and memory T cells do highly express CXCR3. The upregulation of 
CXCR3 is followed after DC-induced T cell activation, prior to T cell proliferation in an 
antigen-specific manner (Groom and Luster, 2011, Oghumu et al., 2013, Tan et al., 2016b). 
 
It was also important to understand whether the expression of YFP in these mice were a 
developmental or environmental effect. As the immune phenotype of mammals is vastly 
different at differing ages of their life, it was important to determine whether there were any 
visible changes to the YFP expression from embryonic mice to old age. Embryos aged E15.5 - 
E16 were used, as at this age the thymus and foetal liver have almost fully developed (Gordon 
and Manley, 2011, Zorn, 2008). During foetal organogenesis the foetal liver is also the main 
site of stem cells and progenitor cells, as opposed to the adult liver, which mainly has metabolic 
functions (Ito et al., 2013). As mice and human age, the CD4+ T cell population changes. As 
mammals get older, the proportion of naïve CD4+ T cells declines, but the percentage of the 
memory CD4+ compartments rises (Nikolich-Žugich, 2005). Aged naïve CD4+ T cells show a 
reduction in CD28 (Lefebvre and Haynes, 2012, Moro-García et al., 2013). CD28 is required 
for the activation of naïve CD4+ T cells, and as this becomes downregulated with age, it was 
important to investigate whether this also occurred in the YFP+ naïve CD4+ T cell population 
or whether this population shows any other phenotypic differences. 
 
Further phenotyping and analysis of these YFP+ naïve CD4+ T cells were carried out to identify 
the surface markers of these cells, to investigate potential importance for T cell differentiation, 
and investigations were carried out to find if these YFP+ naïve CD4+ T cells play a defining 
role during pathogenic response in the mucosa. The ideal way to view how these YFP+ naïve 
CD4+ T cells functioned in vivo was to transfer them into a Rag2-/- mice. Typically, in the T 
cell transfer colitis model, which is a wasting disease, it has been shown to be predominately 
an IFNγ driven disease model, with IL-17A also being produced to certain lower levels (Aranda 




transfer of naïve CD4+ T cells from T-bet-/- mice results in an IL-17A driven disease (Gökmen 
et al., 2013).  
 
Bystander activation of both CD4 and CD8 T cells has been shown to occur where unrelated T 
cells become stimulated and activated from cytokines produced from other antigen-specific T 
cell stimulation (Boyman, 2010). Furthermore, bystander activation of T cells has been shown 
by previous groups to be essential for the proliferation and expansion of other T cells (Boyman, 
2010, Tough et al., 1996). Relevant to the memory-phenotype (MP) T cell phenotyping for the 
YFP+ naïve CD4+ T cells, it has been shown that bystander activation occurred in MP CD8+ T 
cells by IFNγ, IL-12 and IL-18 (Tough et al., 2001). Unfortunately, not as much is known about 
bystander activation in bulk CD4+ T cells, let alone MP CD4+ T cells. However, some 
bystander activation of CD4+ has been observed which relies on an IL-2 dependent manner. 
This may have different effects to the MP CD8+ bystander activation that has been observed 
by other groups due to IL-2 being required for cell survival of CD4+ T cells (Boyman, 2010). 
It has also been shown that the CD4+ T cell bystander activation might require an antigen 
response to be able to activate other cells (Eberl et al., 2000, van Aalst et al., 2017, Di Genova 
et al., 2010). Upon identifying this subset of naïve YFP+ CD4+ T cell, it would be important to 
determine whether they have any effect via bystander activation on the other non-YFP 
expressing CD4+ T cells. 
4.1 Phenotyping the naïve YFP+ CD4+ T cells in the T-betcre x 
ROSA26YFPfl/fl mice 
Figure 18 showed more extensive phenotyping data of these cell types, including CD28, CD27 
and CCR7, and within more peripheral organs than previously shown, to further distinguish 































Figure 18: Extensive phenotyping of the T-betcre x ROSA26YFPfl/fl shows consistent levels of YFP+ CD4+ T 
cells in the major organs and lymphoid tissue  
A. Representative flow cytometry plots showing naïve CD4+ T cells (live CD3+ CD4+ CD62L+ CD44- CCR7+ 
CD28+ CD27+), effector CD4+ T cells (live CD3+ CD4+ CD62L- CD44+ CCR7- CD28+ CD27-) and central memory 
CD4+ T cells (live CD3+ CD4+ CD62L- CD44+ CCR7- CD28- CD27-) in the thymus, spleen, colon, mesenteric 
lymph nodes, peripheral lymph nodes and the liver of the T-betcre x ROSA26YFPfl/fl. B. Dot plot showing the 
overall percentage of cells expressing YFP from the same gated naïve, effector memory and central memory CD4+ 
T cells in each of the organs. (n = 3 for thymus, colon, pLN, n = 5 for liver, n = 6 for mLN and n = 8 for spleen). 
Kruskal-Wallis test performed with Dunn’s corrections showing overall statistical analysis for all groups. 
Dot plots showing YFP expression in naïve, effector and central memory CD4+ 
T cells in different organs in the T-betcre x ROSA26YFPfl/fl mice 
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Representative flow plots showing YFP expression in naïve, effector and central 




Around 0.5-1% of definitive naïve CD4+ T cells were YFP+ (Figure 18B) and showed that 
between these different organs there was a significant difference in the amount of YFP 
expression. As stated previously, YFP expression in effector memory and central memory cells 
was expected to be high because a subset of both memory populations will have upregulated 
T-bet upon TH1 differentiation. This is shown again in the thymus, spleen, colon, mLN, pLN 
and liver of these mice, with a range of 30-70% YFP+ cells in the effector memory population 
and 20-40% in the central memory population. The lack of cells in the flow plots showed that 
there are not many central memory cells, especially in the thymus, colon and liver in these 
healthy mice.  
4.2 Identifying the naïve YFP+ CD4+ T cells 
After finding these novel YFP+ T-bet fate mapped naïve CD4+ T cells, the next step was to 
identify this cell and further test its function. The T-bet fate mapping mouse is a novel mouse 
line and therefore any cell populations that do not fully fit with assumptions made from 
previous research are of interest. Potential identities of these YFP+ naïve CD4s, based on 
existing research, are explored below. 
 
4.2.1 Are these YFP+ naïve T cells stem cell-like memory T cells? 
Figure 19 below shows the gating strategy used to identify these stem cell-like memory cells 
and the subsequent phenotyping from it is shown in Figure 20. The spleen, mLN and liver were 



























Figure 19: Gating strategy for identifying stem cell-like memory T cells in the T-betcre x ROSA26YFPfl/fl 
mice 
A. Gating strategy shown for identifying stem cell-like memory T cells in the naïve (CD62L+ CD44-) 







































Figure 20: Phenotyping of the stem cell-like memory T cells in the T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots showing YFP+ expression in the naïve and stem cell-like memory cell populations 
in the spleen. B. Representative flow histograms comparing typical stem cell-like memory cell surface markers in 
YFP- vs YFP+ naïve CD4 T cells in the spleen. C. Representative flow histograms comparing typical stem cell-
like memory cell surface markers in YFP- vs YFP+ naïve and effector memory CD4 T cells. These cells were 
gated using FMOs and isotype controls for CXCR3, IL-7R, CD122, CD95, CD27 and CD28. (n = 12) 
20B Phenotyping stem cell-like memory CD4+ T cell surface markers between naïve YFP+ 
and naïve YFP- in the T-betcre x ROSA26YFPfl/fl mice 
YFP expression in naïve CD4+ T cells and in stem cell-like memory CD4+ T cells 
in the T-betcre x ROSA26YFPfl/fl mice 
20C 
20A 
Phenotyping stem cell-like memory CD4+ T cell surface markers between naïve YFP+, 




Figures 19A and 20A show that not only are there very few CD122+ and CD95+ CD4+ stem 
cell-like memory cells found in the spleen, but also very few of these do not express YFP in 
comparison with the naïve CD4+ population, which still have around 2% YFP expression, as 
previously seen. This supports the hypothesis that these naïve YFP+ CD4 T cells are not stem 
cell-like memory T cells. This was further demonstrated by gating on the naïve (CD62L+ CD44-
) YFP- and YFP+ CD4+ T cell populations, and then analysing the different cell surface markers 
separately in Figure 20B and further comparing them to the memory population (CD44+ 
CD62L-) YFP- and YFP+ population in Figure 20C. Compared to the naïve YFP- and YFP+ 
CD4 T cell population, both had equal expression of CCR7, CD28 and CD27 in comparison 
with the isotype control. Sca-1 and LFA-1 were both high in comparison with the control and 
positive, but there was no difference between the naïve YFP- and naïve YFP+ cells.  
 
Figure 20C shows the comparison between the naïve YFP-, naïve YFP+, effector memory YFP- 
and effector memory YFP+ cells. This comparison highlighted that the standard memory 
markers, like CD95 and CD122, were higher in the two effector memory populations in 
comparison with both naïve populations, as expected since these markers are upregulated when 
they become effector memory cells. Contrasting this are the naïve markers, CD27 and CD127, 
which are downregulated in the two memory populations. The flow plots and surface marker 
expression were the same for mLN and liver, but these are not shown here. 
 
4.2.2 Are these YFP+ naïve T cells virtual memory or memory-naïve 
T cells? 
 
To test whether the YFP+ naïve CD4 T cells here are virtual memory T cells or memory naïve-
like TMNP cells, similar flow cytometry phenotyping experiments to those with the stem cell-




















Figure 21: Gating strategy of the TMNP and virtual memory cells in the T-betcre x ROSA26YFPfl/fl mice 
A. Gating strategy shown for identifying memory naïve-like and virtual memory T cells in the naïve (CD62L+ 












Gating strategy used for identifying both memory-naïve T (TMNP) cells and virtual 





























Figure 22: Phenotyping of the TMNP and virtual memory cells in the T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots showing YFP+ expression shown in the naïve (CD62L+ CD44- CD28+ CD27+ 
CXCR3- α4β1-) and the TMNP cells (CD62L+ CD44- CD28+ CD27+ CXCR3+ α4β1+) in the spleen. C. 
Representative flow plots showing the YFP+ expression in the virtual memory T cells (CD62L- CD44+ CD122+ 
CD49d- CXCR3+) in the spleen. D. Representative flow histograms showing the surface marker expression 
from YFP- vs YFP+ naïve and effector memory CD4 T cells from the spleen. These cells were gated using FMOs 
and isotype controls for CXCR3, α4β1, CD122, CD95, CD27 and CD28. (n = 12)  
Phenotyping TMNP and virtual memory CD4+ T cell surface markers between naïve YFP+, 
naïve YFP-, effector YFP+ and effector YFP- in the T-betcre x ROSA26YFPfl/fl mice 
YFP expression in naïve CD4+ T cells and in virtual memory CD4+ T cells in the 
T-betcre x ROSA26YFPfl/fl mice 





Figures 21A and 22A show that within the CD62L+ CD44- CD27+ CD28+ population there are 
very few single CXCR3+ and single α4β1+ cells, and even fewer double positive ones (the TMNP 
cells). These markers are also present within the CD44+ CD62L- memory population and 
therefore it was a useful biological control for the CD62L+ CD44- population. The only YFP+ 
population that existed was found in the double negative (CXCR3- α4β1-) population, which 
should be the truly naïve CD4+ T cells. Therefore, these YFP+ naïve CD4+ T cells are not the 
same TMNP that have been identified by other groups. 
 
Figure 22B shows the YFP+ expression for the CD44+ CD62L-. Since virtual memory cells are 
identified by this, as well as CD49d and CXCR3. In the CD44+ CD62L- CD49d- CXCR3+ 
population, which are the virtual memory cells, there was a high level of YFP+ (around 75% of 
cells) but as these cells cannot be found in the CD62L+ CD44- CD49d- CXCR3+ population, 
the naïve CD49d- CXCR3+ cells might not be related to virtual memory cells. 
 
Lastly, Figure 22C shows the surface markers of YFP+ vs YFP- naïve and effector memory 
cells. This again shows that the naïve CD4+ T cells have similar expressions of the markers 
previously shown in figure 20C, including the 20-30% YFP+ CXCR3+. Both the YFP- and YFP+ 
naïve CD4+ T cells were negative for α4β1+, especially in comparison with the effector memory 
CD4+ T cells.  
 
Figures 20C and 22C highlighted that these naïve YFP+ CD4+ T cells are phenotypically 
different to both YFP- and YFP+ memory cells. 
 
4.2.3 Are these YFP+ naïve CD4+ T cells precursors to CD5high 
pathogen-independent memory-phenotype (MP) cells? 
 
Since Kawabe et al. lacked a T-bet fate mapping mouse, they could not determine if MP cells 
were derived from a population of naïve CD4+ T cells that have previously expressed T-bet. 
They showed that all MP cells highly expressed CD5 and were able to develop from peripheral 
naïve CD4+ T cells even after their mice had been given a thymectomy. However, using the T-
betcre x ROSA26YFPfl/fl mice, the expression of CD5 can be analysed in these YFP+ naïve T 

















Figure 23: Phenotyping the CD5+ YFP naïve T cells in the T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots showing CD5+ YFP+ expression in naïve gated (live CD3+ CD4+ CD62L+  
CD44-) CD4+ T cells in the spleen, mLN, colon and liver. B Dot plot showing the number of CD5+ YFP+ cells in 
the spleen, mLN, colon and liver. (n=6 for spleen and mLN, n=5 for colon and n=3 for liver). Kruskal-Wallis test 
performed with Dunn’s corrections showing overall statistical analysis for all groups. 
 
Figures 23A and 23B show that all the YFP+ cells are CD5high but not all the CD5+ cells are 
YFP+. The gate was gated using a CD5 isotype control and FMO to judge where the expression 
of CD5 started. Only around 10% in the spleen, 3% in the mLN, 15% in the colon and a range 
of 15-30% in the liver are YFP+ CD5+. The naïve YFP+ cells could be precursors to MP cells 
that Kawabe et al. identified. Further analysis of these cells would be necessary to identify 
them more precisely. 
4.3 Investigating whether the YFP+ naïve CD4 T cell subset differs with 
age 
Although the identity of this population has not yet been clarified, understanding whether the 
frequency of these YFP+ naïve CD4+ T cells vary with age was essential. Although these mice 
were not housed in germ-free or pathogen-free isolators, the foetal and even 1-week old 
Representative flow plots showing CD5+ expression in YFP+ naïve CD4+ T cells 
in the T-betcre x ROSA26YFPfl/fl mice 
































neonates should not have fully established immune systems and thus their naïve CD4 T cells 
should be naïve. Therefore, this would give an idea of whether the YFP+ CD4 T cells are 
already present from the developing foetus and/or if the presence of a microbiota and an 
immunological environment are necessary for them to be present.  
 
4.3.1 The YFP+ naïve CD4+ T cells could not be found in the foetus of 
these mice 
 
For these experiments, the T-betcre mother was used as a YFP- control, since the parents are 
breed as separate lines and the offspring are only used at the F1 generation, and we had other 
suitable genotyped T-betcre x ROSAYFPfl/fl adult (6-8 weeks old) mice that we used to compare 
the foetal YFP expression against. Unfortunately, there were no CD4 or CD8 T cells found in 









































Figure 24: Phenotyping the cells in the E15.5-E16 foetus of T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots showing naïve (CD62L+ CD44-), effector (CD62L- CD44+) and central memory 
(CD62L+ CD44+) CD4+ T cells in the adult liver, adult spleen and foetal liver of T-betcre x ROSA26YFPfl/fl mice. 
B. Representative flow plots showing naïve (CD62L+ CD44-), effector (CD62L- CD44+) and central memory 
Representative flow plots showing YFP expression in naïve, effector and central memory 
CD8+ T cells from foetal and adult T-betcre x ROSA26YFPfl/fl mice  
Representative flow plots showing YFP expression in naïve, effector and central 




(CD62L+ CD44+) CD8+ T cells in the adult liver, adult spleen and foetal liver of T-betcre x ROSA26YFPfl/fl mice. 
(n=3 for the adult liver and spleen, n=1 for foetal liver but pooled from 10 foetuses) 
Analysis of the CD4+ and CD8+ T cells in the foetal liver provided interesting preliminary 
results since the ten foetal liver samples had to be pooled into one sample and therefore this 
experiment needs repeating in order to observe if this potential finding is conclusive. However, 
firstly, from Figure 24A, it can be observed from this one sample that there were no YFP+ naïve 
or central memory CD4+ T cells found in the foetal liver, but there were some (around 9%) 
YFP+ effector memory CD4+ T cells. From this one sample, there was a high percentage (over 
90%) of YFP+ naïve CD8+ T cells and only around 2-3% YFP+ effector memory CD8+ T cells 
(Figure 24B). These cells were still in utero, and therefore would only have been exposed to 
any maternal antigens from the mother. This could make the observation of the high percentage 
of YFP+ naïve CD8+ T cells interesting especially considering that in adult mice only around 
0.5-1% of naïve CD8s were YFP+. Therefore, there could be the possibility that these YFP+ 
naïve CD8s either die or the remaining YFP- CD8+ T cells expand massively upon birth. From 
this one sample analysis no YFP+ naïve CD4+ could be found in the foetal liver, hypothesising 
that the expression of T-bet+ fate mapped naïve T cells only occurs after birth during neonatal 
development. Formation of these cells could be driven more by the microbiota and other 
environmental factors post-birth. Another potential observation made here was the low 
percentage of both CD4 and CD8 T cells in the foetal liver. This could have been due to a lack 
of proliferation due to a lack of antigen activation as foetuses.  
 
4.3.2 Naïve YFP+ CD4+ T cells are present within in the periphery in 
neonates 
 
After observing a possible lack of YFP+ naïve CD4+ T cells in the foetal liver, 1-week-old mice 
were phenotyped next. Surface markers typically found on memory and naïve CD4+ T cells 






















Figure 25: Phenotyping of the 1-week-old T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots and overall dot plot showing the percentage of YFP+ naïve (CD62L+ CD44-) CD4+ 
T cells in the spleen, liver, mLN, colon and small intestine of 1-week old T-betcre x ROSA26YFPfl/fl mice. B. 
Representative flow histograms showing CCR7, CD28, CD27, CD95 and CXCR3 expression on either YFP- or 
YFP+ naïve (CD62L+ CD44-) CD4+ T cells in the spleen of 1-week old T-betcre x ROSA26YFPfl/fl mice. (n=5 for 
spleen, liver, n = 3 and n=1 for colon and small intestine). Kruskal-Wallis test performed with Dunn’s corrections 
showing overall statistical analysis for all groups. 
 
Figure 25A shows that there is significant difference in the percentage of YFP+ CD4 naïve T 
cells in the different organs of 1-week old litters. Around 5% and 0.5% of naïve CD4+ T cells 
expressed YFP in the liver and spleen respectively. This percentage of naïve CD4+ T cells 
matched the proportion seen in the 6-8-week-old mice. At 1 week old, there were still very few 
cells in the mLN, pLN and colon due to the size of the mice. The peripheral organs of these 
mice have yet to require much cell infiltration at mucosal sites of inflammation. This made it 
more difficult to analyse the cells within these organs and mice had to be pooled together to 
get sufficient numbers for flow analysis. Interestingly, of the naïve CD4+ T cells that were 
present in the mLN, pLN and colon there were no YFP+ cells that could be identified. Figure 
Representative flow plots showing naïve and memory surface markers of 
YFP- and YFP+ naïve CD4+ T cells from T-betcre x ROSA26YFPfl/fl mice 


































25B showed differences to the previous data shown in the 6-8-week-old mice. These YFP+ 
naïve CD4+ T cells in the spleen were shown not to express the migratory chemokines receptors 
CCR7 and CXCR3 and the costimulatory molecule CD28, but they were CD27+. This indicates 
that the naïve YFP+ CD4+ require more of an environmental microbiota immune response to 
migrate from the spleen into the peripheral sites of the mucosa.  
 
4.3.3 During weaning, the YFP+ naïve CD4+ T cells develop a 
phenotype more similar to those in adult mice 
 
During their first 3 weeks, the mice are fed milk from their mother and are also adapting to the 
environmental microbiota within the cages that they are housed. These environmental 
responses prime the immune system of the mice with external pathogenic antigens, which naïve 
CD4+ T helper cells will specifically recognise and become activated and proliferate, and which 
are no longer only from maternally found antigens from when the foetus was developing or 
from the milk during weaning. Therefore, examination of YFP expression at this stage of 
































Figure 26: Phenotyping of the 3-week-old T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots and overall dot plot showing the percentage of YFP+ naïve (CD62L+ CD44-) CD4+ 
T cells in the spleen, liver, mLN, colon and small intestine of 3-week-old T-betcre x ROSA26YFPfl/fl mice. Kruskal-
Wallis test performed with Dunn’s corrections showing overall statistical analysis for all groups. B. Representative 
flow histograms showing CCR7, CXCR3 and CD122 expression on either YFP- or YFP+ naïve (CD62L+ CD44-) 
CD4+ T cells (shown on the top left) in the spleen of 3-week old T-betcre x ROSA26YFPfl/fl mice. (n=6 for spleen 
and liver n = 4 for mLN, n=3 for colon and SI). Kruskal-Wallis test performed with Dunn’s corrections showing 
overall statistical analysis for all groups. 
 
The 3-week-old mice showed that despite the number of naïve CD4+ T cells increasing in each 
of the organs as the mice get older, the percentage of YFP+ naïve CD4+ T cells do not increase 
in the spleen and liver and stay at the same level as the 6-8-week-old mice. The YFP+ naïve 
CD4+ cells are still not visible in the mLN, colon and small intestine though and this may still 
Representative flow plots showing naïve and memory surface markers of YFP- and YFP+ naïve 
CD4+ T cells from 3-week-old T-betcre x ROSA26YFPfl/fl mice 
Percentage of YFP+ naïve CD4+ T cells in organs of 3-week-old T-betcre x ROSA26YFPfl/fl mice 




























be due to the lack of environmental microbiota antigens present in the gut of the mice. Figure 
26B shows the difference in splenic YFP+ naïve CD4+ cells to the 1-week old YFP+ naïve CD4+ 
T cells. From the histograms, unlike in the 1-week old naïve CD4s, these naïve CD4s have now 
expressing migratory chemokine receptors, CCR7 and CXCR3, the latter of which expressed 
on more cells (around 60%) in these 3-week-old mice in comparison to the adult 6-8-week-old 
ones previously phenotyped (around 30%). Also, it was surprising to find that these YFP+ naïve 
CD4s highly expressed CD122, as later in adulthood they stop expressing CD122 (Figure 20 
and 22).  
 
4.3.4 Are there any phenotypic difference between younger and older 
YFP+ naïve CD4+ T cells in these mice? 
 
Figure 27 shows mice aged 25 and 50 weeks old. These ages were used due to availability of 
mice at the time, but mice are considered old for breeding around the age of 25 weeks and 



























Figure 27: Phenotyping of 25 and 50-week-old T-betcre x ROSA26YFPfl/fl mice 
A. Representative flow plots and overall dot plot showing the percentage of YFP+ naïve (CD62L+ CD44-) CD4+ 
T cells in the spleen and liver for 25-week-old mice and the spleen, liver, mLN and colon of 50-week-old T-betcre 
x ROSA26YFPfl/fl mice. B. Representative flow histograms showing CD27, CD28, CD95, CXCR3 and α4β1 
expression on either YFP- or YFP+ naïve (CD62L+ CD44-) and memory (CD62L- CD44+) CD4+ T cells in the 
spleen of 50-week old T-betcre x ROSA26YFPfl/fl mice. (n=4 for spleen, liver, mLN and colon). Mann-Whitney 
test used for 25 week old mice and Kruskal-Wallis test performed with Dunn’s corrections showing overall 
statistical analysis for all groups used for 50 week old mice. 
 
The most interesting observation from the aged mice was that the percentage of YFP+ naïve 
increases with age in the spleen, from 0.5-1% in 6-8-week-old mice to around 1.5% in the 25-
week-old mice and finally around 2% in the 50-week-old mice. Despite the mice getting older, 
there does not seem to be a reduction in naïve CD4+ T cells, including the YFP+ naïve CD4 T 
cells. Furthermore, the surface markers expressed on these naïve CD4+ T cells in aged mice do 
not differ much in comparison with the younger adult mice. Expression of CD28 was still 
present, and expression remains higher in the YFP+ naïve CD4s. The 20-30% of YFP+ naïve 
CD4 T cells that were CXCR3+ in the older adult mice is similar to that observed in the younger 
adult mice. 
Representative flow plots showing naïve and memory surface markers of YFP- and 




4.4 Are the YFP+ naïve CD4 T cells functionally different to YFP- naïve 
CD4 T cells?  
The flow cytometry data demonstrates that YFP+ naïve CD4 T cells are phenotypically 
different to YFP- naïve CD4 T cells and are possibly a novel and unknown cell type. There has 
been much research into naïve CD4 T cell immunology performed in the past by many different 
groups. Many of these groups have looked at naïve CD4 T cell differentiation, plasticity and 
their functional aspects during pathological responses in both in vitro and in vivo analysis.  
 
4.4.1 In vitro analysis of the YFP+ naïve CD4 T cells shows a dominant 
IFNγ production and possible predetermined TH1 phenotype 
 
In vitro T cell culture and T cell skewing of naïve CD4 T cells have been performed by many 
groups in the past, including within our lab (Brown et al., 2015, Canavan et al., 2016, Gökmen 
et al., 2013), to observe the differentiation and function of naïve CD4+ T cells.  
In vitro T cell cultures were first performed with only IL-2 and no skewing conditions. This 
initially involved sorting and purifying the YFP- and YFP+ naïve and memory T cells from a 
BD Aria cell sorting machine using the gating strategy described in the methods section. The 
purified sorted naïve and memory CD4+ T cells were then plated out at 1 x 106/ml onto anti-
CD3 and anti-CD28 pre-incubated plates for 2 days and cultured with IL-2 for 7 days. Cells 
were then stimulated with PMA and ionomycin for 4 hours with monensin after 2 hours. The 








28A Representative flow plots showing cytokine production from naïve CD4+ T cells 





















Figure 28: In vitro culture of YFP+ CD4+ T cells shows that even without skewing YFP+ CD4+ T cells can 
produce a large amount of IFNγ upon activation and stimulation. 
A. Representative flow plots showing cytokine responses and T-bet expression from in vitro cultured cell with 






 T cells from T-betcre 
x ROSA26YFPfl/fl mice (Experiment was done in triplicate (except for naïve YFP+ cells, which were pooled into 
one well) and replicated twice). B. Representative flow plots and overall dot plot showing cytokine responses and 







 T cells from T-betcre x ROSA26YFPfl/fl mice. (Experiment was done in triplicate 
and replicated twice) C. IFNγ and IL17A production from the supernatant of the cultured cells measured by 
ELISAs (n = 6 for YFP- naïve CD4 T cells, YFP- effector CD4 T cells and YFP+ effector CD4 T cells and n = 2 
for YFP+ naïve CD4 T cells). Kruskal-Wallis test performed with Dunn’s corrections showing overall statistical 
analysis for all groups and individual comparisons. 
ELISA showing cytokine production from the supernatant of naïve and 
memory CD4+ T cells cultured in vitro 
Representative flow plots showing cytokine production from memory CD4+ 












































































































































Remarkably, anti-CD3/CD28 stimulation and IL-2 led to high IFNγ production in comparison 
with the YFP- naïve CD4 T cells. The YFP+ T cells also maintain their YFP+ expression after 
activation. YFP- effector cells were able to produce both IL-17A and IFNγ, whereas the YFP+ 
cells predominately produced IFNγ and barely any IL-17A. The ELISA data further confirmed 
the flow data showing that the YFP+ CD4+ T cells were more predisposed to producing IFNγ, 
probably due to their previous expression of T-bet. Also, it was useful to observe that the YFP- 
memory IFNγ producing cells became YFP+ and T-bet+. This helped to confirm that the mouse 
model was working correctly. 
 
Next, differences in the differentiation of YFP- and YFP+ naïve CD4+ T cells when exposed to 
specific skewing conditions into TH1, TH2, TH17 and Tregs lineages were tested. This was 
important to demonstrate if the T-bet fate mapped naïve CD4+ T cells would still be able to 
skew towards these cell types and if they were still producing more IFNγ as seen previously 










Figure 29: In vitro T cell skewing of YFP+ CD4+ T cells shows that even under TH2, TH17 and Treg skewing 
conditions YFP+ CD4+ T cells can produce IFNγ upon activation and stimulation. 
A. Representative flow plots showing cytokine responses from in vitro skewed cell on pre-incubated anti-






 T cells from T-betcre x ROSA26YFPfl/fl mice.  
(experiment performed in triplicate and repeated twice) 
 
29A 




Similarly, to the cells cultured only in IL-2, the YFP+ naïve CD4+ T cells under skewed 
conditions showed a likely trend to be able to produce high amounts of IFNγ and less of the 
other lineage specific cytokines; in comparison with their YFP- naïve CD4+ T cell counterpart. 
However, more replicates and repeats of this are necessary to conclude the skewing data.  
 
In conclusion, both non-polarised and polarised in vitro cultures showed that YFP+ naïve CD4+ 
T cells have their own unique function compared to the YFP- naïve CD4+ T cells. They have a 
spontaneous and predetermined ability to readily produce high amounts of IFNγ. These YFP+ 
naïve CD4+ T cells could be early TH1 immune responders to pathogens and provide an early 
source of IFNγ. 
 
4.4.2 In vivo analysis of the YFP+ naïve CD4 T cells 
 
Figure 30 shows the typical T cell transfer from wildtype mice into Rag2-/- mice, demonstrating 
significantly high IFNγ production with little IL-17A production in this model (Figure 30B). 
Cells were sorted and purified using the same method as described before and 0.5x106 CD4+ T 
cells were transferred to each Rag2-/- mice by intraperitoneal injections. Typically, in the 
normal T cell transfer model, wasting can be observed after around 6 weeks of the initial 





























Figure 30: T cell transfer of 500,000 naïve CD4+ T cells generates a predominately IFNγ response and only 
a small IL-17A response. 
A. Clinical data showing weight loss, spleen weight and colon weight in Rag2-/- mice given 500,000 naïve CD4+ 
T cells (n = 11 for colon, mLN and spleen). Multiple T test with Bonferonni-Dunn’s correction performed on 
percentage weight change where ** = P<0.01, and Mann-Whitney Tests on colon and spleen. B. Representative 
flow plots and overall dot plot from spleen, mLN and colon showing IFNγ and IL-17A production after T cell 
transfer (n = 11 controls and n = 15 TCT for colon, mLN and spleen) with Mann-Whitney Tests performed. ** = 
P<0.01 
 
The limiting factor for the transfers of YFP+ CD4+ naïve T cells was the small number of naïve 
T cells that could be found in these mice. In Figure 31, transferring 100,000 YFP+ naïve T cells 
alone was performed to test the model with reduced transfer of cells.  
Representative flow plot and dot plots showing cytokine production in a typical T cell transfer 
























































































































































































































































Figure 31: T cell transfer of 100,00 naïve YFP+ CD4+ T cells have a reduced disease phenotype despite still 
generating a predominately IFNγ response and lacks an IL-17A response. 
A. Clinical data showing weight loss, spleen weight and colon weight in Rag2-/- mice given 100,000 naïve YFP+ 
CD4+ T cells and showing the same clinical features from the standard 500,000 naïve T cell transfer model (n=11 
controls, n=15 for standard TCT and n=2 for YFP+ TCT). Mann-Whitney Tests performed on colon and spleen. 
B. Representative flow plots showing cytokine response from live CD3+ CD4+ cells from spleen, mLN and colon 
showing IFNγ and IL-17A production after T cell transfer and histograms showing T-bet and RORγt expression 
from IFNγ and IL-17A producing cells. (n = 2) 
 
Figure 26A shows that mice which received 100,000 naïve YFP+ CD4+ T cells started to have 
a similar trend to weight loss after 7 weeks; in comparison with the standard TCT mice, 
Clinical data showing percentage weight change and organ weights after 
100,000 naïve YFP+ CD4+ T cell transfer 
Representative flow plot and dot plots showing cytokine production and 
transcription factor expression after 100,000 naïve YFP+ CD4+ T cell transfer 
31B 
31A 





















































































whereas the untreated mice carried on gaining weight. However, with only a small sample size, 
more repeats of this will be needed to confirm this. From these two mice, there was still a 
possible comparison in weight loss with the standard 500,000 T cell transfer. Regarding, the 
organ weight loss, there was a significant increase seen in the spleen, but not in the colon 
weights in comparison to the control healthy organ weights. However, this macroscopic clinical 
feature is significantly decreased when compared to the standard 500,000 T cell transfer 
protocol. This could suggest that the mice needed to be kept for longer for a disease phenotype 
to become more established, or that 100,000 cells were not enough to generate a significant 
disease phenotype. However, Figure 31B did preliminary demonstrate that there was no IL-
17A cytokine response found in the spleen, mLN or colon from these two samples. There was 
also a high amount of IFNγ production seen only in the spleen. Furthermore, as shown in the 
colon, the transferred YFP+ CD4+ T cells were still YFP+ and still present within the mice and 
were able to migrate and survive to the colon. These data suggest that the YFP+ naïve CD4+ T 
cells are not able to cause a sufficient immune response without the bulk of the usual YFP- 
CD4+ T cells that are present. Further repeats of these 100,000 naïve YFP+ T cell transfers will 
need to be performed in order to confirm this but due to the low percentage of YFP+ naïve 
CD4+ T cells found in the spleen and other organs of the T-betcre x ROSA26YFPfl/fl mice. 
 
However, to get a better comparison of T cell transfer colitis disease read outs between the 
YFP- vs YFP+ naïve CD4+ T cells, equal numbers of naïve YFP- and YFP+ CD4+ T cells needed 
to be transferred into separate Rag2-/- mice. As reported already, since the percentage of YFP+ 
naïve CD4+ T cells was low in these mice, 25,000 cells were transferred in order to get some 
replicates. The results from this T cell transfer are shown in Figure 32. Supernatant was 
extracted from organ culture, in which a uniform 3mm biopsy punch sample from the colon 
was taken and placed in media and cultured for 48 hours at 37°C. Unfractionated cells from 
spleen, mLN and colon were also cultured for 48 hours at 37°C. Both supernatants were then 
























Figure 32: T cell transfer of 25,000 naïve YFP- and naïve YFP+ CD4+ T cells do not get a disease phenotype 
but YFP+ CD4+ T cell transferred still have an increased production of IFNγ and reduced IL-17A when 
compared to YFP- CD4+ T cell transferred. 
A. Clinical data showing weight loss, spleen weight and colon weight in Rag2-/- mice given either 25,000 naïve 
YFP+ or naïve YFP- CD4+ T cells. B. Representative flow plots showing cytokine response from live CD3+ CD4+ 
cells from spleen, mLN and colon showing IFNγ and IL-17A production after T cell transfer. C. Representative 
flow plots showing the expression of YFP in the CD3+ CD4+ naïve YFP- and naïve YFP+ T cells in the spleen, 
mLN and colon in the Rag2-/- mice after T cell transfer. D. Cytokine production of IFNγ and IL-17A from 
supernatant of colon organ cultures measured by ELISA. E. Cytokine production of IFNγ from supernatant of 
unfractionated cell cultures from colon, spleen and mLN measured by ELISA. (n = 3 for each transfer and n = 6 
for control). Kruskal-Wallis test performed with Dunn’s corrections showing overall statistical analysis for all 
groups and individual comparisons. 
IFNγ production from cell cultures of spleen, mLN and colon from YFP- and YFP+ naïve CD4+ T 
cell transfers 
IFNγ and IL-17A production from organ cultures of colon 
biopsies from YFP- and YFP+ naïve CD4+ T cell transfers 
Representative flow plots showing 
YFP expression from YFP- and YFP+ 
naïve CD4+ T cell transfers 
Representative flow plot and dot plots showing 
cytokine production after 25,000 naïve YFP+ 
and YFP- CD4+ T cell transfer 
Clinical data showing percentage weight 
change and organ weights after 25,000 



















































































































Figure 32A showed that these mice did not develop any significant wasting disease, and this 
may be due to the much smaller number of naïve T cells that were transferred. Although both 
sets of recipient mice did not show signs of wasting, neither did they gain as much weight as 
the control mice. Furthermore, there was an overall significant difference when comparing the 
organ weights of untreated mice, YFP- naïve T cell transfer and YFP+ naïve T cell transfer 
mice. However, there was only a significance increase in the spleens and colons between 
untreated and the YFP- naïve T cell recipient mice. Despite the lack of wasting due to the low 
starting cell number transferred, the CD4+ T cells were, not only still able to migrate to the 
colon, mLN and spleen after 9 weeks of transfer, but they were functionally able to produce 
cytokines. Figure 32B showed representative plots that the mice which received YFP+ naïve T 
cells were predisposed to producing greater amounts of IFNγ and almost no IL-17A in 
comparison with the transferred YFP- naïve T cells. Figure 32C further confirmed that a large 
proportion of YFP- naïve CD4+ T cells became YFP+, consistent with IFNγ production and T-
bet expression, and the injected YFP+ CD4+ T cells all remain YFP+. Figure 32D and 32E show 
that even without PMA and ionomycin stimulation and simply culturing the full colon organ 
piece and unfractionated cells from spleen, mLN and colon, there was a significant increase in 
IFNγ production from the YFP+ CD4+ T cell transferred mice in the colonic cell cultures and 
from the organ cultures. Further repeats of these transfers would be necessary to confirm the 
findings in these data though. 
4.5 Do YFP+ naïve CD4+ T cells require bystander activation for IFNγ 
production or provide bystander activation to YFP- naïve CD4+ T 
cells? 
 
The data from both the 100,000 and 25,000 transfers of YFP+ CD4+ T cells into the Rag2-/- 
showed that they were unable to provoke a wasting disease phenotype or cause macroscopic 
inflammation of target organs; but still potentially to have the ability to produce IFNγ. As 
discussed before, CD4+ T helper cells have been shown to exhibit bystander activation effects. 
Bystander activation is where unrelated T cells become stimulated and activated from 
cytokines, such as IL-15 and IFNγ, produced from other antigen-specific T cell stimulation 
(Boyman, 2010). It has also been shown that the CD4+ T cell bystander activation might able 




CD4+ T cells had any potential bystander effect with their predisposed IFNγ production on 
YFP- naïve CD4+ T cells.  
 
It was important to observe if naïve YFP- CD4+ T cells were able to become YFP+ in vivo in a 
non-disease setting by transferring them into a congenic CD45.1 mice. Use of the congenic 
CD45.1 model is useful in order to identify the donor CD4+ T cells from the CD45.2 T-betcre x 
ROSA26fl/fl mice. Next, using this congenic mouse model, if an immune response could be 
generated in both in vitro and in vivo at different proportions of CD45.2 YFP+ CD4 T cells to 
CD45.1 CD4+ T cells, to demonstrate IFNγ bystander activation of the CD45.2 YFP+ CD4 T 
cells on the CD45.1 CD4+ T cells in order to develop an inflammatory response and cause 
disease from the T cell transfer. 
 
4.5.1 Transferred naïve YFP- CD45.2 CD4+ T cells do not become YFP+ 
without the presence of a disease phenotype 
 
10 x 106 CD45.2+ naïve YFP- CD4+ T cells were transferred into CD45.1 mice and after 8 
weeks of transfer the mice were analysed. In control experiments, transferring 10 x 106 CD45.2 


























Figure 33: T cell transfer of 10,000,000 naïve CD45.2+ CD4+ YFP- T cells into CD45.1 mice do not develop 
a disease phenotype and remain YFP-. 
A. Representative flow plots showing rediscovery of CD45.2+ CD4+ T cells in the CD45.1 mice in the spleen, 
mLN and colon post-transfer. B. Dot plot showing the percentage and exact cell number of CD4+ CD45.2+ found 
in the CD45.1 mice. C. Dot plot showing the percentage and exact cell number of YFP+ CD4+ CD45.2+ found in 
the CD45.1 mice. (n = 4). Kruskal-Wallis test performed showing overall statistical analysis for all groups. 
 
The YFP- CD45.2 CD4+ T cells that are transferred into the CD45.1 mice was shown to migrate 
to the organs in the mice and there was a significant difference in the amount and percentage 
of CD4+ CD45.2 T cells found in the colon, spleen and mLN post-transfer. However, of these 
the CD45.1 mice were healthy and this could be the reason for why the CD45.2 CD4+ T cells 
did not become YFP positive at all and did not produce any cytokines as they were not 
stimulated (data not shown). This also potentially showed that the YFP- naïve CD4+ T cells 
from these mice do not spontaneously express T-bet and become YFP+ without an 
inflammatory environment to stimulate  them with an inflammatory TH1 response, which was 
Dot plot showing the percentage 
and exact cell number of CD4+ 
CD45.2+ found in the CD45.1 mice 
Representative flow plots showing the population of CD45.1 and CD45.2 cells in 
different organs of CD45.1 congenic mice post-CD45.2 YFP- naïve CD4+ transfer  
33A 
33B 33C Dot plot showing the percentage and 
exact cell number of YFP+ CD4+ 
CD45.2+ found in the CD45.1 mice 






































































































shown in the in vitro culture experiments with YFP- naïve CD4+ T cells. Furthermore, the 
possibility that the presence of other T cells (both CD4 and CD8), within the CD45.1 mice, 
does not have a bystander cytokine activation effects on the CD45.2 YFP- CD4+ T cells to 
stimulate them.  
 
4.5.2 IFNγ production from CD45.2 YFP
+ 
cells was observed when 





In vitro analysis of sorted naive YFP- CD4+ and naïve YFP+ CD4+ T cells (both CD45.2) and 
naïve CD45.1 CD4+ T cells were cultured separately and co-cultured together to test for 
bystander activation from IFNγ production. These sorted cells were plated on pre-incubated 
CD3/CD28 and only given IL-2 and no skewing conditions. Cells were taken off and 
intracellular cytokine flow cytometry was performed after either 3 days, 5 days or 7 days of 
culture and the final supernatants were kept for ELISAs. As performed previously, 25,000 
YFP+ T cells were transferred in vivo with potentially some organ weight differences seen and 
also IFNγ production. Therefore, this number of co-cultured cells (resulting in 50,000 together) 
was also tested here in vitro, before an in vivo co-transfer of CD45.2 and CD45.1 cells into a 































Figure 34: In vitro culture of CD45.1, CD45.2 YFP+ and CD45.2 YFP- with IL-2 and anti-CD3/CD28 shows 
spontaneous production of IFNγ by CD45.2 YFP+ to still occur. 
A. Representative flow plots showing in vitro culture of sorted naïve (CD62L+ CD44-) CD4+ T cells at 50,000 
cells per well of CD45.1, CD45.2 YFP+ and CD45.2 YFP- with IL-2 and anti-CD3/CD28 showing IFNγ 
production after 3, 5 and 7 days of culture. B. Representative flow plots showing the in vitro co-culture of sorted 
naïve (CD62L+ CD44-) CD4+ T cells of CD45.1 and CD45.2 YFP+ with IL-2 and anti-CD3/CD28 at different 
ratios shown of 50,000 cells per well after 7 days of culture. C. Representative flow plots showing the amount of 
IFNγ production from in vitro co-culture of sorted naïve (CD62L+ CD44-) CD4+ T cells of CD45.1 and CD45.2 
YFP+ with IL-2 and anti-CD3/CD28 at different ratios shown of 50,000 cells per well after 7 days of culture. 
(n=3) 
Representative flow plots showing the proportion of CD45.1:CD45.2 YFP+ in vitro 
co-culture 
Representative flow plots showing the proportion of CD45.1:CD45.2 YFP+ in vitro 
co-culture 
Representative flow plots showing IFNγ production from in vitro culture of sorted 







Although this experiment was only performed once and needs repeating to increase the sample 
representative size, there were some promising potential results in the in vitro cultures of the 
CD45.1, CD45.2 YFP- and CD45.2 YFP+, despite only starting with 50,000 cells. The CD45.2 
YFP+ CD4+ T cells were still able to make large amounts of IFNγ after 5 days of culture with 
only IL-2 and CD3/CD28 stimulation, although oddly the day 7 cultures did not show high 
IFNγ production, like in Figure 28. Unexpectedly, the day 3 cultures of the CD45.2 YFP+ 
showed a large proportion of YFP- CD4+. Interestingly, the CD45.2 YFP- CD4 T cells and the 
CD45.1 CD4+ T cells did not suggest to be producing a substantial level of IFNγ, as was seen 
previously with the CD45.2 YFP- CD4 T cells in Figure 28. Interesting, the sorted YFP+ naïve 
CD4+ T cells appeared to lose YFP expression as seen in the flow plots for day 3, where so few 
cells are YFP+ in comparison with day 5 and day 7 where they all are YFP+. This doesn’t make 
sense in the model and will need further replicates and also testing to see if this was the case in 
this experiment. 
Following the results observed above showing that potentially the IFNγ production solely came 
from the YFP+ naïve CD4+ T cell population during in vitro culture, in vitro co-cultures of 
CD45 YFP+ with CD45.1 CD4+ T cells were cultured at ratios of 50:50, 25:75, 10:90 and 1:99 
in a total of 50,000 cells in IL-2 and anti-CD3/CD28 for 5 days. Figure 34B shows that even at 
a ratio of 10:90 the CD45.2 YFP+ T cells can still visibly be found in the cultures. As well as 
the cells proliferating and surviving at a ratio of 10:90, they were shown to still be functioning 
and together able to produce some IFNγ (Figure 34C). From Figure 34, there was plausibility 
that there might be a role for the YFP+ CD4+ T cells having bystander activation effect by 
spontaneously producing IFNγ and being able to act on the CD45.1 CD4+ T cells and further 
stimulate them. However, these in vitro experiments were performed in triplicate and therefore 
these observations could further be concluded if more experiments were performed.  
 
4.5.3 In vivo co-transfer of CD45.1 and CD45.2 YFP+ naïve CD4+ T 
cells shows bystander activation of CD45.2 YFP+ naïve CD4+ T 
cells to produce a sufficient disease phenotype 
 
From the results of the in vitro co-culture, a co-transfer was next attempted of the naïve YFP+ 




injected at a ratio of 10:90 since in vitro they were still identifiable in culture and able to 
produce IFNγ. This was intended to cause a colitis disease within the mice, which is driven by 










Figure 35: Rag2-/- mice co-transferred with 25,000 cells at a 90:10 ratio of CD45.1:CD45.2 YFP+ naïve CD4+ 
T cells  
A. Clinical data showing weight loss after 7 weeks of co-transferred naïve CD4+ T cells in Rag2-/- B. 
Representative flow plots showing IFNγ and IL-17A production from either the CD45.1+ CD4+ CD25- T cells or 
CD45.2 YFP+ CD4+ CD25- T cells. (n=5) 
 
Co-transfer of both the naïve YFP+ CD45.2 CD4 T cells and naïve CD45.1 CD4+ T cells 
showed the possibility that they could produce a disease phenotype, with the weight loss after 
7 weeks, similar to that of the normal T cell transfer, despite the lack of initial starting cell and 
in contrast to when the naïve YFP+ CD4+ T cells were transferred alone in Figure 32. From the 
flow plot, the YFP+ CD4+ T cells are producing only IFNγ and the CD45.1 CD4+ T cells are 
producing a small amount of IFNγ and a lot more IL-17A. This experiment will need repeating 
in order to show this again and obtain further proof that the IFNγ from the YFP+ CD4+ T cells 







The main aim of this chapter was to attempt to characterise this potentially newly identified 
small population of T-bet fate mapped naïve CD4+ T cell. These cells have been shown not to 
be stem cell-like naïve or virtual memory cells, but they were CD5high and could be precursors 
to previously reported MP cells (Kawabe et al., 2017). Interestingly, 30% of the YFP+ naïve 
CD4 T cells showed increased CXCR3+ expression compared to the YFP- naïve T cells. 
CXCR3 has been shown to be regulated by the expression of T-bet and T-bet is required for the 
migration of both CD4+ and CD8+ T cells (Groom and Luster, 2011, Oghumu et al., 2013, Tan 
et al., 2016b). These T-bet fate mapped YFP+ CXCR3+ CD4+ T cells are interesting: they could 
be predetermined early immune responders that are able to migrate to areas of infection more 
readily due to their higher expression of CXCR3. Interestingly, CD28 remained highly 
expressed in the CD44+ CD62L- effector CD4+ T cells, although it has previously been reported 
to become downregulated when naïve T cells become activated. 
 
The data gathered from these different aged T-betcre x ROSA26fl/fl mice shows that these YFP+ 
naïve CD4 T cells appear to develop during the development of the mouse only after birth and 
are even visible from as early as 1 week after birth. It has been shown that T and B cells are 
not fully developed at birth and have also been shown to skew towards a TH2-like response 
instead of a TH1 response (Adkins et al., 2004, Basha et al., 2014, Papaioannou et al., 2019). 
The data shown here however suggests that there is a requirement for an environmental antigen 
to be present that the mice interact with after birth and only after birth does T-bet become 
expressed in a subset of naïve CD4+ T cells. This further enhances the idea that T-bet fate 
mapped naïve CD4+ T cells are predisposed and early inflammatory responders that react to 
environmental antigens. However, this experiment has only been performed once, and due to 
the lack of cell numbers the embryonic foetal livers had to be pooled; the conclusions would 
be stronger if this experiment were replicated. The older 25-week and 52-week mice also 
further demonstrate that the cells are still present in old age and not an artefact of the breeding 
as they are consistent in their expression as the mice age. Old mice are considered to be old at 
18months, where thymic involution and the decline of naïve T cell output occurs (Aw and 
Palmer, 2011, Aw et al., 2007, Palmer, 2013). The phenotyping data gathered here therefore 




reduction seen in the population and percentages of naïve CD4+ T cells in the mice and if the 
percentage of YFP+ naïve CD4+ T cells decline too. 
 
In vitro and in vivo analyses of these YFP+ T cells show that they have a different function to 
the YFP- naïve T cells. They produce high amounts of IFNγ both in vivo and in vitro and from 
the T cell skewing experiments can cause a possible switch to TH1 cell type with increased 
IFNγ production in the different skewed subtypes. This was more prominent in the YFP+ T cell 
transfer experiments. Unfortunately, they were only performed once with a small sample size 
and would ideally need repeating to confirm reproducibility. However, preliminary data 
suggest YFP+ naïve CD4+ T cells have a function in vivo and possibly act as early IFNγ TH1 
responders when there is inflammation present. But this data also suggested that the YFP+ naïve 
T cells are unable to initiate an inflammatory response on their own, and therefore might be 
able to induce bystander activation of the YFP- naïve CD4 T cells to make them produce IFNγ.  
 
Lastly, as shown by the co-transfer experiments, these YFP+ CD4+ naïve T cells have bystander 
activation effects, which polarise naïve YFP- CD4+ T cells in response pathogens and activate 
them to produce IFNγ. From the previous findings, the bystander activation shown here of the 
CD45.1 CD4+ T cells by the CD45.2 YFP+ CD4+ T cells is able to drive the colitis and cause 
disease. This further demonstrated that these YFP+ naïve CD4+ T cells have a role within the 
naïve CD4+ T cell compartment. As bystander activation has previously been reported in MP 
cells and this data shows that the YFP+ naïve CD4 T cells also act with bystander activation 
(Boyman, 2010, Eberl et al., 2000), this data further supports the hypothesis that these cells 
could be precursors to the CD5+ MP cells, as shown previously in the phenotyping data in this 












Results: Identifying a role for T-bet in CD4+ T cell plasticity 
 
As explained in Chapter 1, the plasticity of CD4+ T cells has been widely studied, including 
the role of cytokines, master regulator transcription factors and signal transducers and 
activators of transcription (STATs) in controlling and determining this plasticity (Caza and 
Landas, 2015, Zhou et al., 2009). Although the differentiation of naïve CD4+ T cells has been 
previously studied and described extensively, research into plasticity of CD4+ T helper subsets 
is still at an early stage. When naïve CD4+ T helper cells are given a sufficient signal from 
cytokines and the transcription factors, they undergo activation and differentiate. However, 
these CD4+ T helper cells have not become terminally differentiated. When a change in the 
inflammatory environment occurs, altering the cytokines that the subsets of CD4+ T helper cell 
experiences, then these previously activated effector cells can switch helper subset. This 
provides a more efficient response to pathogens than having to constantly prime naïve CD4+ T 
cells (Evans and Jenner, 2013, Hertweck et al., 2016, Kanhere et al., 2012, Lord et al., 2005, 
Nakayamada et al., 2012, O’Shea and Paul, 2010, Zhu and Paul, 2010).  
 
The use of the T-betcre x ROSA26fl/fl mouse allows tracking previous T-bet expression in 
effector cytokine producing CD4+ T cells at both healthy and disease models. As helper T cells 
have been shown to be so plastic, using this mouse model allows experiments on both YFP- 
IL-17A+ cells and YFP+ IL-17A+ cells in vitro and in vivo to see if they can switch to a TH1-
like phenotype.  
 
Furthermore, the role of T-bet in CD4+ T helper can be characterised and the change after 
differentiation and plasticity can be monitored by deleting T-bet after the development of adult 
mice, by using a CreERT2 x T-betfl/fl tamoxifen inducible deletion model. This mouse model 
was established within the lab, whereby T-betfl/fl mice were bred with CreERT2. The CreERT2 
is a ligand-dependent chimeric Cre recombinase (Feil et al., 1996, Feil et al., 1997, Metzger et 
al., 1995, Sanchez-Fernandez et al., 2012, Zhang et al., 1996). The Cre enzyme is fused to the 
mutated hormone-binding domains of the oestrogen receptor. In normal circumstances, this 
Cre is inactive, however it is possible to be activated using the chemical compound 4-




the Cre with tamoxifen, which is converted to OHT, allows for exterior temporal control of 
the Cre enzyme. Since their first documentation in 1996 by Feil et al., the majority of these 
CreERT2 models have now been used in conjunction with floxed mice models to allow 
temporally controlled deletion of tissue-specific or cell-specific models (Feil et al., 2009). In 
the CreERT2 x T-betfl/fl mouse line, upon delivery of the tamoxifen, the Cre enzyme is activated 
and T-bet is deleted in all cells. TH2 cell function to expel helminths during a parasite infection. 
Upon infection by helminths, TH2 cells produce IL-13, IL-4 and express GATA3 and STAT6 
(Harvie et al., 2010, Pelly et al., 2016, Reynolds et al., 2012). Using models of IBD in the 
CreERT2-Tbetfl/fl mice would provide a physiological readout of plasticity of CD4+ T cells in 
the absence of T-bet.  
 
5.1 Use of the T-bet fate mapping mouse line shows that previous T-bet 
expression allows for TH17 cell plasticity 
 
5.1.1 Previously naïve YFP- CD4+ T cells become effector YFP+ IL-
17A-producing CD4+ T cells with the induction of colitis 
 
As shown in chapter 4, the T cell transfer model of colitis is principally driven by IFNγ but is 
also associated with IL-17A production. Using this same model, the transfer of YFP- naïve 
CD4+ T cells was used to show the plasticity of the effector cells and allowed the plasticity of 
T-bet fate mapped cells to be tested. Figure 31 shows the YFP- T cell transfer data using the 
same protocol as before, where 0.5 x 106 purified naïve YFP- CD4+ T cells were transferred, 







































Figure 36: A subset of IL-17A+ IFNγ- producing CD4+ T cells express YFP during disease. 
A. Clinical data showing weight loss, spleen weight and colon weight 8 weeks after transfer of naïve CD4+ YFP- 
T cells into Rag2-/- mice (n=3 for control and n=7 from TCT mice showing Mann Whitney Test). B. Representative 
flow plot showing cytokine response from stimulated and unstimulated live CD3+ CD4+ CD25- cells from colon 
and mLN after 8 weeks after transfer of naïve CD4+ YFP- T cells into Rag2-/- mice. (n=11) showing Mann Whitney 
Test C. Representative histograms showing YFP expression, T-bet expression and RORγt expression in IFNγ- IL-
17A-, IFNγ+ IL-17A-, IFNγ+ IL-17A+ and IFNγ- IL-17A+ producing cells from the colon. D. Dot plots showing 
YFP expression in IFNγ- IL-17A-, IFNγ+ IL-17A-, IFNγ+ IL-17A+ and IFNγ- IL-17A+ producing cells in colon and 
mLN (n=5). Kruskal-Wallis test performed showing overall statistical analysis for all groups and with Dunn’s 
corrections for individual comparisons. *** = P<0.001 
YFP expression from the colon and mLN 
IFNγ and IL-17A production from the colon and mLN 






























































































































































Figure 36 shows a normal level of wasting colitis disease after 8 weeks and the mice suffered 
with increased colon and spleen sizes like Figure 30 from Chapter 4. The clinical data showed 
a significant difference from the YFP- naïve CD4+ transferred mice when compared with the 
control mice. Cytokine production was significantly found to be produced in the form of IFNγ 
with some IL-17A production too (Figure 36B). Figure 36C and 36D showing that there was 
YFP+ IL-17A producing cells from the representative histograms of YFP expression and that 
there was a statistically significant difference between the percentage of YFP+ cytokine 
producing subtypes. The histograms for T-bet and RORγt showed that these effector TH1 and 
TH17 cells were still positive for their representative transcription factors that control their 
differentiation. The IFNγ+ IL-17A- single producing CD4+ T cells were highly T-bet+ and 
RORγt- and therefore YFP+. The IFNγ+ IL-17A+ double producing CD4+ T cells showed 
intermediate levels of both T-bet expression and RORγt and as expected there were some 
double producing CD4+ T cells which were YFP+. In comparison, the IFNγ- IL-17A+ single 
producing CD4+ T cells were RORγt+ and T-bet-. However, interestingly there were a small 
(approximately 20%) subset of IL-17A+ IFNγ- cells that were YFP+ in both the colon and the 
mLN, although these were not significantly different in comparison with the percentage of 
YFP+ expressing IFNγ+ IL-17A- single producing CD4+ T cells. Since all the naïve CD4+ T 
cells entered the mice as YFP- when they were transferred, this however potentially suggests 
that during the differentiation of the TH17 CD4
+ T cells to produce IL-17A, some of the TH17 
cells expressed T-bet; even if afterward they stopped expressing T-bet. Using this mouse model 
to trace the lineage of T-bet expressing TH17 cells could provide further potential insight into 
the plasticity of TH17. 
 
5.1.2 In vitro culture of YFP+ IL17A+ IFNγ- CD4+ T cells show a 
predominance to switching to IFNγ production 
 
The data shown in Figure 36 showed the potential for certain YFP+ IL-17A+ effector CD4+ T 
cells to possibly switch to an IFNγ producing phenotype. Therefore, in order to try and test 
this, a cytokine secretion assay was performed in order to sort and purify the different cytokine 
YFP expressing cells. IL-17A+ YFP-, IL17A+ YFP+, IFNγ+ YFP- and IFNγ+ YFP+ producing 
CD4+ T cells from the mLN and colon of the Rag2-/- mice that had originally received naïve 
YFP- CD4+ T cells, as shown in the previous figure, were sorted and purified. The gating 




populations were then plated onto pre-incubated anti-CD3/CD28 plates and given IL-2 for their 
survival, similar to the protocol shown in the in vitro culture of the naïve YFP+ CD4+ T cells. 
Flow cytometry and ELISAs of the supernatant were analysed from these in vitro cultured cells 






















































Figure 37: IL-17A+ IFNγ- YFP+ CD4+ T cells produce more IFNγ and less IL-17A than IL-17A+ IFNγ- YFP- 
CD4+ T cells upon reactivation and re-stimulation ex vivo of T cell transfer colitis induced mice. 
A. Gating strategy used to sort purified cytokine secreting CD4+ T cells from the mLN and colon of Rag2-/- mice 
transferred with naïve YFP- CD4+ T cells. B. Representative flow plot from the mLN and colon showing cytokine 
response from stimulated cytokine secretion YFP- or YFP+ T cells after 7 days in culture in vitro. C. ELISA data 
showing cytokine production for IFNγ and IL-17A from the supernatant of the cultured cytokine secretion YFP- 
or YFP+ CD4+ T cells from both mLN and colon (n=4, with experiment performed twice). Kruskal-Wallis test 
performed showing overall statistical analysis for all groups and with Dunn’s corrections for individual 
comparisons. 
 
The flow plots and ELISA data in Figure 37 show the subsequent cytokine responses from the 
effector cells after 7 days of in vitro culture after TCR re-stimulation ex vivo. The ELISA data 
showed that there was a significant difference between all cell types sorted but there was only 
the IFNγ+ YFP+ significantly producing more IFNγ than the IL-17A+ YFP- cells in the colon 
and mLN, and as expected the IFNγ+ YFP+ significantly producing more IFNγ than the IFNγ+ 
ELISA data showing IFNγ and IL-17A production from in vitro cultured 
cytokine secretion sorted effector CD4+ T cells 
Representative flow plots showing IFNγ and IL-17A production from in vitro 






YFP- cells in the mLN. Remarkably, this potentially showed a possibility that the IL-17A+ 
YFP+ CD4+ T cells were, upon re-stimulation, able to produce a considerable amount of IFNγ 
and less IL-17A, especially in the colon, when compared with the IL-17A+ YFP- CD4+ T cells 
in both intracellular cytokine staining and by ELISAs; although these were not statistically 
significant, there was a trend towards this and with more sample repeats this would probably 
become significant. This helped to demonstrate that there could be the possibility that initial T-
bet+ fate mapped IL-17A+ CD4+ cells can switch to a more TH1-like phenotype and produce 
IFNγ more readily, especially in a disease setting upon stimulation of TCR.  
 
5.1.3 Transfers of YFP+ IL17A+ IFNγ- CD4+ T cells into RAG2-/- mice 
reveals a possible predominance to switching to IFNγ production 
 
From the data in Figure 37, the cytokine secretion assay allowed us to further adoptively 
transfer these sorted colitogenic effector cytokine producing cells from the colitis drive T cell 
transfer modelled cells into another Rag2-/-. In vivo characterisation and differences between 
IL-17A+ YFP-, IL17A+ YFP+, IFNγ+ YFP- and IFNγ+ YFP+ CD4+ T cells could be established 
by transferring them into another Rag2-/- mouse. These populations were quite small and 
therefore after the sort only 1.5 x 104 of each population were able to be transferred to separate 
Rag2-/- mice. Figure 38 shows that the transferred CD4+ T cells could be identified in all six 
recipient mice. Similarly, to the previous T cell transfer experiment, clinical data was recorded, 
and intracellular cytokine responses were measured using flow cytometry as before. Organ 
cultures using 3mm biopsy punches and unfractionated cell cultures for 24 hours were set up 
and ELISAs were performed, using the same concentration of cells (1 x 106/ml) for each 
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Figure 38: IL-17A+ IFNγ- YFP+ CD4+ T cells produce more IFNγ and less IL-17A upon retransfer into Rag2-
/- mice. 
A. Weight changes over 9 weeks and spleen and colon weight at the end of the 9 weeks B. Gating strategy used 
to identify the CD4+ T cells that had been transferred. C. Flow plots from the spleen and colon of post-transferred 
Rag2-/- mice identifying the CD4+ T cell population in each organ D. Representative flow plots showing IL-17A 
and IFNγ production from the colon and spleen of recipient Rag2-/- mice. E. ELISA data for IL-17A, IFNγ, TNFα 
and IL-22 from the supernatant of unfractionated cell cultures from the spleen, mLN and colon. F. ELISA data 
for IL-17A, IFNγ, TNFα and IL-22 cytokine production from the supernatant of colonic organ culture. (n=1 for 
IFNγ+ YFP- and IFN γ+ YFP+ and n = 2 for IL-17A+ YFP-, IL-17A+ YFP+ and Rag2-/- controls) 
ELISA data showing cytokine production from organ cultures 
ELISA data showing cytokine production from unfractionated cell 






Firstly, to note that these results all need repeating due to the very low sample size, but they 
provided a tiny insight into the possible effects of the plasticity of T-bet YFP+ IL-17A cells 
and their potential to switch to an IFNγ phenotype. Clinical data from the cytokine secretion 
sorted specific T cell transfer showed a possible trend for the IFNγ+ YFP+ recipient mice, which 
appeared  to not gain as much weight, and the IL-17A+ YFP+ recipient mice had looked like 
they were starting to lose weight in comparison to the untreated Rag2-/- control mice. 
Surprisingly, given that such a small starting number of cells were transferred, the IFNγ+ YFP+, 
IL-17A+ YFP- and IL-17A+ YFP+ recipient mice showed a potential trend to have larger spleens 
and colons compared to the Rag2-/- control mice; despite not showing wasting disease (Figure 
38A). Figures 38B and 38C show the gating strategy and the CD4+ live gate for the cells of the 
individual recipient mice. This was important to show because the starting number of CD4+ T 
cells that were transferred was low, therefore it was vital to ensure that these CD4+ T cells 
could be identified within the spleen and colon to illustrate that they not only survived but also 
were able to migrate to sites of inflammation. The intracellular cytokine response shows a trend 
that the IFNγ+ YFP+ recipient mouse produced more IFNγ in the colon compared to the IFNγ+ 
YFP- transferred mouse (Figure 38D). The comparison in both spleen and colon between the 
IL-17A+ YFP- and IL-17A+ YFP+ recipient mice showed that the IL-17A+ YFP- cells had a 
trend to  producing larger amounts of IL-17A and little IFNγ and the IL-17A+ YFP+ cells, in 
contrast, produced less IL-17A and switched to producing more IFNγ. The ELISA data, in 
Figure 38E and 38F, from both unfractionated cell cultures and colon organ culture further 
helped to confirm this trend in cytokine switch from IL-17A to IFNγ in both YFP+ IFNγ and 
YFP+ IL-17A+ recipient mice and with further increased sample sizes could even become a 
statistically significant difference. The lack of wasting disease may have been due to the small 
number of cells transferred to the new Rag2-/- mice, similar to how little disease phenotype was 
observed in the 25,000 T cells transferred with the naïve YFP+ CD4+ T cells. More repeats of 
this transfer would be needed to test this and also transfers of more cell numbers would be 
ideal, since as seen in Figure 32 with the increased numbers of naïve YFP+ CD4+ transferred 
between 25,000 to 100,000 had clinical and phenotypic differences in inducing disease. 
 
5.1.4 Summary of the plasticity of YFP+ TH17 cells 
 
Previous studies within this group have shown that the suppression of TH17 cell differentiation 




However, now with the use of the T-bet lineage traceable mice and the T cell transfer model, 
an insight into the presence of differentiated effector IL-17A producing CD4+ T cells that are 
YFP+ and RORγt+ but T-bet-. The data shown in this thesis showed that there is a possibility of 
a pathogenic IL-17A-producing effector TH17 cells that have previously expressed T-bet, 
demonstrating the plasticity of TH17 cells. Cytokine secretion sorts of these cells further 
showed a potential trend that in both in vivo and in vitro experiments, the IL-17A YFP+ CD4+ 
T cells had the potential to switch into an IFNγ producing phenotype and downregulate IL-17A 
production in comparison to the IL-17A YFP- CD4+ T cells. This suggested that initial fate 
mapped expression of T-bet drives this plasticity in TH17 cells to become TH1-like. A possible 
observation was that the transferred IL-17A YFP+ T cell did not cause more pathological 
disease than the other subtypes of cytokine producing CD4+ T cells, although more repeats of 
this will be needed to prove this. However, the transfer of all sorted cytokine producing effector 
T cells by the cytokine secretion assay needs repeating to get more reliable and statistically 
significant results. 
 
5.2 Using the inducible deletion model of T-bet in fully developed CD4+ T 
cell populations to test for plasticity under healthy conditions 
 
The T-betcre x ROSA26fl/fl mouse line is a useful tool to investigate the plasticity of CD4+ T 
cells in relation to their lineage of T-bet expression. However, the ability to conditionally delete 
T-bet in a mouse at any given time and space is potentially even more useful to show the 
plasticity of CD4+ T cells. This has allowed experiments to test the plasticity of both CD4+ T 
cells and innate lymphoid cells after the cells have developed within the mouse and control 
deletion of T-bet before inducing disease within these CreERT2 x T-betfl/fl tamoxifen inducible 
deletion mouse model. T-bet fl/fl mice were previously generated by our group and crossed with 
ERT2 mice to generate either Cre-ERT2+/- (Het) or Cre-ERT2-/- (WT) mice expressing T-bet fl/fl 
(Hom). In vivo depletion of T-bet was induced by consecutive intraperitoneal injections of 
tamoxifen on five consecutive days with one injection per day. Unless stated otherwise, tissues 





5.2.1 In vitro tamoxifen induced deletion of T-bet in cultures of CD4+ 
cells from CreERT2-Tbetfl/fl mice 
 
For in vitro experiments, tamoxifen was given directly into cell culture media. Initial 
experiments were performed to test the length of time and dose response required to induce 
some T-bet deletion or reduction in CD4+ T cells. Bulk CD4+ T cells were sorted from the 
spleen of CreERT2-Tbetfl/fl mice and cultured at 1 x 106/ml on CD3/CD28 with IL-2. The cells 
were also treated with in vitro tamoxifen for either 0, 4, 6, 12 or 24 hours and at 
concentrations of either 0, 0.25, 0.5, 1 or 2µM. Litter mate CreERT2-Tbetfl/fl mice, which were 




















Figure 39: In vitro testing of dose response and optimal time for exposure of cultured CD4+ T cells from 
CreERT2-Tbetfl/fl with tamoxifen. 
A. Representative flow plot and histograms showing the expression of T-bet in live CD3+ CD4+ T cells from 
WT/Hom and Het/Hom of CreERT2-Tbetfl/fl after giving 2µM for either 4 hours, 12 hours or 24 hours. (n = 3) 
39A Flow plot and histograms showing T-bet expression between in vitro cultured cells 
from WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice treated with tamoxifen at 




Despite using different concentrations of tamoxifen, the only concentrations that showed any 
effect of T-bet expression in CD4+ T cells was the 2µM dose. This experiment also established 
that the cells required at least 24 hours to achieve a considerable T-bet deletion/reduction in 
expression in CD4+ T cells. At 24 hours exposure at 2µM, there is almost a 50% reduction in 
the percentage of cells expressing T-bet. The histogram showed the T-bet level was reduced 
by 10% (from around 40% to 30% comparing WT/Hom with Het/Hom). Interestingly, giving 
tamoxifen for the times and concentrations shown was not able to completely reduce T-bet 
expression in bulk cultured CD4+ T cells in vitro. This observation potentially showed that 
in this CreERT2-Tbetfl/fl model, tamoxifen Cre induced T-bet deletion does not completely 
reduce T-bet expression in fully developed CD4+ T cells. From work within the lab 
investigating this same model in ILCs, the in vitro culture of sorted ILC1s from the colon of 
these mice showed marked reduction (over 50%) in T-bet. Consequently, this shows that the 
in vitro experiments with tamoxifen were able to reduce T-bet in these mice, but not in CD4+ 
T cells.  
 
5.2.2 In vitro skewing experiments in CD4+ T cells after tamoxifen-
induced T-bet deletion 
 
In vitro experiments investigating specific T cell skewing protocols after treatment with 
tamoxifen were performed. The aim was to examine the effect of T-bet deletion CD62L+ CD44- 
naïve CD4+ T cell differentiation. Treatment with tamoxifen did not reduce the amount of T-
bet expression in CD4+ T cells in the presence of IL-2 only. For these skewing experiments, 
cells were treated with 1µM tamoxifen for the last five days, after the initial two days of 
activation on CD3/CD28. Standard skewing cytokine conditions were used as listed previously. 
Naïve CD62L+ CD44- CD4+ T cells were sorted from CreERT2-Tbetfl/fl mice using the same 






































Figure 40: In vitro testing of naïve CD4+ T cell skewing after tamoxifen induced deletion of T-bet in CD4+ 
T cells from CreERT2-Tbetfl/fl mice. 
A. Representative flow plots and MFIs showing cytokine production (gated from unstimulated cells) from skewed 
CD4+ T cells from WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice treated with tamoxifen. B. Representative 
histograms showing transcription factor expression from skewed CD4+ T cells from WT/Hom and Het/Hom 
CreERT2-Tbetfl/fl mice treated with tamoxifen. (cells plated in triplicate). Kruskal-Wallis test performed for all 
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In vitro tamoxifen treatment of CD4+ T cells in different differentiation skewing conditions 
showed some possibly interesting results. The transcription factor expression histograms 
potentially showed a trend that giving tamoxifen for five days after activation with CD3/CD28 
reduced T-bet expression in TH1 cells (Figure 40B) from Het/Hom (blue) vs WT/Het control 
(red), although the MFI from these did not show a significant reduction in T-bet expression 
between the Het/Hom vs WT/Het control. Remarkably, GATA3 and RORγt expression showed 
a trend to being increased in T-bet-deleted cells in the Het/Hom TH1, TH2 and TH17 skewed 
cells from the histogram plots, although again the increase in MFI for both GATA3 and RORγt 
expression was not statistically significant. The cytokine response data, in Figure 35A, showed 
that despite the reduction in T-bet in the TH1 skewed cells there was no significant reduction 
in the percentage or MFI of IFNγ from Het/Hom treated with tamoxifen. Furthermore, there 
were only minor and, again, not significant increases in IL-13 and IL-17A production in TH2 
and TH17 cells respectively, despite the relative increased expression of their respective 
transcription factors. Results from this skewing experiment showed a non-significant trend that 
despite the reduction in T-bet, the cytokine production was not vastly increased. However, it 
did demonstrate that the in vitro model of tamoxifen was able to slightly reduce T-bet 
expression in TH1 cells. 
 
5.2.3 In vivo tamoxifen induced deletion of T-bet in CD4+ cell of 
CreERT2-Tbetfl/fl mice 
 
In vivo experiments were performed at healthy state to observe the effect that administering 
tamoxifen would have on CD4+ T cell population in CreERT2-Tbetfl/fl mice. As described 







































Figure 41: In vivo testing of tamoxifen induced deletion of T-bet in CD4+ T cells from CreERT2-Tbetfl/fl. 
A. Representative gating strategy used for gating of CD4+ T cells in the spleens of CreERT2-Tbetfl/fl mice. B. 
Representative flow plot showing the percentage of CD4+ in the spleen and mLN from WT/Hom and Het/Hom 
CreERT2-Tbetfl/fl mice treated with tamoxifen. C. Representative flow plots and dot plot showing T-bet 
expression in the spleen and mLN from live CD3+ CD4+ CD25- T cells from WT/Hom and Het/Hom CreERT2-
Tbetfl/fl mice treated with tamoxifen D. Representative histograms and dot plots showing T-bet expression in 
the spleen and mLN from both naïve (CD62L+ CD44-) and effector (CD44+ CD62L-) CD4+ T cells from WT/Hom 
and Het/Hom CreERT2-Tbetfl/fl mice treated with tamoxifen. (n = 3) Mann Whitney test performed for statistical 
analysis. 
T-bet expression from naïve and effector CD4+ cells in vivo tamoxifen treatment of 
CreERT2-Tbetfl/fl mice 
T-bet expression from CD4+ cells in vivo tamoxifen treatment of CreERT2-Tbetfl/fl mice 
Gating strategy used for in vivo tamoxifen 
treatment of CreERT2-Tbetfl/fl mice 
Percentage of CD4+ cells in vivo tamoxifen 











































The in vivo experiments showing tamoxifen induced deletion of T-bet in healthy CreERT2-
Tbetfl/fl mice provided some interesting prospective findings with respect to the CD4+ T cell 
population. Firstly, the percentages and amount of both naïve (CD62L+ CD44-) and effector 
(CD44+ CD62L-) CD4+ T cells do not reduce at all when given tamoxifen and inducing Cre 
deletion (Figure 41B). T-bet was expressed within the CD4+ CD25- T cell population in the 
Het/Hom mice and has not been deleted despite the use of tamoxifen (Figures 41C). Whilst 
there was also no significant change in the percentage of T-bet expressing specific effector and 
naïve CD4+ T cells (Figure 41D). This experiment was performed in collaboration with another 
project looking at the temporal deletion of T-bet in ILCs. In these same mice, during in vivo 
administered tamoxifen, the ILC1s were completely lost and T-bet reduction occurred in the 
NK cells. Evidence of the ILC cell loss and T-bet reduction again demonstrated that the results 
in the CD4+ T cells was not due to the tamoxifen administration failing.  
 
Both these experiments were performed under healthy conditions where CD4+ T helper cell 
plasticity is not necessary. Hence, plasticity of CD4+ T helper cells would need to be 
investigated in both TH2 and TH17 driven disease models. 
 
5.3 Using the inducible deletion model of T-bet to test for plasticity in 
pathological environments 
 
5.3.1 Testing the plasticity of TH2-driven parasite models after 
inducing T-bet deletion 
 
The aim was to understand the plasticity of CD4+ T cells upon deletion of T-bet using models 
of helminth infection in the CreERT2-Tbetfl/fl mice. As described previously, tamoxifen was 
administered for five consecutive days via intraperitoneal injections. After two weeks, mice 
were infected with either Nippostrongylus brasiliensis (Nippo) or Heligmosomoides polygyrus 
(H. poly) via oral gavage. Tissues were extracted after either seven days or nine days for Nippo 
experiments or fourteen days for the H. Poly infections. Results from these experiments are 
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Figure 42: Infection with Nippostrongylus brasiliensis after tamoxifen-induced deletion of T-bet in CD4+ T 
cells from CreERT2-Tbetfl/fl mice. 
A. Dot plot showing eggs per gram and worm count in the WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice post 
infection with Nippo and tamoxifen treatment. B. Representative gating strategy from the spleen of CreERT2-
Tbetfl/fl mice. C. Representative flow plots showing CD44 and CD62L expression on live CD3 + CD4+ CD25- 
from WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen treatment and 7 days of Nippo infection. D. 
Representative flow plots showing IFNγ and IL-13 production (gated from unstimulated controls) from CD44+ 
CD62L- effector CD4+ T cells in WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen treatment and 
7 days of Nippo infection. E. Dot plots showing IFNγ and IL-13 production (gated from unstimulated controls) 
from CD44+ CD62L- effector CD4+ T cells in WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen 
treatment and 7 days of Nippo infection. F. Representative flow plots and dot plot showing IFNγ and IL-13 
production (gated from unstimulated controls) from CD44+ CD62L- effector CD4+ T cells in WT/Hom and 
Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen treatment and 9 days of Nippo infection. G. Representative 
histograms and dot plots showing T-bet and GATA3 expression (gated off isotype controls in black) from the 
lungs of CD44+ CD62L- effector CD4+ T cells in WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen 
treatment and 9 days of Nippo infection. (n = 4 for day 9 and n = 7 for day 7 infections). Mann Whitney test 
performed for statistical analysis. 
Histogram and dot plots showing transcription factor from effector CD4+ in 
CreERT2-Tbetfl/fl mice treated with Nippo for 9 days 
Flow plots and dot plots showing cytokine production from effector CD4+ in 






The Nippo egg and worm count showed no significant differences when tamoxifen was given 
in either of the groups of mice. Figure 42A did demonstrate, though, that eggs and worms were 
still present on day 7, but by day 9 were cleared from the mice. Surprisingly, use of the Nippo 
parasite model caused loss of all naïve (CD62L+ CD44-) CD4+ T cells and only effector cells 
(CD44+ CD62L-) could be found (Figure 42C). This could possibly be due to tamoxifen usage 
in the CreERT2 being cleaved or being downregulated. However, this has not been reported 
on. The loss of naïve (CD62L+ CD44-) CD4+ T cells is odd since only one pathogen was given 
and should only have induced the response from certain naïve T cells that would respond that 
that. The cytokine response from mice infected on day 7, surprisingly showed no IL-13 
production in the lung, mLN and Peyer’s patches, despite day 7 showing the largest number of 
eggs and worms. There was only a slight increase in IL-13 production in the spleen in 
comparison with the WT/Hom control and Het/Hom, although this was not significant. This 
could potentially show that when deleting T-bet in this model there is a minimal switch to more 
of a TH2-IL-13 response. The tissue from the infected mice at day 9 showed a marked, but not 
significant, increase in IL-13 production in the lung especially in the tamoxifen treated 
Het/Hom mice (Figure 42F). Figure 42G, further, shows that effector CD4+ the Het/Hom 
tamoxifen treated mice, did not have significant reduced levels of T-bet or significantly 
increased levels of GATA3 expression.  
 
ILC data acquired from these mice by others in the lab again were differentto the CD4+ T cell 
data. Data from day 7 showed an IL-13 response from ILC2s, although there was no difference 
in the amount of IL-13 production between the WT/Hom and Het/Hom, whereas data from day 
9 showed no IL-13 cytokine response from the ILC2 population in either genotype of mice. 
Since the innate immune response is quicker than the adaptive immune response, data from 
within the lab further helped to demonstrate this. Similar to the in vivo experiment performed 
on the healthy Cre-ERT2 Tbetfl/fl mice, there was a reduction in the percentages of ILC1 seen in 
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Figure 43: Parasite infection with Heligmosomoides polygyrus after tamoxifen induced deletion of T-bet in 
CD4+ T cells from CreERT2-Tbetfl/fl. 
A. Dot plot showing egg per gram and worm count in the WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice post 
infection with H.Poly and tamoxifen treatment. B. Representative gating strategy from the spleen of CreERT2-
Tbetfl/fl mice C. Representative flow plots showing CD44 and CD62L expression on live CD3+ CD4+ CD25- 
from WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen treatment and 14 days of H.Poly infection. 
D. Representative flow plots showing IFNγ and IL-13 production (gated using unstimulated controls) from 
CD44+ CD62L- effector CD4+ T cells in WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen 
treatment and 14 days of H.Poly infection. E. Dot plots showing IFNγ and IL-13 production from CD44+ 
CD62L- effector CD4+ T cells in WT/Hom and Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen treatment and 
14 days of H.Poly infection. F. Representative histograms and dot plots showing T-bet and GATA3 expression 
(gated off isotype controls shown in black) from CD44+ CD62L- effector CD4+ T cells in WT/Hom and 
Het/Hom CreERT2-Tbetfl/fl mice after tamoxifen treatment and 14 days of H.Poly infection. (n=3 in both 
groups). Mann Whitney test performed for statistical analysis. 
 
H. Poly parasite infection experiments in these Cre-ERT2 x T-betfl/fl mice showed very similar 
results to the Nippo infected mice. Firstly, egg and worm counts were visible, although not as 
high as in the Nippo infection, and again the results showed no significant difference between 
the WT/Hom compared with the Het/Hom when both were given tamoxifen prior to infection. 
Histogram and dot plots showing transcription factor from effector CD4+ in 





The egg and worm counts were not as high as the Nippo counts, possibly due to the reading 
being taken at 14 days; at which point H. Poly infections are known to be cleared by around 
day 10 (Filbey et al., 2014). Similarly to the Nippo infection, upon treatment with H. Poly there 
were no CD62L+ CD44- naïve CD4+ T cells to be found and only effector CD44+ CD62L- CD4+ 
T cells were found within the CD4+ T cell compartment, which again didn’t make sense, 
whereas in the DSS model in Figure 44, there are naïve CD4+ T cells present still. Figure 43E 
showed similar results to the Nippo infection experiments, the level of IFNγ and IL-13 
production from the tissue was not as great as expected for a pathogen response. However, 
interestingly there was an increase in the amount of IL-13 production in only the lungs in 
comparison between the Het/Hom and WT/Hom mice, although this was not significant. These 
data were consistent with the transcription factor expression data, shown in Figure 43F, when 
treated with tamoxifen. There was a slight trend in reduction in T-bet expression and only a 
significant (P=0.05) increase GATA3 expression in the lungs, and a trend in an increase in 
GATA3 expression in the other tissue, when comparing the Het/Hom mice with the WT/Hom 
control mice.  
 
Again, comparing CD4+ T cell population response with ILC data from others in the lab, there 
was a marked reduction in the percentages of ILC1s present in all tissue from the Het/Hom 
mice treated with tamoxifen, as seen with the other in vivo experiments. The ILC2 population 
in the lungs of the tamoxifen treated Het/Hom mice also produced a vast amount of IL-13. 
 
5.3.2 Summary of plasticity of TH2-driven parasite models after 
inducing T-bet deletion 
 
Both the Nippo and H. Poly parasite infection models showed that there was no deletion or 
reduction of T-bet and only an increase in GATA3 expression in the Het/Hom mice in the H. 
Poly infection to drive expulsion of the worms and eggs compared with WT/Hom mice. There 
was a trend, even though not significant, showing an increase in IL-13. This showed that 
despite the slight reduction of T-bet, this was not enough to drive plasticity of TH1 cells towards 
a TH2 phenotype. This further demonstrates that the amount of plasticity between TH1 and TH2 





5.3.3 Testing the plasticity of TH17-driven DSS-induced colitis after 
inducing T-bet deletion 
 
The aim was to test plasticity of TH17 cells after the induction of tamoxifen using the DSS 
colitis model in the Cre-ERT2 T-betfl/fl mice. 3% DSS was given in the drinking water to mice 
over a period of five days and then given normal water for five days afterwards. Mice were 
monitored during this time for their weight and analysed after for clinical differences in spleen 


























Gating strategy used for CreERT2-Tbetfl/fl mice treated with 3% DSS 
Clinical data showing weight loss and organ weights in for CreERT2-Tbetfl/fl mice 
































Figure 44: DSS-induced colitis in tamoxifen treated WT/Hom and Het/Hom CreERT2 Tbetfl/fl mice. 
A. Clinical data showing weight loss, spleen weight, colon weight and colon length in WT/Hom and Het/Hom 
CreERT2 T-betfl/fl mice given tamoxifen and then either fresh water (FW) or 3% DSS. B. from the spleen of 
CreERT2-Tbetfl/fl mice. C. Cytokine response showing IFNγ, IL-17A and IL-13 production in the spleen, colon, 
mLN and liver of CD44+ CD62L- effector CD4+ T cells from WT/Hom and Het/Hom CreERT2 T-betfl/fl mice 
given tamoxifen and then either fresh water (FW) or 3% DSS. D. Transcription factor showing T-bet, GATA3 
and RORγt production in the spleen and colon, of WT/Hom and Het/Hom CreERT2 T-betfl/fl mice given tamoxifen 
and then either fresh water (FW) or 3% DSS. (n= 8 for fresh water treated mice and 14 for DSS treated mice). 
Kruskal-Wallis test performed for all groups and with Dunn’s corrections for individual comparisons 
Representative histograms showing transcription factor expression in the spleen and colon from 
WT/Hom and Het/Hom CreERT2 T-betfl/fl mice given tamoxifen and 3% DSS 
Representative flow plots showing cytokine response in the spleen, colon, mLN and liver from 







DSS-induced colitis in tamoxifen treated WT/Hom and Het/Hom CreERT2 T-betfl/fl mice 
provided some interesting data. Firstly, the clinical data demonstrated that the WT/Hom mice 
lost more weight than the Het/Hom mice, although this was not significant, possibly indicating 
that the reduction in T-bet results in less severe disease. This was also seen by the significantly 
higher disease activity index score at day 9 between the WT/Hom and Het/Hom mice treated 
with DSS. However, the spleen weight, colon weight and colon lengths were not significantly 
different between the WT/Hom and Het/Hom treated with DSS but were significantly different 
between all 4 groups. In the DSS treated mice, effector CD4+ T cells producing IFNγ, IL-17A 
or IL-13 was not observed when compared with the fresh water treated healthy mice. However, 
as expected, there was a significant reduction in IFNγ and an increase in IL-17A in the spleen 
and colon of the T-bet-deleted Het/Hom mice. This was further confirmed by transcription 
factor expression data. RORγt exhibited increased expression in the colon, whilst T-bet 
expression was slightly reduced after treatment of Het/Hom mice with DSS and tamoxifen 
compared to the WT/Hom mice.  
 
As with the parasite infection experiments, the ILCs were investigated in these mice in parallel 
with the CD4+ T cells. As was seen in the previous models, the percentage of ILC1s was 
significantly diminished. The remaining ILC1s that were still present were found to have 
significantly reduced T-bet expression. Despite this, there was no difference in IFNγ, IL-13, 
IL-5 and IL-17A production in the ILC population. 
 
5.3.4 Summary of the plasticity of TH17 driven disease using DSS-
induced colitis after inducing T-bet deletion 
 
These experiments using the DSS-induced colitis model did not demonstrate as great a switch 
from the TH1-IFNγ CD4
+ T cells to TH17-like IL-17A producing CD4
+ T cells as expected. 
The clinical data showed that the WT/Hom mice lost more weight than the Het/Hom mice, but 
the other clinical readouts showed equivalent disease phenotypes. This provided further proof 






5.4  Discussion 
 
Although a lot of the data in this chapter needs repeating due to the low sample size, especially 
the cytokine capture assay T cell transfers, there is a trend to potentially seeing a role that T-
bet may have in controlling the plasticity of CD4+ T helper cells when either historically 
expressed or temporally deleted. The T-bet fate mapping mouse and induced T-bet deletion 
model have been shown here to have potential as good models to investigate the role of T-bet 
in controlling plasticity of CD4+ T cells.  
 
Firstly, the observation of T-bet fate mapped TH17 cells showed that T-bet plays a role in 
driving IFNγ production in TH17 cells. The data shown here potentially showed that T-bet fate 
mapped cells were also more able to switch to a more TH1-like phenotype if they had expressed 
T-bet in the past. However, this experiment needs repeating to confirm this due to the small 
sample size and difficulties experienced in replicating the experiment. However, when the 
opposite was not observed in the DSS-induced tamoxifen treated mice, which showed that the 
deletion of T-bet from these TH17 RORγt
+ IL-17A producing cells did not drive increased IL-
17A production. These experiments showed that it was the expression of T-bet that caused the 
TH17 cells to become TH1-like but the reduction in T-bet does not drive a more TH17-like state.  
The cytokine secretion T cell transfer data has only been produced once and the findings are 
therefore still preliminary, and repetition would enhance reliability. However, the data has 
some implications despite the low sample size. Morrison et al. in 2013 showed that when either 
3 x 104 IFNγ+, IL-17A+ or IFNγ+ IL-17A+ cells were transferred into Rag2-/- mice with 
Helicobacter hepatic induced colitis, after they were sorted using the cytokine secretion assay, 
the IFNγ+ IL-17A+ producing cells switched and produced predominately IFNγ, whereas the 
IL-17A+ single positive cells remained IL-17A producing (Morrison et al., 2013). The T-bet+ 
and RORγt+ T cells preferentially switched into an IFNγ+ TH1-like phenotype. Sorting of IL-
17A+ and IFNγ+ cells showed that IL-17A+ T cells that have previously expressed T-bet were 
more likely to switch into a TH1-like phenotype and produce IFNγ (Morrison et al., 2013). This 
plasticity is accompanied by a much-reduced disease colitis phenotype compared with the 
Morrison et al. results. The expression of T-bet, even if only the past, allows for TH17 cells to 





Observations made from the in vitro and in vivo tamoxifen experiments were surprising. The 
administration of tamoxifen in both in vitro and in vivo models did not cause deletion or even 
reduction in the expression of T-bet in CD4+ T cells. Furthermore, unlike in ILC1s where the 
reduction of T-bet in ILC1s causes them to be lost (data not shown), T-bet is clearly not an 
essential requirement for the survival of fully developed CD4+ T cells. The parasite infection 
models showed that the deletion of T-bet also was unable to drive switching to a TH2-like 
phenotype, although there were slight increases in expression of GATA3 and TH2 cytokine 
production. These experiments further demonstrated TH2 and TH1 cells to be stable, as has 
previously been reported. The DSS-induced colitis models were also unable to show any 
plasticity between TH1 and TH17 cells despite the increase in IL-17A production and RORγt 
expression in the colon of these mice. These findings are interesting in context with past 
research with the loss of T-bet, in which full T-bet knockout (T-bet−/−) mice were used. In these 
experiments, the mice were found to be deficient in TH1 cells and also developed either TH2 or 
TH17 mediated diseases depending on what disease model the group were researching (Neurath 
et al., 2002, Bettelli et al., 2004, Finotto et al., 2002) . In these T-bet−/− mice, they found that 
they were also more resistant to the development of TH1 mediated disease. Using the tamoxifen 
deletion model allowed for normal CD4+ T cell development before then attempting to delete 
T-bet in these cells and as seen in my data, either the use of tamoxifen is not able to delete T-
bet within developed naïve and effector CD4+ T cell compartment or more time points and a 
higher dose of injections are required. However, since T-bet deletion occurred in the ILC 
compartment of these mice and when used by Wang et al showed T-bet deletion in TFH cells 
occurred when used at the same dose and time points as used in my experiments (Wang et al. 
2019). Wang et al. interestingly showed some reduction in the population of TFH cells from 
fully mature CD4+ T cells but the population of cells were not completely lost (Wang et al. 
2019). From their results, they also showed the CD4+ CD44+ population still existed when 
tamoxifen was given, and this was supported by my data too (Wang et al. 2019). The complete 
loss of CD4+ T cells expressing CD62L, still should not be the case in this mouse line, and yet 
it is seen in all organ types and in both the WT/Hom control line and Het/Hom, meaning the 
deletion of T-bet was not to blame. Whereas when using the DSS model, the naïve (CD62L+ 
CD44-) CD4+ T cells are visible, shown in Figure 44B. Therefore, further analysis needs to be 







Results: Identifying a role for T-bet in other immune cells 
 
As well as being the master transcription factor for CD4+ T cell differentiation, T-bet is 
involved in the function of many other immune cells (Szabo et al., 2000). There are other mouse 
models within the lab which have been used to study the impact T-bet has in these other 
immune cells at both a steady healthy state and in response to pathogen induction.  
Treg cells also express T-bet to promote CXCR3 expression and aid in their migration to sites 
of inflammation (Tan et al., 2016a). CXCR3+ Tregs increased the onset and severity of 
autoimmune diabetes in T-bet-/- mice. Use of a Foxp3cre Tbetfl/fl mouse line allowed specific 
deletion of T-bet in Foxp3 expressing cells only, i.e. the Treg population. This makes this mouse 
line more suitable than a global T-bet knockout mice (Levine et al., 2017, Pandiyan and Zhu, 
2015). Also, the role of T-bet in Tregs was investigated in relation to transplantation rejection in 
these mice, using a heart transplant model. Previous data have shown that Tregs require 
chemokines such as CCR6, CXCR3, CCR4 to be able to home to prevent graft rejection 
(Burrell et al., 2012). It has been shown though to be involved in the homing of Tregs to cardiac 
allografts. T-bet has been shown to control the expression of CXCR3 and in T-bet knockout 
mice it was found that Tregs lack CXCR3 but keep normal expression levels of CD103 and 
CCR6 (Lee et al., 2005). Xiong et al. also showed that activated T-bet-/- Tregs express increased 
CCR4 surface marker expression (Xiong et al., 2016). 
Lastly, as previously discussed, innate lymphoid cells (ILCs) were a novel innate cell 
population, which was discovered only a few years ago (McKenzie et al., 2014, Spits and 
Cupedo, 2012). Since then, many similarities have been found between ILCs and CD4+ T 
helper cells, both in terms of their immune function and cytokine production. Since the 
discovery of ILCs, conventional NK (cNK) cells have been coined “killer ILC1s”, due to their 
cytotoxic properties similar to cytotoxic T cells, and ILC1s have been named “helper-ILC1s” 
(Diefenbach et al., 2014). Further, cNK cells have been shown to have different surface marker 
properties dependent on which tissue they reside in. cNK also are not fully dependent on T-bet 
for their development. cNKs require both T-bet and Eomes to function. T-bet-/- mice still have 




require T-bet when at the immature NK cell stage and help to stabilise the immature NK state 
during NK cell development (Gordon et al., 2012). Using the anti-CD40 colitis model to induce 
an IFNγ driven disease phenotype in the colon has allowed for study into the interaction of 
ILC1s in inflammation (Powell et al., 2012, Buonocore et al., 2010, Uhlig et al., 2006). This 
model also affects the liver and causes severe hepatitis, which is also driven by an IFNγ 
response from ILC1s. Liver ILCs and NK cells are defined as being TRAIL- DX5+ NKp46+ 
cells, which are the liver resident NK cells and TRAIL+ DX5- NKp46+ cells as liver ILC1s 
(Daussy et al., 2014, Marquardt et al., 2015, Peng et al., 2013, Takeda et al., 2005, Tang et al., 
2016). T-bet is essential to the differentiation and effector function of ILC1s, and ILC1s have 
been found to be important in defence against many pathogens involved in diseases like IBD 
(Fuchs, 2016, Abt et al., 2015), liver disease (Liu and Zhang, 2017), ischemia injury in kidneys 
(Victorino et al., 2015) and also cytomegalovirus in the salivary glands (Schuster et al., 2014).  
Therefore, the role of T-bet in ILC1s and NK cells in relation to colitis and liver disease will 
be discussed and further investigated.  
 
6.1 The role of T-bet in CD4+ Treg 
 
Using a Foxp3cre Tbetfl/fl mouse model allowed for observations to be made in specific T-bet 
deletion in only Foxp3 expressing Tregs. Initial experiments performed were to analyse the 
difference in effector function these T-bet-/- Tregs would have in comparison with normal Tregs. 
The Foxp3 expression in this mouse line was also identifiable due to a YFP insert in the Foxp3 





















Figure 45: Phenotyping of the Foxp3cre x T-betfl/fl mouse line at steady state 
A. Representative gating strategy shown from the spleen of the Foxp3cre x T-betfl/fl mouse line. B Dot plots 
showing the percentage of IL-10 producing Foxp3+ CD4+ in stimulated cells from mLN, pLN and spleen from 
Foxp3cre x T-betfl/fl and using Foxp3cre litter mates as controls. (n = 4 for both genotypes) 
 
The Foxp3cre Tbetfl/fl mice showed that when T-bet deletion occurred in Foxp3+ CD4+ Treg cells 
there is a slight increase in IL-10 producing cells in the lymphoid organs, although this data 
was not significant. However, this trend of an increase in IL-10 produced by these T-bet 
deficient Tregs is contradictory from previously reported research. Koch et al., showed that in 
there was a slight reduction in TGFβ and IL-10 in T-bet-/- Tregs (Koch et al., 2009a).  
 
As already described, T-bet has been involved in the chemokine expression on Tregs and 
therefore it would be of interest to investigate any effects after deleting T-bet in Tregs. The 






























Dot plot showing percentage of IL-10 producing 
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Figure 46: Cardiac allografts between Foxp3cre mice and Foxp3cre x T-betfl/fl 
A. Survival graph showing transplanted cardiac allograft survival between Foxp3cre control mice and Foxp3cre x 
T-betfl/fl, mice were culled upon cessation of allograft. B. Representative histogram plots and bar graph of MFI 
showing the donor specific antibody response in serum of cardiac transplanted Foxp3cre control mice vs Foxp3cre 
x T-betfl/fl at day 0 and rejection. (n = 10 for Foxp3cre and 8 for Foxp3cre x T-betfl/fl mice). Kruskal-Wallis test 
performed showing overall statistical analysis for all. 
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There was no significant change in graft survival for the transplanted heart between the litter 
mate control Foxp3cre mice and T-bet-deficient Tregs of Foxp3
cre T-betfl/fl mice(Figure 46A). 
Figure 46B shows the flow cytometry data for donor specific antibody (DSA) response in 
serum taken from both test groups. Both the histogram and MFI of DSA response shows that 
there was no statistical difference in level of rejection between the Foxp3cre mice and Foxp3cre 
x T-betfl/fl test mice, even though between all 4 groups the Kruskal-Wallis test showed 
significant difference between all groups.  
 
6.2 The role of T-bet in NK cells and ILC1s in liver disease 
 
6.2.1 Activation of CD40 causes severe inflammation of the colon, but 
also causes severe inflammatory hepatocellular injury in the 
liver 
 
As previously stated, ILC1s are involved in IBD. One of the models of colitis involves the 
activation of myeloid cells, by anti-CD40 in Rag2-/- mice, to produce IL-12 and IL-23 and 
cause an increase in IFNγ production from ILC1s in the intestine, which drives the wasting 
disease and systemic inflammation (Uhlig et al., 2006, Buonocore et al., 2010, Powell et al., 























Figure 47: Typical colitis clinical aspects of the anti-CD40 colitis model in Rag2-/- mice 
A. Clinical data showing overall weight loss over seven days, colon and spleen mass at the end point and 
representative macroscopic photo of spleens from Rag2-/- given isotype control or anti-CD40 via intraperitoneal 
injections. B. Representative flow plot and histogram showing the increase in lymphocyte infiltration and 
increased Gr-1 neutrophil population within the colonic lamina propria of Rag2-/- (n = 9 for isotype control treated 
and n=20 for anti-CD40 treated mice). Mann-Whitney test performed showing statistical analysis and * showing 
P<0.05 and ** showing P<0.01 
 
In this standard model of colitis, systemic inflammation of the colon and spleen were observed. 
From previous published data and Figure 47, there is a big infiltration of Gr-1+ neutrophils. 
This is most likely driven by the activation of myeloid cells producing IL-12 and IL-23 and 
recruiting both neutrophils and pro-inflammatory ILC1s to the mucosal site. However, even 
though the anti-CD40 model affects the mice systemically, the liver of these mice has not been 
reported on, especially as the hepatic portal vein flows directs from the colon to the liver. 
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Figure 48: Clinical aspects in the liver of the anti-CD40 colitis model in Rag2-/- mice 
A. Clinical data showingmacroscopic photographs of livers and liver mass from Rag2-/- given either isotype 
control or anti-CD40. B. Representative haemotoxylin and eosin histology staining showing the histological 
differences in Rag2-/- given either isotype control or anti-CD40. C. Alanine transaminase and alkaline phosphatase 
readings from the serum of either Balb/C Rag2-/- or C57/B6 Rag1-/- with either control or anti-CD40 treatment. D. 
Representative flow plots showing the IFN, IL-17A and IL-4 production from live CD45+ cells from the liver of 
Rag2-/- mice either treated with isotype control or anti-CD40. E. qPCR data showing the IFN, IL-17A, IL-4, IL-
12p40 and IL-23p19 production from whole pieces of liver of Rag2-/- mice either treated with isotype control or 
anti-CD40. F. Representative flow plots showing increased macrophage infiltration in the liver (gated on live 
CD45+ cells) of Rag2-/- mice either treated with isotype control or anti-CD40. G. Representative F4/80 (shown in 
brown) histology staining showing F4/80+ cells in Rag2-/-given either isotype control or anti-CD40 via 
intraperitoneal injections. (n = 9 for isotype control treated and n=20 for anti-CD40 treated mice). Mann-Whitney 
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Figure 48 significantly demonstrates that Rag2-/- mice suffer from severe acute liver 
inflammation in the anti-CD40 colitis model. When anti-CD40 was administered, there was 
marked increase in liver masses in the mice and macroscopically the livers of these mice were 
paler and white spots were visible on the surface of the liver (Figure 48A). Histologically, the 
anti-CD40 treated livers showed increased infiltration of lymphocytes and the white spots that 
were seen macroscopically were identified as zones of necrosis. Furthermore, there was also 
hepatic portal vein thrombosis observed in some mice (marked in blue in Figure 48B). Serum 
from the mice was analysed for the enzymes: alanine transaminase (ALT) and alkaline 
phosphatase (ALP), to determine where the main source of liver injury was occurring. 
Consequently, the ALT and ALP readings from the mice treated with anti-CD40 showed them 
to have highly elevated ALTs and no changes to their ALP levels. This was further proved 
using flow cytometry and qPCR, where a large production of IFNγ was found in the CD45+ 
cells in the liver, and they also showed much greater relative gene expression from the qPCR 
results. As was reported by Uhlig et al. in 2006, there was a vast production of IL-12 and this 
was shown by the qPCR mRNA result in Figure 48E where there was highly elevated gene 
expression for IL-12. This was further highlighted by the increased infiltration of CD11b+ 
F4/80+ macrophages shown both by flow (Figure 48F) and histologically (Figure 48G). 
 
6.2.2 Hepatic CD90+ NKp46+ cells are more prolific activated 
producers of IFNγ 
 
As described, ILC1s are the main group of cells producing IFNγ in the anti-CD40 colitis model 
in the intestine. Therefore, analysis of the cells involved in causing the severe hepatitis and 























Figure 49: IFNγ production in the liver is produced predominately from CD90+ NKp46+ cells 
A. Representative flow plot gated on live CD45+ cells in the liver and dot plot showing the percentage of IFNγ 
producing cells in the same samples with CD90+ and CD90- gated cells in Rag2-/- given either isotype control or 
anti-CD40. B. Representative flow plots showing IFNγ production from either CD90- NKp46+ or CD90+ NKp46+ 
cells from the liver in Rag2-/- given either isotype control or anti-CD40. C. Representative Nkp46 (shown in 
brown) histology staining showing the increase and cluster of Nkp46+ cells in Rag2-/- given either isotype control 
or anti-CD40. D. Representative histograms showing typical NK cell markers gated off Nkp46+ CD90+ cells in 
the liver in Rag2-/- given either isotype control or anti-CD40. (n = 9 for isotype control treated and n=10 for anti-
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Analysis of the CD45+ cells in the liver showed that CD90 was significantly upregulated in 
NKp46+ cells when comparing the treated and untreated samples. Additionally, the Nkp46+ 
CD90+ produced significantly higher levels of IFN-γ production compared with the NKp46+ 
CD90- in the treated and non-treated mice. The histology samples stained for NKp46 in the 
anti-CD40 treated mice were found in abundance mainly around the zone of necrosis. Figure 
44D shows higher levels of activation of typical NK cell markers like CD69, Ly49G2, NKG2D 
and CD11c in the live Nkp46+ hepatocytes from the anti-CD40 treated mice. These results 
indicate that the large IFNγ production were from highly activated NKp46+ CD90+ cells. 
Further analysis to determine if they were ILC1s or cNK cells was needed.  
 
6.2.3 Conventional NK cells and not ILC1s are the main population of 
IFNγ producing cell in anti-CD40 mediated hepatitis  
 
The previous data only indicated that the cells responsible were NKp46+ CD90+ cells. 
However, as NKp46+ CD90+ cells encompass conventional NK cells, ILC1s and NKp46+ 
ILC3s, more thorough phenotyping of these cells was required. Liver ILC1s and cNK cells 





























Figure 50: Phenotyping the CD90+ NKp46+ NK and ILC1 population in the liver 
A. Representative gating strategy from the liver of Rag2-/-mice given isotype control. B. Graph showing the 
percentage of either TRAIL- DX5+ NKp46+ NK cells or TRAIL+ DX5- NKp46+ ILC1s from the liver in Rag2-/-
given either isotype control or anti-CD40. C. Representative histograms and dot plots showing NK markers from 
the TRAIL- DX5+ NKp46+ NK cells in the liver of Rag2-/-given either isotype control (n = 6) or anti-CD40 (n = 6 
or 9). Two-way ANOVA with Sidak multiple corrections performed and Mann-Whitney Test performed for 
statistical analysis 
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The main type of cell present in the liver during the induction of anti-CD40 was the TRAIL- 
DX5+ NK cell. More surprisingly, the TRAIL+ DX5- ILC1s reduce and almost disappear in 
number when given anti-CD40. Phenotyping of typical NK cell markers showed that these 
TRAIL- DX5+ cells were NK cells and furthermore, upon administering anti-CD40, they highly 
expressed both the activating receptors, Ly49D and Ly49H, and the inhibitory receptors, 
Ly49E/F and Ly49G, although the expression of Ly49E/F was not significantly different 
between the control and anti-CD40 treated cells. Both untreated and anti-CD40 treated NK 
cells were also high producers of both perforin and granzyme B, as well as being Eomeshigh.  
 
6.2.4 Anti-CD40 mediated hepatitis is not dependent on T-bet to drive 
the disease phenotype 
 
Since NK cells are not completely dependent on T-bet for their survival, it was interesting to 
investigate if T-bet has an essential role in IFNγ producing anti-CD40 mediated hepatitis. To 











































































Clinical data showing weight loss of the liver after treatment of anti-CD40 
ALT readings from serum after 






















Figure 51: Comparing liver disease in Rag2-/- vs TRnUC mice with anti-CD40 
A. Clinical data showing weight loss, liver and ALT levels from the serum in the liver of Rag2-/- and TRnUC mice 
given either isotype control or anti-CD40 B. Representative flow plots showing the NK (CD45+ NKp46+ TRAIL- 
DX5+) and ILC1 (CD45+ NKp46+ TRAIL+ DX5-) percentages, using the gating strategy as before, in the liver of 
Rag2-/- and TRnUC mice given either isotype control or anti-CD40. C. Bar graph showing the NK (CD45+ NKp46+ 
TRAIL- DX5+) and ILC1 (CD45+ NKp46+ TRAIL+ DX5-) percentages, using the gating strategy as before, in the 
liver of Rag2-/- and TRnUC mice given either isotype control or anti-CD40. D. IFNγ and IL-17A production from 
T-bet+ TRAIL- DX5+ NK cells of Rag2-/- and TRnUC mice given anti-CD40 (n = 2 for Rag2-/-  isotype control, 5 
for Rag2-/-  with anti-CD40, 4 for TRnUC control and 9 for TRnUC with anti-CD40). Two-way ANOVA with 
Sidak multiple corrections performed and Kruskal-Wallis test performed showing overall statistical analysis. 
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The TRnUC mice developed a similar disease phenotype compared to the clinical aspects of 
the Rag2-/- mice, in terms of enlarged liver mass and heightened ALT levels. They suffered less 
drastic weight loss. Whereas, in the anti-CD40 driven hepatitis, the NK cells drive the disease, 
and this is shown by the continued presence of TRAIL- DX5+ NK cells in the TRnUC mice 




As explained above, T-bet is involved in the expression of chemokine surface receptors, such 
as CXCR3, CCR4 and CCR6, in CD4+ Treg cells. Furthermore, Tregs are highly involved in 
tolerance and preventing graft transplantation rejection. Using the whole MHC mismatched 
Balb/C (H2d donors) and C57BL/6 (H2b recipients) mice model of transplantation (Corry et 
al., 1973), investigations could be made into the role of T-bet in Tregs in cardiac allografts by 
transplanting Balb/C hearts into the Foxp3cre T-betfl/fl mice. From the data shown in the heart 
transplant in T-bet-deficient Tregs, there was no significant change in graft survival when 
compared with the control Tregs. In fact, in this model, there was slightly worse survival rate in 
the Tregs lacking T-bet. Since T-bet
-/- Tregs showed increased expression in CCR4, but are also 
required for the expression of CXCR3, T-bet-/- Tregs may not been able to migrate effectively 
to the cardiac graft. DSA responses are readouts of hyperacute and acute rejection from 
transplanted grafts (Haarberg and Tambur, 2014). No difference is seen in T-bet-deficient Tregs 
mice in these experiments: this shows that T-bet is not capable in preventing graft rejection and 
nor is it able to prolong the survival of grafts. The in vivo studies showed that deleting T-bet in 
Tregs, however, increased the amount of IL-10 produced. This means that functionally they have 
potential to reduce the inflammation from TH1 driven phenotypes.  
 
The anti-CD40 model of colitis has been well documented in the colon by both groups within 
this lab and by other groups (Buonocore et al., 2010, Powell et al., 2012, Uhlig et al., 2006). In 
this study the impact of innate immune activation following systemic delivery of agonistic anti-
CD40 monoclonal antibodies (mAbs) to Rag2-/- mice was evaluated in the gut. However, no 
reports have been made in this model with regards to the liver. Therefore, we administered 
agonistic anti-CD40 mAbs to Rag2-/- mice in order to study innate immunity in the liver.  The 
anti-CD40 model of colitis also affected the liver causing severe acute hepatitis, which was 




colon, where the main disease inducing cell are ILCs, and furthermore when T-bet was 
deficient the ILC1s in the colon disappeared and the IFNγ production switched to an IL-17A 
phenotype (Powell et al., 2012). The liver disease was observed with the typical weight loss 
wasting model but also enlarged livers and increased ALT levels. ALT measures direct 
hepatocellular damage via damage to cell membrane functions of the liver cells (Lenaerts et 
al., 2005), whereas ALP is an enzyme found within the cells of the biliary duct in the liver. 
This highlighted that the inflammation experienced by these mice was due to injury directly to 
the hepatocytes and not being produced from the biliary ducts. Moreover, the ALT readings in 
C57/B6 Rag1-/- mice were more than double the reading in Balb/C Rag2-/- showing that this 
was predominantly an IFNγ driven disease as C57/B6 background mice have previously been 
shown to be more TH1-like in their phenotype and Balb/C background mice to be TH2 driven 
(Watanabe et al., 2004). The main liver cell type found to induce the disease was NKp46+ 
CD90+ TRAIL- DX5+ NK cells, which also had increased NK cell activation markers when 
anti-CD40 was administered. Unlike in the colon, in the liver disease model, T-bet is not a 
determining factor in causing this disease. This is expected as NK cells are not reliant on the 
expression of T-bet to function. Despite the disease phenotype not being dependent on T-bet, 
there was a 6-fold increase in Tbx21 gene expression in the Rag2-/- mice, when given anti-
CD40, and is upregulated leading to the IFNγ production (Data not shown). Despite the disease 
phenotype not being dependent on T-bet, it is expressed in the Rag2-/- mice, when given anti-
CD40, and is upregulated leading to the IFNγ production. However, there was still a small 
amount of IFNγ production from the NKp46+ CD90+ TRAIL- DX5+ NK cells in the TRnUC 
mice. 
 
Further experiments will be and are required to obtain better understanding of the hepatitis 
model in this setting. However, current data suggests that activation of anti-CD40 in the liver 
causes severe acute inflammation. Using known reposited RNA sequencing data sets and 
obtaining human samples from the different types of human hepatitis would be valuable 
information in order to try and identify this pathway within patients suffering from the same 
version of anti-CD40 activated hepatitis. This would allow for any potential treatments that 
patients could be directed towards in order to help treat their liver inflammation. 
 
Furthermore, IL-22 was first discovered in 2000 (Xie et al., 2000a). IL-22 has shown differing 




has been shown to be both protective and inflammatory depending on the impacting situation 
(Hainzl et al., 2015, Li et al., 2014, Mizoguchi et al., 2018, Sugimoto et al., 2008, Xie et al., 
2000b). However, IL-22 has not been reported on yet in this model of hepatitis and so a clearer 




































7.1  The use of the lineage T-bet expressing mouse model provided insights 
into immune cells that have previously expressed T-bet 
 
The data in this thesis was useful to identify populations of cells that were expected to express 
T-bet. The use of a novel T-betcre x ROSA26YFPfl/fl mouse line has been revolutionary in being 
able to trace the lineage of cells that have expressed T-bet in their past, despite not expressing 
T-bet at the time. As described already, T-bet expression is important for the function of many 
immune cells, including CD4+ T cells (Szabo et al., 2000, Koch et al., 2012, Lazarevic et al., 
2010), CD8+ T cells (Intlekofer et al., 2005), B cells (Peng et al., 2002), DCs (Lugo-Villarino 
et al., 2003), ILCs (Bernink et al., 2017, Klose et al., 2013), NK cells (Townsend et al., 2004), 
NKT cells (Matsuda et al., 2006), γδ T cells (Yin et al., 2002). From the phenotyping data of 
the spleen of the T-betcre x ROSA26YFPfl/fl mice, the percentage of cells expressing YFP were 
representative of the cells that have been reported to require T-bet expression for either their 
development, maturation and/or function. This was a good indication that the mouse model 
itself was a viable and usable mouse model to trace the lineage of T-bet expressing cells. 
Furthermore, this novel mouse line has been pioneering in being able to trace the lineage of 
cells that have expressed T-bet in the past, despite not necessarily being T-bet+ anymore. 
 
The most interesting finding from the phenotyping data in this thesis was the observation of 
the YFP+ identified naïve CD4+ T cells. The percentage of these cells that were discovered 
within each of the organs in the mouse were very small (around 0.5-5% depending on the organ 
and age), and therefore, even from previous research by other groups, these cells may have 
gone undetected in not only mice but also humans. This is because naïve CD4+ T cells are naïve 
and therefore have been shown to not express the relevant and appropriate master transcription 
factors required for their different subtype of helper CD4+ T cells until they have differentiated. 
Therefore, previous studies typically show negative T-bet expression in naïve CD4+ T cells 




mouse line, the novel discovery of previous T-bet+ naïve CD4+ T cells has been found. These 
cells were found to be functionally active and different to their YFP- naïve CD4+ subset. From 
the in vitro anti-CD3/CD28 culture data, it was found that the YFP+ naïve T cells were able to 
produce a large amount of IFNγ both with only IL-2 and with the differentiation skewing 
conditions. In fact, even when given the skewing conditions, the YFP+ CD4+ T cells were found 
to be able to possibly switch to a more TH1 cell type and increase the production of IFNγ in 
that differentiated subtype of CD4 T cell. This was even more evident in the YFP+ naïve T cell 
transfer experiments, which showed increased production of IFNγ. Furthermore, the co-
transfer experiments of CD45.1:CD45.2 YFP+ naïve CD4+ T cells at a low cell ratio of 90:10 
showed possible bystander activation of the naïve CD45.1 CD4+ T cells to produce increased 
IFNγ (Boyman, 2010, van Aalst et al., 2017), suggesting that these naïve YFP+ CD4+ T cells 
could be early responders to produce IFNγ during inflammation. As these cells have been 
previously unidentified without the use of this T-bet lineage tracking mouse, they might have 
been involved in previous studies of CD4+ T cell biology, especially in response to diseases 
and therefore further studies into their role in disease and CD4+ T cell biology is essential.  
 
However, as shown by the phenotyping data in Chapter 4, these YFP+ CD4+ naïve T cells 
themselves still have also yet to be fully identified. They were identified to express the typical 
surface markers that CD4+ naïve T cells expressed (CD25- CD44- CD62L+ CCR7+ CD27+ 
CD28+). However, the YFP+ CD4+ T cells did not fit any of the other known surface markers 
that had been used to identify the previously published naïve-like cell types, like stem-cell like 
naïve T cells (Gattinoni et al., 2011, Gattinoni et al., 2009), memory T cells with a naïve 
phenotype (Pulko et al., 2016) or virtual memory T cells (Haluszczak et al., 2009). But, they 
were CD5high and could be precursors to previously reported MP cells (Kawabe et al., 2017). 
Remarkably, there was an increase in CXCR3+ expression in 30% of YFP+ naïve CD4 T cells 
showed increased CXCR3+ expression compared to the YFP- naïve T cells. CXCR3 has been 
shown to have an importance during the differentiation of naïve CD4+ T cells into effector TH1 
cells (Groom and Luster, 2011) and is driven by T-bet expression (Lord et al., 2005). These T-






Ongoing and future experiments are planned to further analyse and phenotype these YFP+ naïve 
CD4+ T cells. Firstly, the expression of CD31 on these cells was not studied and this would be 
important to identify whether these cells are recent thymic emigrants (RTEs) (Hue et al., 2006). 
Although these were discounted due to the percentage of YFP+ naïve CD4+ T cells remaining 
consistent as the mice got older. In humans, CD31+ expressing RTEs have been shown to 
decrease rapidly with age, around 85% in children and declining to 40% in adults older than 
sixty (Song et al., 2015). Furthermore, it has been shown that CD31 expression on naïve CD4+ 
T cells ceases once the TCR becomes activated (Demeure C et al., 1996). The data from groups 
have shown that CD31 acts as a negative regulator of TCR and BCR signalling in both T and 
B cells (Henshall et al., 2001, Kohler and Thiel, 2009, Newton-Nash and Newman, 1999, 
Ignacio et al., 2017). With this in mind, if possible, further data on the older aged phenotyping 
of the mice would also be beneficial as in this thesis the oldest mice phenotyped were 50-week-
old mice and mice have a lifespan of at least two years. Therefore, if even older mice could be 
phenotyped that would be ideal in order to get a full spectrum of how these YFP+ naïve CD4+ 
T cells behave as the mice become really old.  
 
The YFP+ naïve CD4+ T cell data presented in this thesis so far has only shown functional 
proteomic data. The main problem with obtaining the genomic data for this was being able to 
acquire enough cells from each of the naïve CD4+ YFP+ T cell sorts and getting a sufficient 
amount of RNA extracted even with using the small cell number RNA extraction kits by 
Qiagen, like the RNeasy Micro Kit. However, currently, RNA-seq data is being sourced with 
assistance due to the low yield of good quality RNA. The RNA-seq data will look at the 
comparison between YFP- naïve CD4+ T cells, YFP+ naïve CD4+ T cells, YFP- effector memory 
CD4+ T cells and lastly YFP+ effector memory CD4+ T cells, in order to look at the difference 
in gene expressions between the different subsets on CD4+ T cell and more importantly between 
the YFP- and YFP+. The hypothesis would be that the YFP+ naïve CD4+ T cells would have 
increased gene expression in T-bet mediated genes like IFNγ, compared with the YFP- CD4+ T 
cells. This would be expected if the cells have already previously expressed T-bet in order to 
become YFP+. Further genomic plans would be to use ChIP-seq data to investigate the change 
in protein and DNA modifications along the genome in these different subsets of CD4+ T cells, 
especially in relation to the T-bet region of the genome. The hypothesis being that the YFP+ 
cell subsets would have more open chromatin regions around the T-bet region and have higher 




levels of H3K27me3 showing repression of a gene. Lastly, single cell sequencing and TCR 
repertoire sequencing would be important in order to investigate the difference in TCR 
signalling in these different YFP+ and YFP- subset of cells. The hypothesis being that there 
would be a difference in the YFP+ naïve CD4+ T cells with respect TCR activation and their 
antigen repertoire. Furthermore, using this genomic data could also help us to potentially 
identify if these YFP+ naïve CD4+ T cells are present in humans, as the genomic data could be 
compared with the genomic data already available from the human equivalent data sets. Since 
it is impossible to obviously trace the lineage of the cells in a human, this would be the most 
ideal method to see the functional relevance and be able to identify these cells in humans. 
 
Further functional experiments would also be important to further investigate the role and 
expression of T-bet in these cells. Establishing if these YFP+ fate mapped cells still express T-
bet is difficult to the nature of when and where transcription factors are regulated and 
expressed. Plus, using external stimuli like PMA and ionomycin or cytokines in order to induce 
T-bet expression can masks which YFP+ cells are T-bet+. However, from the in vitro skewed 
TH1 cells, all YFP
+ cells were also T-bet+. It has been shown that naïve CD4+ T cells are T-bet- 
(Ariga et al., 2007), but this was never checked in the naïve YFP+ CD4+ T cell panels used and 
ought to be just to confirm that this is still the case. 
 Within the group, a T-bet amcyan reporter mouse has been bred and this mouse line is able to 
trace cells currently expressing T-bet and marks them in an amcyan colour. However, whenever 
the cells stop express T-bet they lose their amcyan colour, therefore this mousseline is unable 
to trace the cells expressing T-bet but able to report on the ones presently expressing T-bet. 
Initial experiments performed have shown issues with the breeding of the T-betAmcyan mouse 
with the T-betcre x ROSA26fl/fl and results from T cell skewing have not shown results that 
would have been expected. Initial phenotyping of the T-betAmcyan mouse line revealed that there 
was 0.5-1% amcyan+ naïve CD4+ T cells, which correlated with the phenotyping data of the T-
betcre x ROSA26YFPfl/fl mouse data. However, when naive CD4+ T cells were taken from the 
T-betcre x ROSA26YFPfl/fl x T-betAmcyan mouse and skewed to TH1 using the TH1 skewing 
conditions, the cells were not shown to be Amcyan+ as well as being YFP+, which they would 
have been expected to be as differentiated TH1 cells should presently express T-bet, as well as 





7.2  The expression of T-bet is not necessary to maintain CD4+ T cell 
survival or plasticity 
 
T-bet has been shown to be important in the plasticity of TH2 cells (Hegazy et al., 2010, Kanhere 
et al., 2012, Murphy et al., 1996, Sundrud et al., 2003), TH17 cells (Bending et al., 2009, 
Garrido-Mesa et al., 2013, Hirota et al., 2011) and Treg cells (McPherson et al., 2015, Koch et 
al., 2012, Koch et al., 2009a, Koch et al., 2009b) to become more TH1-like, especially in 
response to inflammation and pathogens. The majority of the studies performed in the past have 
been on global T-bet knockout or conditional T-bet knockout and the results from this thesis 
have shown new data using the temporal deletion of T-bet with the ERTH2cre x T-betfl/fl mouse 
line. Interestingly, when using tamoxifen to delete T-bet in adult mice to show a difference in 
CD4+ T cells, in both in vitro and in vivo experiments, there did not seem to be deletion or even 
reduction in the expression of T-bet in CD4+ T cells. Unlike in ILC1s where the reduction of 
T-bet in ILC1s causes them to be lost (data not shown), T-bet is clearly not an essential 
requirement for the survival of fully developed CD4+ T cells or possibly the temporal deletion 
of T-bet is not enough to delete T-bet from the fully mature CD4+ T cells and the cells are able 
to express T-bet themselves and compensate for any attempted loss of T-bet. T-bet has been 
shown to promote the expression of FasL (Eshima et al., 2012, Eshima et al., 2018) and FasL 
has been shown to be important in the deletion of mature T cells (Nicholas Crisps, 1994). This 
therefore contradicts the findings shown when tamoxifen treatment was used as the mature 
CD4+ T cells were not deleted. 
 
The parasite infection models showed that the deletion of T-bet also was unable to drive 
switching to a TH2-like phenotype, although there were slight increases in expression of 
GATA3 and TH2 cytokine production. These experiments further demonstrated TH2 and TH1 
cells to be stable, as has previously been reported (Zhou et al., 2009). The DSS-induced colitis 
models were also unable to show any plasticity between TH1 and TH17 cells despite the increase 
in IL-17A production and RORγt expression and therefore the CD4+ T cells must require 
external cytokine stimuli, such as TGFβ and IL-6, as well as the transcriptional change or 






The plasticity experiments using the T-betcre x ROSA26fl/fl showed interesting results. From 
the cytokine secretion sorted T cell transfer experiments shown in Chapter 5, it was observed, 
although from a n of 1, that the YFP+ IL-17A+ cells were able to switch to a more TH1-like 
phenotype and produce a higher amount of IFNγ as they had previously expressed T-bet. 
However, again due to the small cell numbers acquired, it was difficult to perform these 
experiments and repeating them would be required in order to make this assumption into a real 
observation. Further experimental plans for these cells again would involve investigating how 
they differ from each other on a genomic level by using RNA-seq, ChIP-seq and single cell 
sequencing.  
 
7.3  A novel model of hepatitis involving the activation of CD40L on NK 
cells 
 
Using the anti-CD40 model of colitis (Uhlig et al., 2006), a novel model of hepatitis has been developed 
and shown in this thesis. Interestingly, the liver disease was mediated by NKp46+ CD90+ TRAIL- 
DX5+ NK cells and not by ILC1s or NKp46+ ILC3s, like in the colon (Fuchs, 2016, Fuchs et 
al., 2013). Similar to the colitis model, the NK cells in the liver cause severe inflammation with 
the production of IFNγ and actually cause visible macroscopic zones of necrosis of the liver. 
This model of anti-CD40 mediated hepatitis was also not dependent on T-bet, which makes 
sense as NK cells do not fully depend on T-bet to develop and as shown in T-bet-/- mice where 
there are still NK cells develop (Simonetta et al., 2016, Townsend et al., 2004).  
 
Future experiments regarding this model will involve investigating the role of IL-22. In the 
colitis model it has been shown that IL-22 to have both a protective and pathogenic role in 
TH17 cell mediated disease, but IL-22 has been reported to have only a protective purpose in 
the innate ILC3 cell mediate colitis (Eken et al., 2014, Hue et al., 2006, Ignacio et al., 2017, 
Song et al., 2015, Powell et al., 2012). Therefore, it would be important to investigate whether 
IL-22 is able to protect the mice from suffering hepatitis. This can be achieved by using a 
RAG2-/- x IL-22-/- mouse and to determine if the clinical data is worse and if there is an increase 
in ALT levels when anti-CD40 is administered. Further experiments to test the role of IL-22 in 
this model of hepatitis would be to induce the disease in the RAG2-/- mice and give either an 




give the RAG2-/- mice recombinant IL-22. In these experiments, if IL-22 is indeed still 
protective and able to stop the disease inflammation like in the colitis model, then the 
hypothesis would be that either knocking out or blocking IL-22 would cause more severe 
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